Jan / Feb 2012 by jo-ann kalaka-Adams

January/February 2012 • Volume 10 • Issue 1

EDITORIAL Modesty and the Skin: Why They Shouldn’t Mix Campbell and Parish

PERILS OF DERMATOPATHOLOGY It’s Not Just Who You Are, It’s Also Where You Are: The Cutaneous Leiomyosarcoma Dilemma Tumer, Castilla, and Lambert

COMMENTARY Origin and Evolution of Syphilis: Drifting Myth Sehgal, Verma, Chatterjee, Chaudhuri, Chatterjee, and Rasool

ORIGINAL CONTRIBUTIONS A New Paradigm in the Treatment of Kerions: Treat the Inflammation Dolder, O’Neill, O’Brien, Ross, Allen, and Allen

Pityriasis Rubra Pilaris: Evolution of Challenges in Promising Treatment Options Sehgal, Srivastava, and Verma

REVIEW The Role of Surgical Debridement in Healing of Diabetic Foot Ulcers Gordon, Lebrun, Tomic-Canic, and Kirsner

CORE CURRICULUM Cutaneous Tuberculosis: A Diagnostic Dilemma Sehgal, Verma, Bhattacharya, Sharma, Singh, and Verma

DEPARTMENTS COSMETIC SCIENCE Repelling Insects With Safe and Effective Alternatives to DEET Epstein

INFECTIOUS DISEASE CAPSULE It May Be Vulgar, but It Isn’t a Bad Word Saunders, Herchline, and Bernstein

CASE STUDIES Unusually Severe Case of Dermatosis Neglecta Turrentine, Blalock, and Davis

Fixed-Drug Eruption Caused by Ashwagandha (Withania somnifera): A Widely Used Ayurvedic Drug Sehgal, Verma, and Bhattacharya

Chronic Lymphocytic Leukemia Revealed by a Granulomatous Zosteriform Eruption Trojjet, Hammami, Zaraa, Bouzguarrou, Joens, Haouet, Osman, and Mokni

CORRESPONDENCE Mycobacterium marinum Cutaneous Infection With Sporotrichoid Distribution Treated With Azithromycin Monotherapy Rallis, Falidas, and Stavropoulos

DIFFERIN® (adapalene) LOTION, 0.1% — THE ONLY RETINOID IN A LOTION FORMULATION

ON THE JOB WITH GENTLE EFFICACY1

58.2% MEDIAN TOTAL LESION COUNT REDUCTION BY WEEK 121* TOLERABILITY PROFILE SIMILAR TO DIFFERIN® (adapalene) CREAM, 0.1%1† AVAILABLE IN AN EASY-TO-USE PUMP DISPENSER

RESULTS PATIENTS WANT IN A FORMULATION THAT DOES THE WORK—

PRESCRIBE DIFFERIN® LOTION, 0.1% TODAY!

A 12-week, multicenter, randomized, double-blind, parallel-group study of patients 12 to 18 years of age with acne vulgaris (N=1075). The most frequent adverse event reported was dryness. Erythema, stinging/burning, and scaling may also occur.1

* †

Important Safety Information Differin® Lotion, 0.1% is indicated for the topical treatment of acne vulgaris in patients 12 years and older. A thin ﬁlm of Differin® Lotion, 0.1% should be applied once per day to the face and other areas of the skin affected by acne. In clinical trials, the most common adverse event (>1%) reported with use of Differin® Lotion, 0.1% was mild to moderate skin dryness. Erythema, scaling, stinging and burning may also occur. Excessive exposure to sunlight and sunlamps should be avoided during treatment, and use of sunscreen products and protective clothing is recommended. Concomitant use of drying or irritating topical products (like products containing resorcinol, salicylic acid or sulfur) should be used with caution. Instruct patients to avoid the eyes, lips and mucous membranes when applying Differin® Lotion, 0.1%, and not to apply to areas that have been depilated with wax products. Differin® Lotion, 0.1% has not been tested in pregnant or nursing women, or with the elderly. Pregnancy Category C. www.differin.com/HCP Please see Brief Summary of Prescribing Information on adjacent page.

DIFFERIN®

Rx only

(adapalene) Lotion 0.1% For Topical Use Only Not For Oral, Ophthalmic, or Intravaginal Use. BRIEF SUMMARY INDICATIONS AND USAGE DIFFERIN Lotion is a retinoid product indicated for the topical treatment of acne vulgaris in patients 12 years and older. CONTRAINDICATIONS None. WARNINGS AND PRECAUTIONS Ultraviolet Light and Environmental Exposure: Avoid exposure to sunlight and sunlamps. Wear sunscreen when sun exposure cannot be avoided. Erythema, scaling, dryness, and stinging/burning may occur with use of DIFFERIN Lotion. ADVERSE REACTIONS Dry skin of mild to moderate severity was the most frequently reported (≥ 1%) treatment related adverse event. Erythema, scaling, dryness, burning/stinging were also seen during treatment. DRUG INTERACTIONS Concomitant use of topical products with a strong drying effect can increase skin irritation. Use with caution, especially in using preparations containing sulfur, resorcinol, or salicylic acid in combination with DIFFERIN Lotion. Wax depilation should not be performed on treated skin. Pregnancy Pregnancy Category C. There are no well-controlled trials in pregnant women treated with DIFFERIN Lotion. Therefore, DIFFERIN Lotion should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Animal reproduction studies have not been conducted with DIFFERIN Lotion. Furthermore, such studies are not always predictive of human response. Human Data In clinical trials involving DIFFERIN Lotion, 0.1% in the treatment of acne vulgaris, women of childbearing potential initiated treatment only after a negative pregnancy test. Two women became pregnant while using DIFFERIN Lotion, 0.1%. One patient delivered a healthy full term baby and the other patient electively terminated her pregnancy. Animal Data No teratogenic effects were observed in rats treated with oral doses of 0.15 to 5.0 mg adapalene/kg/day, up to 25 times (mg/m2/day) the maximum recommended human dose (MRHD) of 2 grams of DIFFERIN Lotion. However, teratogenic changes were observed in rats and rabbits when treated with oral doses of ≥ 25 mg adapalene/kg/day representing 123 and 246 times MRHD, respectively. Findings included cleft palate, microphthalmia, encephalocele and skeletal abnormalities in rats; and umbilical hernia, exophthalmos and kidney and skeletal abnormalities in rabbits. Dermal teratology studies conducted in rats and rabbits at doses of 0.66.0 mg adapalene/kg/day [25-59 times (mg/m2) the MRHD] exhibited no fetotoxicity and only minimal increases in supernumerary ribs in both species and delayed ossification in rabbits. Systemic exposure (AUC 0-24h) to adapalene at topical doses (6.0 mg/kg/day) in rats represented 101 times the exposure to adapalene in patients with acne treated with DIFFERIN Lotion applied to the face, chest and back (2 grams applied to 1000 cm² of acne-involved skin). Nursing Mothers It is not known whether adapalene is excreted in human milk following use of DIFFERIN Lotion. Because many drugs are excreted in human milk, caution should be exercised when DIFFERIN Lotion is administered to a nursing woman. Pediatric Use Safety and effectiveness of DIFFERIN Lotion in pediatric patients under the age of 12 have not been established. Geriatric Use Clinical studies of DIFFERIN Lotion did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Carcinogenesis, Mutagenesis, Impairment of Fertility No carcinogenicity, mutagenicity and impairment of fertility studies were conducted with DIFFERIN Lotion. Carcinogenicity studies with adapalene have been conducted in mice at topical doses of 0.4, 1.3, and 4.0 mg/kg/day (1.2, 3.9, and 12 mg/m²/day),

and in rats at oral doses of 0.15, 0.5, and 1.5 mg/kg/day (0.9, 3.0, and 9.0 mg/m2/day). In terms of body surface area, the highest dose levels are 9.8 (mice) and 7.4 times (rats) the MRHD of 2 grams of DIFFERIN Lotion. In the rat study, an increased incidence of benign and malignant pheochromocytomas in the adrenal medulla of male rats was observed. No photocarcinogenicity studies were conducted with adapalene. However, animal studies have shown an increased tumorigenic risk with the use of pharmacologically similar drugs (e.g. retinoids) when exposed to UV irradiation in the laboratory or sunlight. Although the significance of these findings to humans is not clear, patients should be advised to avoid or minimize exposure to either sunlight or artificial irradiation sources. Adapalene did not exhibit mutagenic or genotoxic effects in vitro (Ames test, Chinese hamster ovary cell assay, mouse lymphoma TK assay) or in vivo (mouse micronucleus test). In rat oral studies, 20 mg adapalene/kg/day (120 mg/m2/day; 98 times the MRHD based on mg/m2/day comparison) did not affect the reproductive performance and fertility of F0 males and females, or growth, development and reproductive function of F1 offspring. PATIENT COUNSELING INFORMATION • Apply a thin film of DIFFERIN Lotion to the affected areas of the skin once daily, after washing gently with a mild soapless cleanser. Dispense a nickel size amount of DIFFERIN Lotion (3-4 actuations of the pump) to cover the entire face. Avoid application to the areas of skin around eyes, lips and mucous membranes. DIFFERIN Lotion may cause irritation such as erythema, scaling, dryness, stinging or burning. • Advise patients to cleanse the area to be treated with a mild or soapless cleanser; pat dry. Apply DIFFERIN Lotion to the entire face or other acne affected areas as a thin layer, avoiding the eyes, lips and mucous membranes. • Exposure of the eye to this medication may result in reactions such as swelling, conjunctivitis and eye irritation. • Patients should be advised not to use more than the recommended amount and not to apply more than once daily as this will not produce faster results, but may increase irritation. • Advise patients to minimize exposure to sunlight including sunlamps. Recommend the use of sunscreen products and protective apparel (e.g., hat) when exposure cannot be avoided. • Moisturizers may be used if necessary; however, products containing alpha hydroxy or glycolic acids should be avoided. • This medication should not be applied to cuts, abrasions, eczematous, or sunburned skin. • Wax depilation should not be performed on treated skin due to the potential for skin erosions. • This product is for external use only. Marketed by: GALDERMA LABORATORIES, L.P., Fort Worth, Texas 76177 USA Manufactured by: Galderma Production Canada Inc., Baie d’Urfé, QC, H9X 3S4 Canada Made in Canada. GALDERMA is a registered trademark. P51503-0 Revised: March 2010

Reference: 1. Data on ﬁle. Galderma Laboratories, L.P. Galderma is a registered trademark. ©2010 Galderma Laboratories, L.P. Galderma Laboratories, L.P. 14501 N. Freeway Fort Worth, TX 76177 DIFF-113 Printed in USA 09/10

www.differin.com/HCP

TABLE OF CONTENTS January/February 2012 • Volume 10 • Issue 1

EDITORIAL Modesty and the Skin: Why They Shouldn’t Mix ................................................................................................ 6 Caren Campbell, BA; Lawrence Charles Parish, MD, MD (Hon)

COMMENTARY Origin and Evolution of Syphilis: Drifting Myth .................................................................................................. 8 Virendra N. Sehgal, MD; Prashant Verma, MD; Kingshuk Chatterjee, MBBS; Anita Chaudhuri, MD; Gautam Chatterjee, MS; Farhan Rasool, MBBS

ORIGINAL CONTRIBUTIONS A New Paradigm in the Treatment of Kerions: Treat the Inflammation ............................................................. 14 Sarah E. Dolder, MD; Brendan J. O’Neill, MD; Meghan M. O’Brien, MD; Amy S. Ross, MD; Robert A. Allen, MD; Herbert B. Allen, MD

Pityriasis Rubra Pilaris: Evolution of Challenges in Promising Treatment Options ............................................. 18 Virendra N. Sehgal, MD; Govind Srivastava, MD; Prashant Verma, MD

REVIEW The Role of Surgical Debridement in Healing of Diabetic Foot Ulcers .............................................................. 24 Katherine A. Gordon, BS; Elizabeth A. Lebrun, MD; Marjana Tomic-Canic, PhD; Robert S. Kirsner, MD, PhD

CORE CURRICULUM Cutaneous Tuberculosis: A Diagnostic Dilemma ............................................................................................. 28 Virendra N. Sehgal, MD; Prashant Verma, MD; Sambit N. Bhattacharya, MD; Sonal Sharma, MD; Navjeevan Singh, MD; Nishant Verma, MD Self-Test Review Questions (p. 34)

DEPARTMENTS COSMETIC SCIENCE Howard A. Epstein, PhD, Section Editor

Repelling Insects With Safe and Effective Alternatives to DEET ....................................................................... 36 Howard A. Epstein, PhD

PERILS OF DERMATOPATHOLOGY W. Clark Lambert, MD, PhD, Section Editor

It’s Not Just Who You Are, It’s Also Where You Are: The Cutaneous Leiomyosarcoma Dilemma ......................... 40 Gizem Tumer, MD; Carmen F. Castilla, BS; W. Clark Lambert, MD, PhD

INFECTIOUS DISEASE CAPSULE Jack M. Bernstein, MD, Section Editor

It May Be Vulgar, but It Isn’t a Bad Word......................................................................................................... 42 David Saunders, MD;Thomas Herchline, MD; Jack M. Bernstein, MD

CASE STUDIES Vesna Petronic-Rosic, MD, MSc, Section Editor

Unusually Severe Case of Dermatosis Neglecta.............................................................................................. 46 Jake E. Turrentine, BS; Travis W. Blalock, MD; Loretta S. Davis, MD

Fixed-Drug Eruption Caused by Ashwagandha (Withania somnifera): A Widely Used Ayurvedic Drug ................ 48 Virendra N. Sehgal, MD; Prashant Verma, MD; Sambit N. Bhattacharya, MD

TABLE OF CONTENTS January/February 2012 • Volume 10 • Issue 1 Chronic Lymphocytic Leukemia Revealed by a Granulomatous Zosteriform Eruption ....................................... 50 Sondes Trojjet, MD; Houda Hammami, MD; Inès Zaraa, MD; Alia Bouzguarrou, MD; Meriem Joens, MD; Slim Haouet, MD; Amel Ben Osman, MD; Mourad Mokni, MD

CORRESPONDENCE Mycobacterium marinum Cutaneous Infection With Sporotrichoid Distribution Treated With Azithromycin Monotherapy ............................................................................................................................ 54 Efstathios Rallis, MD, PhD; Evangelos Falidas, MD; Panagiotis Stavropoulos, MD, PhD

ABOUT OUR JOURNAL SKINmed: Dermatology for the Clinician®, print ISSN 1540-9740, online ISSN 1751-7125, is published bimonthly by Pulse Marketing & Communications, LLC, located at 4 Peninsula Avenue, Sea Bright, NJ 07760.

Editorial EDITORIAL DIRECTOR Sarah D. Staats sstaats@skinmedjournal.com

Printed in the USA. Disclaimer: The Publisher, Editors, and Editorial Board cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; the views and opinions expressed herein do not necessarily reflect those of the Publisher, Editors, and Editorial Board, neither does the publication of advertisements constitute any endorsement by the Publisher, Editors, and Editorial Board of the products or services advertised. The Publisher, Editors, Editorial Board, Reviewers, Authors, and Affiliated Agents shall not be held responsible or in any way liable for the continued accuracy of the information or for any errors, inaccuracies, or omissions of any kind in this publication, whether arising from negligence or otherwise, or for any consequences arising thereafter.

COPYEDITOR Elizabeth Holcomb eholcomb@skinmedjournal.com

MEDIA WEB DIRECTOR Joan Osgoodby joan@skinmedjournal.com

Publishing PUBLISHER Art Kalaka

Copyright: ©2012 Pulse Marketing & Communications, LLC. All rights reserved. No part of this publication may be reproduced, stored, or transmitted in any form or by any means without the prior permission in writing from the Publisher. Requests should be addressed to the Permissions Editor at: Pulse Marketing & Communications, LLC, 4 Peninsula Avenue, Sea Bright, NJ 07760.

ASSOCIATE PUBLISHER James R. Adams jadams@skinmedjournal.com

Corporate PRESIDENT Arthur Kalaka akalaka@skinmedjournal.com

CHIEF EXECUTIVE OFFICER Jo-Ann Kalaka-Adams jadams@skinmedjournal.com

Abstracting & Indexing: The journal is indexed in Index Medicus/ MEDLINE and Embase.

GENERAL COUNSEL Marianne Mckenzie mmckenzie@skinmedjournal.com

To submit a manuscript for peer review, send as an e-mail attachment to the Editor in Chief at lparish@skinmedjournal.com. Please visit www.skinmedjournal.com for Information for Authors.

Pulse Marketing & Communications, LLC 4 Peninsula Avenue • Suite 401 • Sea Bright, NJ 07760 Tel (732) 747-6525 • Fax (732) 747-7010

January/February 2012

EDITORIAL BOARD

EDITOR IN CHIEF

Lawrence Charles Parish, MD, MD (Hon) Philadelphia, PA

DEPUTY EDITORS William Abramovits, MD Dallas, TX

W. Clark Lambert, MD, PhD Newark, NJ

Larry E. Millikan, MD Meridian, MS

Vesna Petronic-Rosic, MD, MSc Chicago, IL

Marcia Ramos-e-Silva, MD, PhD Rio de Janeiro, Brazil

Jennifer L. Parish, MD Philadelphia, PA

EDITORIAL BOARD Mohamed Amer, MD Cairo, Egypt

Howard A. Epstein, PhD Gibbstown, NJ

Jasna Lipozencic, MD, PhD Zagreb, Croatia

Noah S. Scheinfeld, MD, JD New York, NY

Robert L. Baran, MD Cannes, France

Ibrahim Hassan Galadari, MD, PhD, FRCP Dubai, United Arab Emirates

Eve J. Lowenstein, MD, PhD New York, NY

Virendra N. Sehgal, MD Delhi, India

Anthony V. Benedetto, DO Philadelphia, PA

Anthony A. Gaspari, MD Baltimore, MD

George M. Martin, MD Kihei, HI

Charles Steffen, MD Oceanside, CA

Brian Berman, MD, PhD Miami, FL

Michael Geiges, MD Zurich, Switzerland

Marc S. Micozzi, MD, PhD Bethesda, MD

Alexander J. Stratigos, MD Athens, Greece

Jack M. Bernstein, MD Dayton, OH

Michael H. Gold, MD Nashville, TN

George F. Murphy, MD Boston, MA

James S. Studdiford III, MD Philadelphia, PA

Sarah Brenner, MD Tel Aviv, Israel

Lowell A. Goldsmith, MD, MPH Chapel Hill, NC

Oumeish Youssef Oumeish, MD, FRCP Amman, Jordan

Robert J. Thomsen, MD Los Alamos, NM

Joaquin Calap Calatayud, MD Cadiz, Spain

Aditya K. Gupta, MD, PhD, FRCP(C) London, Ontario

Joseph L. Pace, MD, FRCP Naxxar, Malta

Julian Trevino, MD Dayton, OH

Henry H.L. Chan, MB, MD, PhD, FRCP Hong Kong, China

Seung-Kyung Hann, MD, PhD Seoul, Korea

Art Papier, MD Rochester, NY

Snejina Vassileva, MD, PhD Sofia, Bulgaria

Noah Craft, MD, PhD, DTMH Torrance, CA

Roderick J. Hay, BCh, DM, FRCP, FRCPath London, UK

Johannes Ring, MD, DPhil Munich, Germany

Daniel Wallach, MD Paris, France

Ncoza C. Dlova, MBChB, FCDerm Durban, South Africa

Tanya R. Humphreys, MD Philadelphia, PA

Roy S. Rogers III, MD Rochester, MN

Michael A. Waugh, MB, FRCP Leeds, UK

Richard L. Dobson, MD Mt Pleasant, SC

Camila K. Janniger, MD Englewood, NJ

Donald Rudikoff, MD New York, NY

Wm. Philip Werschler, MD Spokane, WA

William H. Eaglstein, MD Palo Alto, CA

Abdul-Ghani Kibbi, MD Beirut, Lebanon

Robert I. Rudolph, MD Wyomissing, PA

Joseph A. Witkowski, MD Philadelphia, PA

Boni E. Elewski, MD Birmingham, AL

Andrew P. Lazar, MD Highland Park, IL

Vincenzo Ruocco, MD Naples, Italy

Ronni Wolf, MD Rechovot, Israel

Charles N. Ellis, MD Ann Arbor, MI

A New Tretinoin Therapy From Triax Pharmaceuticals

ÂŠ2010 Triax Pharmaceuticals, LLC.

Printed in USA

TX-0610-02

January/February 2012

Volume 10 • Issue 1

EDITORIAL

Modesty and the Skin: Why They Shouldn’t Mix Caren Campbell, BA;1 Lawrence Charles Parish, MD, MD (Hon)2

wearing any clothing only serves to hinder and prolong the examination.

ome years ago, the American Cancer Society first mounted a campaign against modesty to publicize the need for breast examinations. All too often, women were not only too embarrassed to let their physicians fully examine their chests, but they were also reluctant to perform self-examination.

Modesty is a behavior, manner, or appearance intended to avoid impropriety or indecency. During a physical examination, modesty is not serving to avoid impropriety or indecency. It is a false modesty. Much like the modesty panel underneath a desk or nude-colored hosiery worn by women, it is a social construct. The impropriety and judgment felt by the patient and others is also created by society.

This was not the case of the young woman who presented with a black lesion on her right breast. She was concerned about the peculiarity of the lesion since its appearance 2 months prior (Figure). Fortunately, modesty did not play a role in her situation. The lesion was quickly excised and proved to be a level 3 melanoma. How many other patients are not so fortunate to have appropriate removal and treatment before it is too late?

The subject of modesty has been examined in detail in other disciplines. For example, one such study on modesty sought to explore the role that culture played, finding that some perspectives on modesty are accounted for by culture, while others are not.3 Modesty was found to be driven by maturity/age, religion/ culture, or esteem/upbringing. For the maturity-driven group, modesty did not play a role in the health care setting, while the religiously/culturally driven group felt modesty should be considered in a health care setting. (Disrobing in this setting was not an issue.) Most interestingly, the esteem-driven group posed the greatest challenge to health care providers, as this group felt it stressful and uncomfortable to undress in the health care setting and would likely avoid screening for reasons of modesty.

CANCER SCREENING Americans should be well informed on the importance of early detection in skin cancer. Much emphasis has been placed on this concept; however, while patients may be attuned to the idea of cancer screening for other body systems, they do not grasp the concept of the full body scan. This diagnostic procedure, needless to say, cannot be accomplished in a proper fashion without disrobing, but many patients are reluctant to do so. As any seasoned clinician can attest, melanomas and nonmelanoma skin cancers can be found in any area of the body from the breasts to the soles. They do not avoid the genitalia, let alone the intertriginous areas. Curiously, primary cutaneous melanomas in hidden anatomic sites are thicker than those in visible sites, likely because of a delay in diagnosis.1,2 Additionally, the problem may be compounded by UV radiation from indoor tanning. Many a tanner disrobes completely to obtain his or her money’s worth at the tanning parlor but is reluctant to have the dermatologist see most of the body.

Although not formally studied, one realizes that body image plays a large role in patient modesty. Patients worry that as the physician examines their skin they are secretly being judged on their lingerie or less-than-ideal body weight. Here, the truth hurts—the clinicians are doing their job—to screen the patient for skin cancer. There are many papers detailing ways to protect patient modesty,4–8 but just as important as the patient’s comfort is the necessity to perform a thorough examination. The most obvious way to accomplish an appropriate examination to detect malignancy, including the scalp, oral cavity, genitals, and nails, would be disrobing.9 The patient may wear a gown to cover surfaces not being examined. An alternative involves the patient disrobing one quadrant at a time. It is both curious and unfortunate when a patient requests a full body scan but only permits limited views of the skin.

MODESTY AT WORK Let’s reflect upon the skin examination. Isn’t its purpose to find anything that might create a problem? The reason for the procedure is to examine visually every skin surface. The act of

From the Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA;1 and the Department of Dermatology and Cutaneous Biology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA2 Address for Correspondence: Lawrence Charles Parish, MD, MD (Hon), 1760 Market Street, Suite 301, Philadelphia, PA 19103 • E-mail: larryderm@yahoo.com

SKINmed. 2012;10:6–7

January/February 2012

EDITORIAL Partnering with those trusted by the patient might improve detection and outcomes for patients too modest for frequent skin examination. Isn’t there an old adage: Modesty killed the cat? REFERENCES 1

Nagore E, Oliver V, Moreno-Picot S, Fortea JM. Primary cutaneous melanoma in hidden sites is associated with thicker tumours—a study of 829 patients. Eur J Cancer. 2001;37:79–82.

Hemo Y, Gutman M, Klausner JM. Anatomic site of primary melanoma is associated with depth of invasion. Arch Surg. 1999;134:148–150.

Andrews CS. Defining and exploring modesty in Jewish American women. J Relig Health. 2010. http://www.springerlink.com.proxy1.lib. tju.edu:2048/content/r666v2x100160487/. Accessed April 23, 2011.

Baillie J. Making a difference to the patient experience. Health Estate. 2010;64:48–50, 52–55.

Wehbe-Alamah H. Bridging generic and professional care practices for Muslim patients through use of Leininger’s culture care modes. Contemp Nurse. 2008;28:83–97.

REFLECTIONS

Yosef ARO. Health beliefs, practice, and priorities for health care of Arab Muslims in the United States. J Transcult Nurs. 2008;19:284–291.

When reflecting upon the situation, the role of modesty in prophylactic screening is raised. What stands out is a lack of compliance in both breast and colon cancer screening due to modesty.10,11 If patients are unwilling to undergo cancer screening developed for the sole purpose of early detection and prevention, we can only conclude that modesty should be considered dangerous to their health.

Roberts KS. Providing culturally sensitive care to the childbearing Islamic family. Adv Neonatal Care. 2002;2:222–228.

Lawrence P, Rozmus C. Culturally sensitive care of the Muslim patient. J Transcult Nurs. 2001;12:228–233.

Craft N, Fox LP, Goldsmith LA. VisualDx: Essential Adult Dermatology. Philadelphia, PA: Lippincott Williams & Wilkins; 2010.

Figure. A level 3 melanoma found on the right breast.

10 Denberg TD, Melhado TV, Coombes JM, et al. Predictors of nonadherence to screening colonoscopy. J Gen Intern Med. 2005;20:989–995. 11 Parsa P, Kandiah M, Abdul Rahman H, Zulkefli NM. Barriers for breast cancer screening among Asian women: a mini literature review. Asian Pac J Cancer Prev. 2006;7:509–514.

Skin self-examination is one method that might prove an alternative for those too modest to allow yearly examination of the entire skin’s surface. Self-examination taught to both patient and partner improves self-efficacy for patients.12

12 Robinson JK, Stapleton J, Turrisi R. Relationship and partner moderator variables increase self-efficacy of performing skin self-examination. J Am Acad Dermatol. 2008;58:755–762.

HISTORICAL DIAGNOSIS & TREATMENT Diagnosis and treatments have advanced over the past century. This feature depicts conditions from a collection of steroptic cards published in 1910 by The Stereoscopic Skin Clinic, by Dr. S. I. Rainforth.

(continued on page 12) SKINmed. 2012;10:6–7

Modesty and the Skin: Why They Shouldn’t Mix

January/February 2012

Volume 10 • Issue 1

COMMENTARY

Origin and Evolution of Syphilis: Drifting Myth Virendra N. Sehgal, MD; Prashant Verma, MD; Kingshuk Chatterjee, MBBS; Anita Chaudhuri, MD; Gautam Chatterjee, MS; Farhan Rasool, MBBS

The venereal form of treponematosis, caused by the spirochete Treponema pallidum, plagued every major city in the preantibiotic era. “Civilization means syphilization,” was an idea touted by Richard von Krafft-Ebing in the late 19th, and early 20th centuries that the effects of modern life make men more susceptible to syphilis and other diseases. Christopher Columbus was thought of as an importer of syphilis to Europe. Because his serendipitous voyages to the New World initiated the process of Spanish colonization, which foreshadowed general European colonization of the New World, it is difficult to rule out the cultural and political animosity created by Columbus and his men. These recent revelations are intriguing and may create dialogue that may subsequently challenge the age-old theory of “East to West” spread of venereal syphilis. This contribution warrants the continuation of study in this direction, taking into account skeletal studies that utilized radiocarbon dating technique and the phylogenetic analysis of the bacterial strains, offering a possible consensus on the origin and evolution of syphilis.

yphilis, a treponemal disease, has undergone discernible metamorphosis in its natural history. The diverse clinical manifestations of syphilis are known to masquerade as a spectrum of clinical entities, earning itself the reputation of being the great imitator.1 Syphilis was even mentioned in Act 3 of Timon of Athens2 by William Shakespeare:

Syphilis, with its antiquity, has carried social stigma. In order to avoid the cultural embarrassment, countries attempted “to pass the buck to others.”6 Accordingly, variations in its nomenclature were likely; the English and the Germans called it the “French disease”; the French called it the “Neapolitan sickness”; the Russians, the “Polish sicknes”; the Poles, the “German sickness”; Flemish, Dutch, Portuguese, and North Americans called it the “Spanish sickness” or “Castilian sickness”; and the Japanese, the “Canton rash” or “Chinese ulcer.” The term Great pox was used for 2 centuries to differentiate syphilis from Smallpox.7

Live loathed and long, Most smiling, smooth, detested parasites, Courteous destroyers, affable wolves, meek bears, You fools of fortune, trencher-friends, time’s flies, Cap and knee slaves, vapours, and minute-jacks! Of man and beast the infinite malady Crust you quite o’er! What, dost thou go? Soft! take thy physic first—thou too—and thou;— Stay, I will lend thee money, borrow none.

Christopher Columbus, the great Italian voyager, whose precise date of birth is only speculated,8 left on his first voyage at the age of 41 years (1492–1493). His journey initiated the process of Spanish colonization, which foreshadowed the general European colonization of the “New World.”9 The idea that “Civilization is Syphilization” has historically stamped Columbus as the importer of syphilis to Europe.10 The current contribution attempts to review the more recent archeological reports, dendrochronologic findings, and radiocarbon dating studies in order to clarify the development of the disease. The origin and evolution of syphilis is currently unknown11 and may continue to puzzle researchers until a plausible consensus is developed.

The name for syphilis is derived from Fracastorius’ 1530 epic poem in three parts, Syphilis sive morbus gallicus (“Syphilis or The French Disease”), about a shepherd boy named Syphilus who insulted the sun god of Haiti and was punished by that god with a horrible disease. The poem suggests using mercury and “guaiaco” as a cure.3,4 Oil of guaiac is a fragrance used in soap, originating from the Palo Santo, sacred tree in Ecuador, which provides an essential oil that heals both body and spirit.5

From the Dermato-Venereology (Skin/VD) Center, Sehgal Nursing Home, Panchwati, Delhi; Department of Dermatology and STD, University College of Medical Sciences, and Associated Guru Teg Bahadur Hospital, Shahdara, Delhi; Department of Dermatology, Burdwan Medical College and Associated Hospital, Burdwan; Apollo Nursing Home, Burdwan; Skin Institute and School of Dermatology, Greater Kailash New Delhi, India Address for Correspondence: Virendra N. Sehgal MD, Dermato-Venerology (Skin/VD) Center, Sehgal Nursing Home, A/6 Panchwati, Delhi 110 033 India • E-mail: drsehgal@ndf.vsnl.net.in

SKINmed. 2012;10:8–12

January/February 2012

COMMENTARY

HYPOTHESIS OF THE ORIGIN OF SYPHILIS

NONUNITARIAN THEORY

THE UNITARIAN THEORY

An African origin hypothesis developed, with endemic treponemes originally acquired from apes, brought back to Europe by the Portuguese during the Age of Exploration.6

Hudson12 has been credited with the unitarian theory, which claims that treponemal diseases originating from one form, free-living treponemes in the mud, ultimately evolve into human saprophytes. “Yaws” appears to have first evolved in Central Africa, from where it spread to engulf the east and north, probably attributable to the importation of slaves to Egypt in 30th century BCE.13,14 Yaws eventually spread to the Arabian Peninsula and the valleys of the Tigris and Euphrates rivers, where it was called Bejel.15 Dissemination of yaws into Europe followed, peaking in the 8th century CE, when the Crusades made the slave trade from Africa more popular by transporting slaves for work to other countries.16,17 The Crusades moved from Europe to the Holy Land between the 11th and 14th centuries.

Another theory for the post-1492 syphilis outbreak mentions the role of a human immunodeficiency virus–like immunosuppressive agent causing an uncharacteristically severe variant of syphilis, lues maligna. PRE-COLUMBIAN PERCEPTION The perception that treponemal infection existed in the preColumbian civilization, which is now the southwestern part of the United States, was documented by the lesions indicative of treponematosis in a burial site found in the central Great House of Chaco Canyon, Pueblo Bonito, New Mexico, an epicenter of a broad culture system that spanned the Four Corners regions, in contrast to numerous reports available from New World skeletal burial remains. This is an interesting revelation, which may open a venue for future workup.20–24

It was between the 17th and 19th centuries that a series of yaws-like diseases, the endemic syphilis, and pinta were identified in individuals who had a poor rural background and overcrowded living conditions. Endemic syphilis prevailed as the Spirocolon of Greece, the hills of Bosnia, the Pian of Nerac in South-West France, the Button scurvy of Ireland, the Sibbens of Scotland, the Radseyege of Scandinavia, Siti of Gambia, Therlijevo of Croatia, Njovera of Zimbawe, Frenjak of the Balkans, and nonvenereal endemic syphilis, Bejel disease. The Dithmarsh evil of Jutland and Schlesweig-Holstein is yet another entity. All of these diseases, including yaws, were considered to be a consequence of either direct or indirect social contact, affecting all age groups. Children and family members were the most susceptible.

COLUMBIAN THEORY It is speculated that treponematoses was absent in Europe in the pre-Columbian era25 until the 13th century CE, when yaws appeared as a possible result of slave trading.26 Berbers and Moors, from North and North-West Africa, established themselves in Southern Europe, mostly in Spain, in the 15th century. Half a century prior to Columbus’ first voyage (1492–1493), Spanish and Portuguese sailors already competed with more extensive journeys down the West coast of Africa and encouraged the migration of the Africans. Despite the efforts for quarantines, yaws spread to the European continent. According to the Columbian theory, venereal syphilis appears to have been brought from the New World and joined so-called endemic syphilis. An outbreak of the epidemic resurfaced upon the return of Columbus and his men from the New World. A similar presentation of the disease was identified in the indigenous people of the New World as well as in the members of Columbus’ crew. The epidemic in the earliest years, popularly called the Morbus gallicus, may have been the combination of 2 diseases; the newly arrived sexually acquired venereal syphilis and the old socially acquired endemic syphilis forms of yaws.19 The changes in clinical presentation, particularly in the first half of the 16th century, might be the result of expanding influences of the Renaissance, including improved personal hygiene. Others explain the devastating Morbus gallicus as the relatively benign venereal syphilis of the New World, afflicting people with no previous contact with the condition and producing more

The histories of Button scurvy and Sibbens have also been documented.18,19 These entities have been defined and classified into endemic syphilis or treponarids, and are considered to be a form of yaws modified by climatic conditions, clothing customs, and even the sharing of drinking utensils. This seems plausible due to the fact that yaws was later shipped via slaves from West Africa to the West Indies. In addition, some treponemes adapted to the conditions by thriving in the moist and warm areas of the body and by mutating into more lethal organisms. The latter was acquired by sexual contact and expressed as syphilis in the contemporary context. In the absence of any viable means to control the transmission of treponemes, the advent of soap in the Arab peninsula and Europe in the 7th and the 14th century, respectively, and its widespread use was acknowledged as a possible mode for the reduced survival of treponemes in treponarids.

SKINmed. 2012;10:8–12

Origin and Evolution of Syphilis

January/February 2012

COMMENTARY

obvious signs and symptoms, both the views commensurate with the Columbian theory. Accordingly, the arguments for and against the Columbian theory are listed below.

207 were relatively complete. Many were buried in wooden coffins, prepared from the wood brought from the Baltic countries. Dendrochronologic examination indicated that the trees had fallen between 1340 and 1369. The interpretation of the findings was, therefore, found to be confusing. Three skeletons showed more variable and more widespread bony lesions. One of these three, number 1216, was that of a man aged between 25 and 35 years. He showed signs of syphilitic stigmata; thickening with areas of localized disease of thigh bones, sabre-like thickening of shin bones, perforation of the palate, and erosion of the skull’s frontal bone, a condition called caries sicca. Caries sicca, a bony finding from gummatous syphilis has been described as “The only reliable and pathognomonic lesion of syphilis….”33 Other findings are of variable reliability.34

• Syphilis, as one form of pathologic treponematosis, has a skeletal signature. Rothschild demonstrated that the osseotype characteristics of syphilis were absent in specimens from pre-Columbian Europe, Africa, and Asia.27 • The sailors with Columbus in 1493 were said to have brought the disease back to Spain. The Spanish fleet, when they fought for King Alfonso II against the French forces of Charles VIII of France in 1494–1495, heavily infected the people of Naples. The illness spread rapidly around Europe and mercenaries, who in 1496 joined Perkin Warbeck in Scotland and with the support of James IV of Scotland, invaded England, bore both arms and the grandgore (Old French; grand gorre: grand = great + gore = syphilis), as it was then called. In 1497, the Minutes of the Town Council of Edinborough (Phil. Trans. XLII. 421) recognized: “This contagious sickness call it the Grandgore.”28 • The osseous evidence documents the presence of syphilis in Hispanola, where Columbus landed. Columbus’ crew had the opportunity and means to contract and spread this venereal disease.27 • In the work “Tractado contra el mal serpentino,” written in 1510 and published in 1539, Ruy Diaz de Isla had been thought to have cured, during the travel of return in Europe, many members of the crew of Columbus, affections from certain luetic manifestations, and thought that the new disease was imported from Hispanola. This view was supported by Bartolomè de Las Casas.29

Carbon-dating of the skeleton showed it to have lived sometime between 1300 and 1420, corresponding to about a century before Columbus’ first voyage in 1492 to 1493. Three paleopathologists opined on the skeleton number 1216. Charlotte Roberts recognized it as treponemal disease but could not distinguish among them,35 while Rothschild suggested that the population frequency of skeletal involvement was too high for treponemal disease. Secondly, the pattern of disease in the Hull site is classic for yaws. It matches in all details the reports of skeletal findings in yaws and is quite different than those for syphilis. Much of what was diagnosed as disease appeared taphonomic.36 George Armalegos, with extensive experience in viewing New World, pre-Columbian bones allegedly showing changes due to syphilis, was impressed but wanted the confirmation in terms of quantity rather than quality. Support for the existence of venereal syphilis in pre-Columbian Europe comes from Dr Mattie Hennenberg37 and his wife based on the examination of 300 Greek skeletons buried in a southern Italian port in 600 BCE, with the claim that many of them showed changes similar to those of the Hull friary skeletons, indicative of syphilis; however, taphonomy could be a confounder. The term taphonomy (from the Greek taphos ´ φος] meaning burial and nomos [vóμoς] meaning law) was [τα introduced to paleontology in 1940 by Russian scientist Ivan Efremov to describe the study of the transition of remains, parts, or products of organisms from the biosphere to the lithosphere, that is a creation of fossil assemblages.38

• The absence of evidence for congenital transmission of the disease in pre-1492 North America suggests that this treponemal disease was not the same venereal form we know today.30 CONTEMPORARY SCENARIO Several archeologic studies have taken cognizance of phylogenetically diverse material at different geographic locations and have gathered together enough evidence to suggest that the disease existed in Europe, long before the birth of Columbus (October 31, 1451–May 20, 1506).31 The osseotype characteristics of syphilis are absent in specimens from pre-Columbian Europe, Africa, and Asia.32 A study was conducted on approximately 240 skeletons exhumed at the site of a medieval friary in Hull. The skeletons were mostly of Augustinian friars, Mendicants serving the local poor, and seamen and prostitutes. Of the 245 well-preserved skeletons found,

Hennenberg, a dental specialist, claimed that the upper central incisor teeth from two skeletons showed “grooves,” proof of congenital syphilis. A second “dig” of old bones from a port near Pompeii offers similar bony findings. Recent research based on exhumed human skeletons from a cemetery at an East London church, St Mary Spital, identified rough patches on skulls and

SKINmed. 2012;10:8–12

Origin and Evolution of Syphilis

January/February 2012

COMMENTARY

limbs of some of the skeletons, pointing toward a syphilitic origin for such findings. This study scores over its predecessors in terms of executing radiocarbon dating of the exhumed samples, estimated to be 95% accurate. Brian Connell, an expert from the Museum of London who studied the bones, opined that the skeletons were buried before the Columbus voyage. He said “We’re confident that Christopher Columbus is simply not a feature of the emergence, and timing of the disease in Europe.”39 Two of the syphilitic skeletons unearthed from the site were from 1200–1250, while the other 5 were from 1250–1400, preceding Columbus’ birth. They were buried with coins and other objects that helped the experts corroborate the radiocarbon dating results.11,39 The Unitarian hypothesis, based on skeletal morphology data,40 has recently been challenged by analysis of the molecular evolution of the tpr C, D, I, K, G, and J genes in the pathogenic genus Treponema.41 The elusive outcome of past research warrants future exploration. The advent of phylogenetic systematic analysis may prove beneficial in exploring the veracity of the findings. It is that field of biology that deals with identifying and understanding the evolutionary relationships among the many different kinds of life on earth, both living (extant) and dead (extinct).

able, especially in view of skeletal evidence supporting origin 2000 to 1800 yBP. In contrast, if the claims of pre-Columbian venereal syphilis outside the Americas are taken into account, the place of origin remains unresolved.

Evolutionary theory states that similarity among individuals or species is attributable to common descent or inheritance from a common ancestor. Thus, the relationships established by phylogenetic systematics often describe a species’ evolutionary history and, hence, its phylogeny, the historical relationships among lineages or organisms or their parts, such as their genes.42 This modality was made use of to analyze the data from 21 genetic regions examined in 26 geographically disparate strains of pathogenic Treponema.43 Of all the strains examined, the venereal syphilis–causing strains originated most recently and were more closely related to yaws-causing strains from South America than to other nonvenereal strains. Old World yaws–causing strains occupied a basal position on the tree, indicating that they first arose in human history, and a simian strain of Treponema pallidum was found to be indistinguishable from them. These results lend support to the Columbian theory of syphilis’ origin, while suggesting that the nonsexually transmitted subspecies arose earlier in the Old World. In yet another study,44 using an integrative phylogenetic and paleopathologic approach, syphilis seems to have emerged in the time span between 5000 years before present (yBP) and 16,500 yBP, in the Americas, because the resulting evolutionary rate is compatible with those observed in other bacteria; however, these studies relied on 2 bacterial isolates from individuals with alleged yaws from a site where antibiotic treatment of yaws had altered the picture. It is unclear what disease was present in the two isolates on which they based their studies. The suggested time span for origin of syphilis of 5000 to 16,500 yBP is still debatSKINmed. 2012;10:8–12

REFERENCES 1

King A, Nicol C, Rodin P, eds. Yaws: endemic syphilis: Bejel: Pinta. In: Venereal Diseases. 4th ed. London, England: Balliere Tindall; 1980: 333–345.

Soellner R. Timon of Athens: Shakespeare’s Pessimistic Tragedy. Columbus: Ohio State University Press; 1979.

Baumgartner L, Fulton JF. A Bibliography of the Poem Syphilis Sive Morbus Gallicus, by Girolamo Fracastoro of Verona. New Haven, CT: Yale University Press; 1935:157–159.

Opdyke DL. Bulnesia sarmientoi. Food Cosmet Toxicol. 1974;12:905

Essential Oils Desk Reference. 4th ed. Orem, UT: Essential Science Publishing; 2007.

Rothschild BM. History of syphilis. Clin Infect Dis. 2005;40: 1454–1463.

Heymann WR. The history of syphilis. J Am Acad Dermatol. 2006;54: 322–323.

Dunn O, Kelly J. The Diario of Christopher Columbus’s First Voyage to America 1492–1493. Norman, OK: University of Oklahoma Press; 1991:333–343.

Stokes JH, Beerman H, Ingraham MR. Modern Clinical Syphilology. Philadelphia, PA: WB Saunders; 1945:1120–1121.

10 Miller H. Secrets of the Dead. London, England: Channel 4 Books: MacMillan; 2000:149–184. 11 Morton R, Rashid S. “The syphilis enigma”: the riddle resolved? Sex Transm Inf. 2001;77:322–324. 12 Hudson EH. Non-Venereal Syphilis: A Sociological and Medical Study of Bejel. Edinburgh and London: E & S Livingstone; 1958. 13 Hackett CJ. On the origin of the human treponematosis. Bull World Health Organ. 1963;29:7–41. 14 Scott HH. The influence of the slave trade in the spread of tropical diseases. Transcr R Soc Trop Med Hygiene. 1943;38:169. 15 Wedad M. Is Bejel, Yaws? (In Arabic). Bagdad, Iraq: Government Press; 1936. 16 Hudson EH. Treponematosis and African slavery. Br J Vener Dis. 1964;40:43–52. 17 Major RH. “Prince Henry the Navigator”: A Life. New Haven, CT: Yale University Press; 2000. 18 Morton RS. The buttons scurvy of Ireland. Br J Vener Dis. 1964;40: 271–274. 19 Morton RS. A clinical look at the morbus gallicus. Eur J Sex Transm Dis. 1985;2:133–140. 20 Marden K, Ortner DJ. A case of treponematosis from pre-Columbian Chaco Canyon, New Mexico. Int J Osteoarchaeol. 2011;21:19–31. 21 Lahr MM, Bowman JE. Paleopathology of the Kechipawan site: health and disease in a southwestern Pueblo. J Archaeol Sci. 1992;19:639–654. 22 Ortner DJ, Tuross N, Stix AI. New approaches to the study of disease in archaeological New World populations. Human Biology. 1992;64:337–360. 23 Verano JW. Advances in the paleopathology of Andean South America. J World Prehistory. 1997;11:237–268. 24 Baker BJ, Armelagos GJ. The origin and antiquity of syphilis: paleopathological diagnosis and interpretation. Curr Anthropol. 1988;29:703–738. 25 Rothschild BM, Coppa A, Petrone PP. “Like a virgin”: absence of rheumatoid arthritis and treponematosis, good sanitation and only rare gout in Italy prior to the 15th century. Reumatismo. 2004;56:61–66.

Origin and Evolution of Syphilis

January/February 2012

COMMENTARY

26 Rothschild C, Rothschild BM. Patterns of periosteal reaction in England from Roman through Elizabethan epochs. J Paleopath 1995;7:130.

the late medieval period. Poster presented at: the 18th Paleopathology Association European Meeting, Vienna, Austria; 2010.

27 Rothschild BM. History of syphilis. Clin Infect Dis. 2005;40:1454–1463.

36 Rothschild BM. History of syphilis. Clin Infect Dis. 2005;40:1454–1463.

28 Pearce JMS. A note on the origins of syphilis. J Neurol Neurosurg Psychiatry. 1998;64:542.

37 Henneberg RJ, Henneberg M. Possible occurrence of treponematosis in the ancient Greek colony of Metaponto. Am J Phys Anthropol. 1995 (suppl 163):107–108.

29 Di Cicco CO. History of syphilis. J Eur Acad Dermatol Venereol. 2005;19:1–11.

38 Efremov IA. Taphonomy: a new branch of paleontology. Pan-Am Geol. 1940;74:81–93.

30 Dutour O, Palfi G, Berato J, Brun JP. The Origin of Syphilis in Europe: Before or After 1493? Toulon: Centre Archéologique du Var; 1995.

39 Columbus Didn’t Sail Syphilis Back to Europe. Medieval Archives Illuminating the Dark Ages for the Digital World. Sci Technol. Oct 27, 2010.

31 Stirland, A. Evidence for pre-Columbian treponematosis in Medieval Europe. In: L’Origine de la Syphilis en Europe Avant ou après 1493? Dutour O, Palfi G, Berato J, Brun JP, eds. Toulon, France: Centre Archéologique du Var; 1995:109–115.

40 Hudson EH. Treponematosis and man’s social evolution. Am Anthropol. 1965;67:885–901.

32 Anderson T, Arcini C, Anda S, Tangerud A, Robertsen G. Suspected endemic syphilis (treponarid) in sixteenth-century Norway. Med Hist. 1986;30:341–350.

41 Gray RR, Mulligan CJ, Molini BJ, et al. Molecular evolution of the tprC, D, I, K, G, and J genes in the pathogenic genus Treponema. Mol Biol Evol. 2006;23:2220–2233.

33 Virchow RLK. Beitrag zur geschichte der lues. Arch Dermatol. 1896;2:1–9.

42 Hillis DM, Moritz C, Mable BK, eds. Molecular Systematics. 2nd ed. Sunderland, MA; Sinauer Associates: 1996

34 Lahr MM, Bowman JE. Palaeopathoogy of Kechipawan Site: health and disease in a south western pueblo. J Archeolog Sci. 1992;19:639–654.

43 Harper KN, Ocampo PS, Steiner BM, et al. On the origin of the treponematoses: a phylogenetic approach. PLoS Negl Trop Dis. 2008;2:e148.

35 Roberts C, Millard A, Pearson G, Macpherson C, Nowell G. The origin and mobility of people with venereal syphilis buried in Hull, England in

44 de Melo FL, de Mello JC, Fraga AM, et al. Syphilis at the crossroad of phylogenetics and paleopathology. PLoS Negl Trop Dis. 2010;4:e575.

HISTORICAL DIAGNOSIS & TREATMENT: SYCOSIS (continued from page 7) SYNONYMS: ACNE SYCOSIS; SYCOSIS BARBAE, SEU MENTI; SYCOSIS NON PARASITICA; MENTAGRA; FOLLICULITIS BARBAE, SEU PILORUM.

Sycosis is a chronic inflammatory disease of hairy parts of the skin characterized by tubercles, papules and pustules, each of which is pierced invariably by the shaft of a hair. In the great majority of cases the disease is limited to the region of the beard in men, though it may occur on the eyebrows, scalp, axillae and pubes. On the face it starts usually as one or more ill defined patches and may remain confined in certain areas or spread so as to include in time the whole bearded region. The disease does not extend to non-hairy parts. The lesions may be discrete and relatively few in number, or, in very severe cases, so numerous and closely set as to form almost continuous patches of infiltration. The inflammation starts in the walls of the hair follicles and the first surface manifestations are papules or tubercles situated at the orifices, with a hair passing through each little elevation. The papules and tubercles soon change into pustules. Occasionally in old patches, pustules develop about the hairs without preceding papulation. The pustules exhibit slight tendency to rupture, but the inflammatory exudate often escapes alongside the hairs from the mouths of the follicles and dries to form small crusts. When the lesions are closely set one crust may cover the openings of several follicles. The removal of such a crust does not expose a raw, oozing surface, but tears the top off a number of pustules. The amount of crusting is never very great. Burning and tension are usually the only subjective symptoms complained of. At the onset of an attack traction on the hairs which issue from inflamed follicles causes considerable pain, but later the root sheaths become swollen with pus and the hairs loosen and may be easily extracted. At times they fall out spontaneously. The hair loss is seldom permanent, though in some cases the thinning

SKINmed. 2012;10:8–12

of the beard is quite noticeable. Untreated the disease persists indefinitely. Periods of quiescence alternate with exacerbations and the outbreak of acute symptoms is as a rule without any apparent cause. Sycosis on the upper lip, which is a favorite location, is often associated with chronic rhinitis. The nasal secretion may be the cause of the sycosis or the sycosis by extension may affect the vibrissae and cause the Schneiderian membrane to become swollen and exquisitely sensitive. Sycosis sometimes develops from eczema of the bearded region. The disease is feebly contagious and in not infrequently transmitted by the barber shop razor. The pyogenic staphylococci are invariably present in the pus. DIAGNOSIS: Numerous pustules pierced by hairs are almost

pathognomonic of the disease. Trichophytosis barbae begins as a scaling spot and later produces a lumpy condition of the skin; from every node many hairs project and these may be twisted, split or broken. The spores are easily found with the microscope. In pustular eczema the pustules are not so accurately located about the hairs, the crusting is greater and the crusts cover raw, oozing surfaces. The disease spreads readily to non-hairy parts. Itching is severe. TREATMENT: Epilation is the most essential part of the treat-

ment. Each day all the hairs in a given area of the affected region should be extracted. Pasta zinci Lassar, N. F., is to be applied plentifully and kept as constantly as possible in close contact with the skin. In very obstinate cases with thickening of the skin the amount of salicylic acid may be increased to 10-15 per cent. Exposures to the X-rays carried to the point of producing a slight erythema and falling of the hair, have a brilliant curative effect, but every precaution must be observed not to cause dermatitis actinica.

Origin and Evolution of Syphilis

January/February 2012

Volume 10 • Issue 1

ORIGINAL CONTRIBUTION

A New Paradigm in the Treatment of Kerions: Treat the Inflammation Sarah E. Dolder, MD; Brendan J. O’Neill, MD; Meghan M. O’Brien, MD; Amy S. Ross, MD; Robert A. Allen, MD; Herbert B. Allen, MD ABSTRACT Kerions result from a massive delayed-type hypersensitivity reaction to a dermatophyte. Treatment traditionally has been directed primarily toward the dermatophyte. The authors propose, however, that inflammation should be the initial target of treatment. Clinical findings and treatment outcomes for two patients with kerions, treated with short courses of anti-inflammatory agents, are presented. Earlier studies showing minimal effects with corticosteroid treatment of kerions may have had design flaws. The anti-inflammatory treatment of kerions is both safe and effective and permits the duration of therapy to be shortened dramatically. (SKINmed. 2012;10:14–16)

e present two patients with kerions who are representative of more than 3 dozen similar patients seen in more than 2 decades of observation in our clinic. Recognizing that kerions are delayed-type hypersensitivity (DTH) reactions,1 we treated all our patients with short courses of anti-inflammatory agents, and all had resolution of their lesions.

kerion, and treatment with prednisolone 1 mg/kg/d and selenium sulfide shampoo was instituted. Three weeks later, the plaque had cleared and new hair started to regrow (Figure 2). Within 2 months, the hair had completely regrown without scarring.

CASE 1

Kerion formation is the inflammatory extreme of tinea capitis, producing a large, painful, crusted plaque on the scalp, often with purulent discharge and cervical lymphadenopathy. Kerions are the result of a massive DTH reaction to a dermatophyte.1 Positive DTH skin tests, lesional histopathology, and immunofluorescence studies are all consistent with this concept,1,5,6 proposed originally by Birt and Wilt7 in 1954 and later supported by Rasmussen and Ahmed.8 Inasmuch as the kerion is an immunologic event, this helps explain why antibiotics, whether antibacterial or antifungal, are ineffective (in spite of positive cultures) and why all our patients responded to anti-inflammatory treatment with complete resolution of the kerions and subsequent regrowth of hair.

Patient 1 was a 7-year-old African American boy who was taking oral cephalexin for a cultured methicillin-sensitive Staphylococcus aureus markedly crusted, boggy, alopectic tumefaction on the left lateral scalp that was associated with markedly enlarged postauricular and posterior cervical nodes. He had taken the antibiotic for 2 weeks without any resolution. A fungal culture obtained from a scaling scalp site distant from the kerion was positive for Trichophyton tonsurans, and the diagnosis was kerion. He was treated with two drops (94 mg) of saturated solution of potassium iodide (SSKI) three times daily2,3 and 2.5% selenium shampoo twice weekly.4 Two weeks later, the crusting, swelling, and adenopathy had resolved, and 2 months later the hair had regrown without scarring. CASE 2 Patient 2 was a 9-year-old African American boy who had been treated with adequate doses of griseofulvin for 4 weeks for a crusted, nodular, alopectic plaque on the posterior scalp (Figure 1) along with a markedly enlarged posterior cervical node. Bacterial and fungal cultures were negative. The clinical diagnosis was

DISCUSSION

Treatment of kerions has been directed primarily toward the underlying dermatophyte, often with protracted courses of griseofulvin; however, we believe the inflammation, rather than the infection, should be the initial focus of kerion treatment. The clinical findings and treatment outcomes for our two patients with kerion treated with short courses of anti-inflammatory agents are representative and exactly similar to the other patients with kerion seen in our clinic.

From the Department of Dermatology, Drexel University College of Medicine, Philadelphia, PA Address for Correspondence: Herbert B. Allen, MD, Department of Dermatology, Drexel University College of Medicine, 219 North Broad Street, Philadelphia, PA 19107 • E-mail: hallen@drexelmed.edu

SKINmed. 2012;10:14–16

January/February 2012

ORIGINAL CONTRIBUTION In patients treated prior to 2001, we saw complete resolution in kerions treated with SSKI in 22 of 25 patients within 2 to 4 weeks. This is similar to the resolution of kerions alluded to by Dobson2 and was also similar to the resolution routinely seen in sporotrichosis.9 The three patients who did not respond to SSKI (2 did not take it due to the taste, and 1 had worsening of his “id” reaction) had rapid clearance on prednisolone. After 2001, when SSKI became scarce because of the threat of nuclear attacks and dirty bombs, we shifted to prednisolone and noted complete response to treatment in 15 of 15 patients. With both treatment protocols, the kerions cleared and the patients’ hair subsequently regrew without scarring.

Figure 1. Case 2: Kerion before treatment shows crusted pustular plaque on posterior scalp with significant lymphadenopathy.

Two prospective randomized, controlled studies by other investigators have examined the treatment of kerions with oral doses of corticosteroids.10,11 Neither demonstrated a difference in the management of kerion between using oral corticosteroids plus griseofulvin vs griseofulvin alone. These findings are contrary to our observations that all our patients responded to short courses of anti-inflammatory agents and are also contrary to oral corticosteroids being recommended for kerions that present simultaneously with “id” eruptions,12 as well as in situations in which the kerion becomes “inflamed.”13 In addition, John Kenney (personal communication, 1983), who treated this disease in many children, routinely included oral corticoids in his regimen for kerions and saw results similar to ours. We believe the findings by some investigators11 demonstrate the natural resolution of kerions. Similarly, findings in another study10 may also show the natural resolution; moreover, their treatment protocol, which included untapered prednisone at a maximum dose of 30 mg/d for only 10 days, in our opinion, may have been insufficient.14 We believe untreated kerions require 3 to 6 months to resolve. Many case reports consistent with this concept have been published.15–17 In one of our patients, who preferred not to take prednisolone and was treated with griseofulvin alone, the kerion took 4 months to resolve. In contrast, patients treated with antiinflammatory treatment responded rapidly. CONCLUSIONS Based on our observations, we believe the addition of prednisolone to the treatment of kerions is safe and allows the duration of therapy to be dramatically shortened. Adjunctive therapy with selenium sulfide shampooing remains useful,4 and griseofulvin may be continued if scaling from tinea capitis remains after the kerion resolves.18 Further studies would help resolve the differences in the prospective trials compared with the clinical observations.

Figure 2. Case 2: Kerion shows total resolution 2 weeks after treatment with prednisone.

SKINmed. 2012;10:14–16

Treatment of Kerions

January/February 2012

ORIGINAL CONTRIBUTION REFERENCES 1

Arenas R, Toussaint S, Isa-Isa R. Kerion and dermatophytic granuloma. Mycological and histopathological findings in 19 children with inflammatory tinea capitis of the scalp. Int J Dermatol. 2006;45: 215–219.

Dobson RL. In: Dobson RL, ed. Yearbook of Dermatology. Chicago, IL: Yearbook Publishers; 1979:124.

Sterling JB, Heymann WR. Potassium iodide in dermatology: a 19th century drug for the 21st century—uses, pharmacology, adverse effects, and contraindications. J Am Acad Dermatol. 2000;43:691–697.

Allen HB, Honig PJ, Leyden JJ, McGinley KJ. Selenium sulfide: adjunctive therapy for tinea capitis. Pediatrics. 1982; 69:81–83.

Woodfolk JA, Platts-Mills TA. The immune response to dermatophytes. Res Immunol. 1998;149:436–445; discussion 522–523.

Woodfolk JA. Allergy and dermatophytes. Clin Microbiol Rev. 2005;18: 30–43.

Birt AR, Wilt JC. Mycology, bacteriology, and histopathology of suppurative ringworm. AMA Arch Derm Syphilol. 1954;69:441–448.

Rasmussen JE, Ahmed AR. Trichophytin reactions in children with tinea capitis. Arch Dermatol. 1978;114:371–372.

Sandhu K, Gupta S. Potassium iodide remains the most effective therapy for cutaneous sporotrichosis. J Dermatol Treat. 2003;14: 200–202.

10 Honig PJ, Caputo GL, Leyden JJ, et al. Treatment of kerions. Pediatr Dermatol. 1994;11:69–71. 11 Hussain I, Muzaffar F, Rashid T, et al. A randomized, comparative trial of treatment of kerion celsi with griseofulvin plus oral prednisolone vs. griseofulvin alone. Med Mycol. 1999;37:97–99. 12 Alvarez MS, Silverberg NB. Tinea capitis. In: Kelly AP, Taylor SC, eds. Dermatology for Skin of Color. New York, NY: McGraw Hill; 2009:253. 13 Tinea capitis. In: James WD, Berger TG, Elston DM, eds. Andrews’ Diseases of the Skin: Clinical Dermatology. 10th ed. Philadelphia, PA: Elsevier; 2006:298. 14 Pomeranz AJ, Sabnis SS. Tinea capitis: epidemiology, diagnosis and management strategies. Paediatr Drugs. 2002;4:779–783. 15 Van Rooij P, Detandt M, Nolard N. Trichophyton mentagrophytes of rabbit origin causing family incidence of kerion: an environmental study. Mycoses. 2006;49:426–430. 16 Schauder S. Itraconazole in the treatment of tinea capitis in children. Case reports with long-term follow-up evaluation. Review of the literature. Mycoses. 2002;45:1–9. 17 Gibbon KL, Goldsmith P, Salisbury JA, Bewley AP. Unnecessary surgical treatment of fungal kerions in children. BMJ. 2000;320:696–697. 18 Allen HB, Honig PJ. Scaling scalp diseases in children. Clin Pediatr (Phila). 1983;22:374–377.

SKINmed. 2012;10:14–16

Treatment of Kerions

ONE PRESCRIPTION. TWO POWERFUL EFFECTS. The power to calm inflammatory acne Inflammation is an important aspect in the pathophysiology of acne1 Both laboratory and clinical studies document the anti-inflammatory effects of minocycline1

Complementary T 3 Calming Wipes Soothing and alcohol-free — part of a complete approach to acne treatment

The power to eradicate P acnes Significant reduction in P acnes —even up to 3 weeks after discontinuation2 A decrease in P acnes can lead to a drop in pro-inflammatory cytokines and reduced inflammation1 Minimal resistance in an in vitro study —The majority of tetracycline-resistant P acnes were cross-resistant to doxycycline—but sensitive to minocycline*3

C ALM I NG

WI P ES (30 WIPES)

The only pelletized form of Minocycline available...

A dual approach to acne care For more information, go to www.minocin-kit.com

The most common adverse events associated with MINOCIN are nausea, vomiting, and diarrhea. CNS adverse effects may include dizziness, vertigo, and headache. Important Information The most common adverse events associated with MINOCIN are nausea, vomiting, and diarrhea. Central nervous system adverse events including light-headedness, dizziness, or vertigo have been reported with minocycline therapy, but are generally transient in nature. Other adverse events include tinnitus, headache, sedation, and skin pigmentation, particularly on the face and mucous membranes. MINOCIN is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines or to any of the components of the product formulation. WARNING: MINOCIN PelletFilled Capsules, like other tetracycline-class antibiotics, can cause fetal harm when administered to a pregnant woman. The use of drugs of the tetracycline class during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years) may cause permanent discoloration of teeth (yellow-gray-brown). Concurrent use of tetracyclines may render oral contraceptives less effective. References: 1. SapadinAN,Fleischmajer R.Tetracyclines:nonantibiotic properties and their clinical implications. JAmAcad Dermatol. 2006;54(2):258-265. 2. Leyden JJ,McGinley KJ,KligmanAM.Tetracycline and minocycline treatment. Arch Dermatol. 1982;118(1):19-22. 3. Hubbell CG,Hobbs ER,RistT,White JW Jr.Efficacy of minocycline compared with tetracycline in treatment of acne vulgaris. Arch Dermatol.1982;118(12):989-992. *In vitro activity does not necessarily correlate to in vivo activity. ©2010 Triax Pharmaceuticals, LLC

Printed in USA.

MN-0810-280

January/February 2012

Volume 10 • Issue 1

ORIGINAL CONTRIBUTION

Pityriasis Rubra Pilaris: Evolution of Challenges in Promising Treatment Options Virendra N. Sehgal, MD;1 Govind Srivastava, MD;2 Prashant Verma, MD3 ABSTRACT Pityriasis rubra pilaris is an uncommon inflammatory dermatosis that is well recognized across the globe. Erythroderma is a common presentation. A precise diagnosis of pityriasis rubra pilaris is based on morphologic features and is classified into 6 types: classic adult onset (type I), atypical adult (type II), classic juvenile (type III), circumscribed juvenile (type IV), atypical juvenile (type V), and human immunodeficiency virus–associated (type VI). Several conventional systemic and/or topical treatments are currently in use. Largely, their results are unsatisfactory and limited by long-term toxicity. The authors investigate the efficacy of a wide spectrum of drugs by examining historical (archive) and promising (modern) treatment modalities for the treatment of pityriasis rubra pilaris. (SKINmed. 2012;10:18–23)

ityriasis rubra pilaris (PRP) comprises a group of chronic disorders that demonstrate circumscribed follicular keratosis with palmoplantar keratoderma. Both familial and acquired forms have been recognized. The former is infrequent and usually occurs in childhood. The bimodal or trimodal distribution usually involves a peak case incidence in the first and second decades of life,1,2 and it affects both men and women. Its etiology and management has remained a challenge. Occasionally, PRP is associated with other diseases, and it was speculated that the disorder might be the result of an abnormal immune response to some antigenic stimuli. Familial occurrence of the disease might point to genes that predispose the individual to develop the disorder after certain precipitating events. The occurrence of PRP in patients with the human immunodeficiency virus (HIV)/AIDS is a topic of recent debate.3 METHODS

CLINICAL CRITERIA/CLASSIFICATION Management of PRP varies according to the type, extent, and age at onset of the disease. Thus, an understanding of the classification of the disease offers insight into individualizing treatment. Griffiths1 classified PRP into 6 types according to the age at onset, behavior, clinical appearance, and prognosis (Table I). Classic adult-onset PRP (type I) shows the characteristic generalized rash with palmo-plantar keratoderma, whereas atypical adultonset PRP (type II) is chronic, with ichthyosiform and lamellar scales on the palms and soles and alopecia of varying degrees. The association of PRP and HIV infection has recently been identified as type VI PRP, and most of the cases have been reported in young heterosexual/homosexual men. It is characterized by nodulocystic and lichen spinulosus–like lesions, with poor prognosis and resistance to treatment.2 Another classification5 divides the disease into 4 types based only on physical findings (Table II); however, Griffiths1 classification continues to be the mainstay in practice for delineating the disease.

Medline/PubMed (1936–2010) was searched using the terms “PRP” and “treatment.” Accordingly, this contribution outlines the published reports on the topic, with the objective to focus on the evolution and challenges of promising treatment options.

CHALLENGES AND PROMISING TREATMENTS

HISTORICALLY (ARCHIVE) IMPORTANT MODALITIES The diagnosis and treatment of PRP have always been a source of great interest. At present, there is no acclaimed treatment

From the Dermato Venereology (Skin/VD) Center, Sehgal Nursing Home, Panchwati, Azadpur, Delhi, India;1 the Skin Institute and School of Dermatology, Greater Kailash, New Delhi, India;2 Department of Dermatology, and STD University College of Medical Sciences and Associated Guru Teg Bahadur Hospital, Shahdara, Delhi, India3 Address for Correspondence: Virendra N. Sehgal MD, Dermato Venerology (Skin/VD) Center, Sehgal Nursing Home, A/6 Panchwati, Delhi, 110 033, India • E-mail: drsehgal@ndf.vsnl.net.in

SKINmed. 2012;10:18–23

03*(*/"- $0/53*#65*0/

January/February 2012

Table I. Pityriasis Rubra Pilaris: Griffiths Clinical Classification

CLINICAL TYPE

LESIONSâ&#x20AC;&#x2122; DISTRIBUTION

NATURAL COURSE

PERCENTAGE OF CASES

$MBTTJD BEVMU

(FOFSBMJ[FE

3FNJTTJPO JO o Z

"UZQJDBM BEVMU

(FOFSBMJ[FE

$ISPOJD JOUSBDUBCMF

$MBTTJD KVWFOJMF

(FOFSBMJ[FE

3FNJTTJPO JO o Z

-PDBMJ[FE

6OQSFEJDUBCMF

(FOFSBMJ[FE

$ISPOJD JOUSBDUBCMF

'BDF BOE VQQFS USVOL

3FGSBDUPSZ

*ODSFBTJOH

$JSDVNTDSJCFE KVWFOJMF "UZQJDBM )VNBO JNNVOPEFÃ«DJFODZ WJSVTo BTTPDJBUFE UZQF

GPS 131 É¨VT BÃªFDUFE JOEJWJEVBMT PGUFO WJTJU BOE TVCTFRVFOUMZ DIBOHF USFBUJOH EFSNBUPMPHJTUT UP BMMFWJBUF UIFJS TJHOT BOE TZNQUPNT .PSF PGUFO UIBO OPU JU JT BO FYFSDJTF JO GVUJMJUZ BT UIF USFBUJOH QIZTJDJBO EFSNBUPMPHJTU Ã«OET JU EJÃ¯DVMU UP USFBU *ODJEFOUBMMZ NPSF UIBO UISFF GPVSUIT PG UIF QBUJFOUT MFTJPOT SFTPMWF TQPOUBOFPVTMZ JO UIF DPVSTF PG UP ZFBST 4FWFSBM USFBUNFOU PQUJPOT BSF BWBJMBCMF 5BCMF *** +VWFOJMF 131 IBT CFFO USFBUFE VTJOH WJUBNJO " TZOUIFUJD SFUJOPJET EJFU TVQQMFNFOUT BOE JOUFOTJWF BOE WBSJFE UPQJDBM UIFSBQJFT (FOFSBM OVUSJUJPO BOE IFBMUI DBSF TIPVME CF SFDPNNFOEFE GPS BMM DIJMESFO XIFO USFBUJOH UIF EJTFBTF 0SBM WJUBNJO " DPE MJWFS PJM IBMJCVU MJWFS PJM WJUBNJO & BOE DBSPUFOF IBWF BMM CFFO USJFE XJUI WBSJBCMF SFTVMUT

0UIFS USFBUNFOU NPEBMJUJFT JODMVEF NFUIPUSFYBUF 22 DZDMPT QPSJOF " TUBOP[PMPM 25 QFOJDJMMJO BOE BOUJUVCFSDVMBS ESVHT )*7 "*%4 BTTPDJBUFE 131 JT SFDBMDJUSBOU UP UIFSBQZ )JHIMZ BDUJWF USJQMF BOUJSFUSPWJSBM ESVH UIFSBQZ IBT TIPXO QPTJUJWF SFTVMUT JO BMMFWJBUJOH TZNQUPNT BOE NBZ DBVTF DPNQMFUF SFHSFTTJPO JO TVDI QBUJFOUT

"QBSU GSPN TZNQUPNBUJD BOE TVQQPSUJWF UIFSBQZ JO FWFSZ DBTF UIF VTF PG XFMM EPDVNFOUFE NFEJDJOFT JT JOEJWJEVBMJ[FE BDDPSEJOH UP QIZTJDJBO QSFGFSFODF 'JSTU MJOF UIFSBQZ JODMVEFT SFUJOPJET BOE PS NFUIPUSFYBUF GPS B GFX XFFLT UP NPOUIT VOUJM SFNJTTJPO JT BDIJFWFE *G UIF QBUJFOU EPFT OPU SFTQPOE UP JOJUJBM USFBUNFOU TFDPOE MJOF UIFSBQZ JOPROMISING (MODERN) MODALITIES DMVEFT DZDMPTQPSJOF B[BUIJPQSJOF PS BOUJSFUSPWJSBM UIFSBQZ É¨F BEWFOU PG TZOUIFUJD SFUJOPJET IBT CSPVHIU BCPVU B SFWPMVUJPO É¨JSE MJOF UIFSBQZ XJUI DBMDJQPUSJPM BDJUSFUJO OBSSPXCBOE JO UIF UIFSBQZ GPS 131 FTQFDJBMMZ JO SFDBMDJUSBOU DBTFT *TPUSFUJOPJO 67 # 5- 21 BDJUSFUJO 67 " 28 PS FYUSBDPSQPSFBM QIPUPBU B EPTBHF PG NH LH E UP NH LH E GPS UP XFFLT IBT UIFSBQZ NBZ CF FNQMPZFE VOEFS DBSFGVM TVQFSWJTJPO QSPWFO UP CF CFOFÃ«DJBM &USFUJOBUF IBT BMTP CFFO TIPXO UP CF FÃªFDUJWF BU B EPTBHF PG NH LH E UP NH LH E GPS UP NPOUIT É¨F EV- RETINOIDS/VITAMIN A DERIVATIVES SBUJPO PG SFNJTTJPO JT WBSJBCMF É¨F TJEF FÃªFDUT PG PSBM SFUJOPJET NBZ &USFUJOBUF21 JT VTFE JO B EPTF PG NH LH UP NH LH EBJMZ XBSSBOU UIF EJTDPOUJOVBUJPO PG UIFSBQZ FTQFDJBMMZ JO DIJMESFO 15â&#x20AC;&#x201C;18 GPS VQ UP NPOUIT É¨F EPTF JT UBQFSFE HSBEVBMMZ GPMMPXJOH BE4ZOFSHJTN PG WJUBNJOT " BOE & IBT BMTP CFFO FÃªFDUJWF JO 131 8 FRVBUF SFTQPOTF *TPUSFUJOPJO PO UIF PUIFS IBOE JT FRVBMMZ FÃªFD"NPOH UIF UPQJDBM UIFSBQJFT WJUBNJO " DBMDJQPUSJPM BOE UB- UJWF JO B EPTBHF PG NH LH UP NH LH EBJMZ NFBO DBMDJUPM IBWF TIPXO QSPNJTJOH SFTVMUT 1IPUPUIFSBQZ QBSUJDVMBSMZ NH LH NH LH EBJMZ HJWFO PWFS B QFSJPE PG UP NPOUIT OBSSPX CBOE 67 # XJUI PSBM SFUJOPJET IBT CFFO TVDDFTTGVM "DJUSFUJO IBT TIPXO TBUJTGBDUPSZ SFTQPOTF JO KVWFOJMF 131 Table II. Pityriasis Rubra Pilaris: Piamphongsant and Akaraphant Classification5

168 PATIENTS TYPES

ADULTS

CHILDREN

5ZQF *

4BMNPO DPMPSFE FSZUIFNBUPVT UIJDL QMBRVFT PO UIF QBMNT BOE TPMFT FYUFOEJOH UP EPSTPQBMNBS BOE QMBOUBS KVODUJPOT

5ZQF **

4DBMZ FSZUIFNBUPVT QBUDIFT PO UIF FMCPXT BOE LOFFT

5ZQF ***

4JNJMBS UP QBUDIFT PG UZQF ** CVU JOWPMWJOH MBSHF BSFBT PG UIF USVOL ZFU OPU HFOFSBMJ[FE

5ZQF *7

SKINmed. 2012;10:18â&#x20AC;&#x201C;23

CLINICAL FEATURES

&YGPMJBUJWF FSZUISPEFSNB BTTPDJBUFE XJUI EJÃªVTF GPMMJDVMBS QMVHHJOH

1JUZSJBTJT 3VCSB 1JMBSJT

03*(*/"- $0/53*#65*0/

January/February 2012

QBUJFOUT JO B QFSJPE WBSZJOH GSPN UP XFFLT "DJUSFUJO DBO FBSMZ BT 3FDFOUMZ B ZFBS PME $BVDBTJBO XPNBO XJUI BMTP CF DPNCJOFE XJUI QIPUPUIFSBQZ BU B EPTF PG NH LH E QSPHSFTTJWF FSZUISPEFSNB BOE UZQF * 131 XBT USFBUFE FÃªFDUJWFMZ XJUI B DPNCJOBUJPO PG TZTUFNJD QFOJDJMMJO BOE WJUBNJO " 35 IMMUNOSUPPRESSIVE THERAPY .FUIPUSFYBUF IBT CFFO JO VTF GPS UIF QBTU EFDBEFT JO TFMFDU DBTFT PG 131 TOPICAL THERAPY IPXFWFS UIF SFTQPOTF IBT CFFO WBSJBCMF " DPNCJOBUJPO PG NFUIPUSFY BUF BOE PSBM SFUJOPJET IBT CFFO USJFE JO QBUJFOUT SFGSBDUPSZ UP PSBM SFUJOPJET 5PQJDBM QJNFDSPMJNVT DSFBN XBT VTFE JO B ZPVOH NBO XJUI BMPOF 4VDI B DPNCJOBUJPO IPXFWFS NBZ DBVTF TJHOJÃ«DBOU IFQBUPUPYJDJUZ 131 MJNJUFE UP UIF TDBMQ BOE GBDF É¨F MFTJPOT DMFBSFE XJUI UIF NFEJDBUJPO XJUIJO XFFLT 5PQJDBM UB[BSPUFOF USFBUNFOU XBT "[BUIJPQSJOF JO B EPTBHF PG NH UP NH EBJMZ IBT CFFO SFDPSEFE UP CF FÃªFDUJWF JO B ZFBS PME "GHIBOJ HJSM XJUI KVWFGPVOE UP CF FÃªFDUJWF JO TFWFSBM TUVEJFT 31 $ZDMPTQPSJOF JO B EPTBHF OJMF DJSDVNTDSJCFE 131 É¨F NFEJDJOF MFE UP SBQJE BOE TVTUBJOFE PG NH LH E IBT CFFO USJFE JO QBUJFOUT XJUI DMBTTJD UZQF 131 SFNJTTJPO 5PQJDBM WJUBNJO " IBT CFFO VTFE BOE DBMDJQPUSJPM8 É¨F EPTF JT UBQFSFE UP NH LH E XJUI BEFRVBUF SFTQPOTF *O BOE UBDBMDJUPM IBWF TIPXO HPPE SFTVMUT &NPMMJFOUT BOE B DPNBEEJUJPO DZDMPTQPSJOF IBT CFFO VTFE FÃªFDUJWFMZ UP USFBU B DBTF PG CJOBUJPO PG EJMVUFE UPQJDBM TUFSPJET BOE LFSBUPMZUJDT BSF XPSUI B KVWFOJMF 131 32 5PQJDBM DBMDJQPUSJPM WJUBNJO % IBT TIPXO FG- USJBM CFGPSF FNCBSLJOH PO BOZ PUIFS NPEBMJUZ 38 Ã«DBDZ JO 131 XJUIPVU TFSJPVT TJEF FÃªFDUT FYDFQU MPDBM JSSJUBUJPO 33 *O BEEJUJPO TFWFSBM PUIFS UIFSBQJFT OBNFMZ WJUBNJO " B DPNPHOTOTHERAPY CJOBUJPO PG WJUBNJOT " BOE & 8 DPE MJWFS PJM IBMJCVU MJWFS PJM 10 11 12 #SPBECBOE 67 # UIFSBQZ XBT VOTVDDFTTGVMMZ USJFE JO B DBTF PG DBSPUFOF BESFOPDPSUJDPUSPQJD IPSNPOF WJUBNJO " and 13 KVWFOJMF DMBTTJD 131 21 É¨F TBNF QBUJFOU IPXFWFS SFTQPOEFE BTDPSCJD BDJE JO UIF QSFTDSJCFE EPTBHFT XFSF VTFE JO UIF QBTU UP OBSSPXCBOE 67 # UIFSBQZ 5- XIFO DPNCJOFE XJUI UP BMMFWJBUF UIF TZNQUPNT PG 131 É¨F SFDPNNFOEFE EPTBHFT BDJUSFUJO "DJUSFUJO DPNCJOFE XJUI MPOH XBWF 67 " 67 " BOE SFTQPOTFT BSF TIPXO JO 5BCMF *** É¨FTF ESVHT BQQFBS UP IBWF CFFO SFQMBDFE JO GBWPS PG OFXFS ESVH UIFSBQJFT XBT TVDDFTTGVMMZ VTFE JO B DBTF PG DMBTTJD 131 28 &YUSBDPSQPSFBM QIPUPDIFNPUIFSBQZ IBT BMTP CFFO B TPVSDF PG BIOLOGICS JOWFTUJHBUJPO 3FDBMDJUSBOU UZQF ** DISPOJD BEVMU 131 IBT BMTP 5VNPS OFDSPTJT GBDUPS 5/' CMPDLFST BT B GFBTJCMF BMUFSOBUJWF UP CFFO USFBUFE FÃªFDUJWFMZ XJUI UIJT UIFSBQZ 131 UIFSBQZ DPOUJOVFT UP TIPX QSPNJTF TJODF JUT JODFQUJPO JO É¨F FÃ¯DBDZ PG QFOJDJMMJO BOE BOUJUVCFSDVMPVT ESVHT BT QPTTJCMF 5/' JT B DZUPLJOF JOWPMWFE JO UIF JOÃ¬BNNBUPSZ QSPDFTT UIFSBQFVUJD BHFOUT GPS UIF USFBUNFOU PG 131 XBT SFDPSEFE BT $ZUPLJOFT BSF DIFNJDBM TVCTUBODFT UIBU EFMJWFS NFTTBHFT CFUXFFO Table III. Pityriasis Rubra Pilaris: Challenges and Promising Treatmentâ&#x20AC;&#x201D;Historical (Archive) Importance

AUTHOR(S)

YEAR(S)

RECOMMENDED DRUG(S)

DOSAGE

RESPONSE/RESULT

PATIENTS

1FUUFS (VOUIFS BOE "MTUPO

7JUBNJO "

*6 QFS E Â´ XL

Good

QBUJFOUT

"ZSFT FU BM8

7JUBNJOT " BOE &

*6 o *6

4ZOFSHJTN PG WJUBNJOT " BOE &

SFQPSU

$PE MJWFS PJM

o N- E

8PSUIXIJMF

$BTF SFQPSU

#SVOTUJOH BOE 4IFBSE

)BMJCVU MJWFS PJM

o N- E

Good

â&#x20AC;&#x201C;

8FJOFS BOE -FWJO

$BSPUFOF

â&#x20AC;&#x201C;

(PPE JO TPNF DBTFT

â&#x20AC;&#x201C;

8FCTUFS BOE 'BML12

"$5) WJUBNJO "

*6 PG WJUBNJO " o VOJUT PG BESFOPDPSUJDPUSPQJD IPSNPOF XL

'BWPSBCMF

QBUJFOUT

*SHBOH13

"TDPSCJD BDJE

0SBM JOUSBNVTDVMBS NH H

6TFGVM JO JTPMBUFE DBTFT

â&#x20AC;&#x201C;

8BUU BOE +JMTPO

1FOJDJMMJO BOE BOUJUVCFSDVMBS

1FOJDJMMJO 7 H E VTVBM BOUJUVCFSDVMBS NFEJDBUJPO

&RVJWPDBM

QBUJFOUT

4LJOOFS FU BM 10

"CCSFWJBUJPOT "$5) BESFOPDPSUJDPUSPQJD IPSNPOF *6 JOUFSOBUJPOBM VOJU

SKINmed. 2012;10:18â&#x20AC;&#x201C;23

1JUZSJBTJT 3VCSB 1JMBSJT

03*(*/"- $0/53*#65*0/

January/February 2012

Table IV. Pityriasis Rubra Pilaris (PRP): Challenges and Promising Treatmentâ&#x20AC;&#x201D;Modern Modalities

AUTHOR(S)

YEAR

RECOMMENDED DRUG(S)

DOSAGE

RESPONSE/RESULT

PATIENTS

&YUSBDPSQPSFBM QIPUPDIFNPUIFSBQZ

â&#x20AC;&#x201C;

.FUIPUSFYBUF

o NH XL

&RVJWPDBM HPPE

â&#x20AC;&#x201C;

"[BUIJPQSJOF

o NH E

Good

3FWJFX

2000

$ZDMPTQPSJOF

NH LH E

(PPE JO SFDBMDJUSBOU 131

$BTF SFQPSU

4ZTUFNJD QSFEOJTPMPOF

o NH LH

6TFGVM JO TPNF DBTFT

QBUJFOUT

4UBOP[PMPM

NH E

(PPE SFTVMU JO TPNF DBTFT

$BTF SFQPSU

7BO EF ,FSLIPG BOE 4UFJKMFO

$BMDJQPUSJPM

5PQJDBM PJOUNFOU EBJMZ

(PPE JO MPDBMJ[FE DBTF

$BTF SFQPSU

)FSCTU FU BM28

2000

3FUJOPJE 67 MJHIU

"DJUSFUJO 67 " NH L E

(PPE SFTVMU

$BTF SFQPSU

,JSCZ BOE 8BUTPO21

2000

"DJUSFUJO BOE OBSSPXCBOE 67 #

"DJUSFUJO NH LH E

&ÃªFDUJWF

â&#x20AC;&#x201C;

$PSBT 7PHU FU BM

2005

'VNBSJD BDJE

)PGFS FU BM

"OEFSTPO30 )VOUFS BOE 'PSCFT

6TVLJ FU BM

-JN BOE É¨BN #SJDF BOE 4QFODFS

â&#x20AC;&#x201C;

6TFGVM

â&#x20AC;&#x201C;

&YUSBDPSQPSFBM QIPUPDIFNPUIFSBQZ

+ DN /mo on DPOTFDVUJWF EBZT

(PPE SFTVMU JO JTPMBUFE DBTFT

â&#x20AC;&#x201C;

"DJUSFUJO BOE FUBOFSDFQU

â&#x20AC;&#x201C;

$MJOJDBM JNQSPWFNFOU

â&#x20AC;&#x201C;

,FSS BOE 'FSHVTPO

*OUSBWFOPVT JNNVOPHMPCVMJO

â&#x20AC;&#x201C;

7FSZ FÃªFDUJWF

â&#x20AC;&#x201C;

(SFHPSJPV FU BM

1JNFDSPMJNVT DSFBN

DSFBN

$MFBSFE DPNQMFUFMZ

$BTF SFQPSU

*OÃ¬JYJNBC

4VDDFTTGVM

2008

*OÃ¬JYJNBC

7FSZ TVDDFTTGVM

2008

*OÃ¬JYJNBC

)BFOTTMF FU BM

%BWJT FU BM50

3VJ[ (FOBP FU BM

.VMMFS FU BM

3V[[FUUJ FU BM

&ÃªFDUJWF B C

$PY FU BM

2008

&UBOFSDFQU

4FDLJO FU BM

2008

&UBOFSDFQU

4VDDFTTGVM

,BSJNJBO 5FIFSBOJ FU BM

2008

5PQJDBM UB[BSPUFOF

&ÃªFDUJWF

$JSDVNTDSJCFE KVWFOJMF 131

#BSUI FU BM

*OÃ¬JYJNBC BOE NFUIP USFYBUF

*OÃ¬JYJNBC NH LH .FUIPUSFYBUF o NH XL

*NQSPWFE

$BTF SFQPSU

0 ,BOF FU BM

"EBMJNVNBC

"EBMJNVNBCD

7FSZ FÃªFDUJWF

8BMMJOH BOE 4XJDL

7FSHJMJT ,BMOFS FU BM

"EBMJNVNBC

/BSSPXCBOE 67 #

&UBOFSDFQU

"EBMJNVNBC

4VDDFTTGVM

$MFBSFE JO NPOUIT

$BTF SFQPSU

Continued Â» SKINmed. 2012;10:18â&#x20AC;&#x201C;23

1JUZSJBTJT 3VCSB 1JMBSJT

03*(*/"- $0/53*#65*0/

January/February 2012

1PQPWB FU BM35

1FOJDJMMJO BOE WJUBNJO "

*OUSBWFOPVT PS JOUSBNVTDVMBS QFOJDJMMJO

(BSDPWJDI FU BM

2010

5VNPS OFDSPTJT GBDUPSoa BOUBHPOJTUΉ*OìJYJNBC BMPOF PS JO DPNCJOBUJPO XJUI BDJUSFUJO

NH LH NH LH E

4VDDFTTGVM JO SFGSBDUPSZ BEVMU POTFU 131 SBOHF o XL

QBUJFOUT

a &UBOFSDFQU TJOHMF VTF QSFëMMFE TZSJOHFT BSF BWBJMBCMF JO NH N- PG B NH N- TPMVUJPO PG FUBOFSDFQU BOE NH N- PG B NH N- TPMVUJPO PG FUBOFSDFQU EPTBHF TUSFOHUIT b&UBOFSDFQU TJOHMF VTF QSFëMMFE BVUPJOKFDUPST BSF BWBJMBCMF JO NH N- PG B NH N- TPMVUJPO PG FUBOFSDFQU D"EBMJNVNBC JT TVQQMJFE BT B TUFSJMF QSFTFSWBUJWF GSFF TPMVUJPO PG BEBMJNVNBC GPS TVCDVUBOFPVT BENJOJTUSBUJPO "EVMU EPTBHF TJOHMF VTF QSFëMMFE QFO PS B TJOHMF EPTF N- QSFëMMFE HMBTT TZSJOHF &ODMPTFE XJUIJO UIF QFO JT B TJOHMF VTF N- QSFëMMFE HMBTT TZSJOHF ɨF TPMVUJPO JT DMFBS BOE DPMPSMFTT BOE IBT B Q) PG BQQSPYJNBUFMZ

DFMMT JO UIF CPEZ "DDPSEJOHMZ 5/' ESVHT UBSHFU UIF FêFDUT PG 5/' ɨF GVTJPO QSPUFJO FUBOFSDFQU BOE SFDPNCJOBOU NPOPDMPOBM BOUJCPEJFT JOìJYJNBC o BOE BEBMJNVNBC BSF DVSSFOUMZ BWBJMBCMF GPS VTF BT B UIFSBQFVUJD NPEBMJUZ GPS 131 *O BEEJUJPO JOUSBWFOPVT JNNVOPHMPCVMJO IBT CFFO TVDDFTTGVMMZ VTFE JO UZQF ** BEVMU POTFU 131

BNJMJBM PDDVSSFODF PG UIF EJTFBTF NJHIU QPJOU UP HFOFT UIBU QSF' EJTQPTF UIF JOEJWJEVBM UP EFWFMPQ UIF EJTPSEFS BGUFS DFSUBJO QSFDJQJUBUJOH FWFOUT ɨF PDDVSSFODF PG UIF EJTFBTF JO QBUJFOUT XJUI )*7 "*%4 IBT TQBSLFE EFCBUF BT UP XIFUIFS JU JT ZFU BOPUIFS WBSJBOU PG 131 4FWFSBM EJTUJODUJWF GFBUVSFT SFDPHOJ[F UIF FOUJUZ

$POWFOUJPOBM TZTUFNJD BOE PS UPQJDBM USFBUNFOUT BSF QSFWBMFOU " DPNCJOBUJPO PG JOìJYJNBC BOE NFUIPUSFYBUF QSPWFE UP CF CFO- -BSHFMZ UIFJS SFTQPOTF JT VOTBUJTGBDUPSZ BOE MJNJUFE CZ MPOH UFSN FëDJBM JO B ZFBS PME XPNBO XJUI FSZUISPEFSNB EVF UP 131 UPYJDJUZ BGUFS TIF GBJMFE UP SFTQPOE UP JOUSBWFOPVT NFUIPUSFYBUF o $POTFRVFOUMZ FNFSHJOH USFBUNFOUT XBSSBOU FêPSU UP CSJOH JOUP 4JNJMBSMZ UZQF *** 131 IBT CFFO USFBUFE TVDDFTTGVMMZ XJUI UIJT MJHIU UIF OFXFS QSPNJTJOH NPEFSO ESVHT JO UIF CBDLHSPVOE PG ESVH &UBOFSDFQU IBT BMTP CFFO USJFE XJUI TVDDFTT CPUI JO IJTUPSJDBM BSDIJWF POFT *OEFFE JU JT OFDFTTBSZ UP FOMJHIUFO QIZKVWFOJMF BOE BEVMU POTFU 131 "EBMJNVNBC USFBUNFOU PG 131 TJDJBOT BCPVU UIF UVSOPWFS PG ESVHT GPS 131 JO PSEFS UP FWPMWF DBVTFE B SBQJE BOE TVTUBJOFE SFNJTTJPO PG UIF EJTFBTF B WJBCMF BOE BDDFQUBCMF UIFSBQZ GPS JUT USFBUNFOU ɨF BEWFOU PG 3FDFOUMZ 5/' BOUBHPOJTUT JOìJYJNBC BOE FUBOFSDFQU XFSF 5/' CMPDLFST IBT CFFO IBJMFE BT B NBKPS CSFBLUISPVHI "DDPSEVTFE JO QBUJFOUT XJUI BEVMU POTFU 131 XIP XFSF SFTJTUBOU PS JO- JOHMZ MJUFSBUVSF TDBOOFE UISPVHI B .FEMJOF TFBSDI IBT SFWFBMFE FMJHJCMF GPS DPOWFOUJPOBM TZTUFNJD USFBUNFOU 'PMMPX VQ XBT QFS- PVUTUBOEJOH DPOUSJCVUJPOT JO UIF QBTU ZFBST *OìJYJNBC GPSNFE BGUFS DPNQMFUF SFNJTTJPO BOE USFBUNFOU EJTDPOUJOVBUJPO FUBOFSDFQU BOE BEBMJNVNBC BSF TPNF PG UIF GBTDJOBUJOH ESVHT 4JY QBUJFOUT PCUBJOFE DPNQMFUF SFNJTTJPO BGUFS B TJOHMF DPVSTF UIBU OFFE UP CF MPPLFE JOUP KVEJDJPVTMZ JO UFSNT PG EPTBHFT EVSBPG BOUJo5/' UIFSBQZ NFBO UIFSBQZ EVSBUJPO XBT XFFLT UJPO BOE MPOH UFSN GPMMPX VQ GPS 131 SBOHF UP XFFLT "MM QBUJFOUT PCUBJOFE TJHOJëDBOU DMFBSJOH XJUI JNQSPWFNFOU JO ǚ PG CPEZ TVSGBDF BSFB BU XFFL REFERENCES 0OMZ B TJOHMF QBUJFOU IBE EJTFBTF SFMBQTF BU UIF GPMMPX VQ QFSJPE 1 Griffiths WA. Pityriasis rubra pilaris–an historical approach. 2. Clinical features. Clin Exp Dermatol. 1976;1:37–50. PG NPOUIT ɨF JOGPSNBUJPO PO CJPMPHJDT BT B USFBUNFOU NP2 Sehgal VN, Srivastava G, Dogra S. Adult onset pityriasis rubra pilaris. EBMJUZ JO 131 JT PVUMJOFE JO 5BCMF *7 Indian J Dermatol Venereol Leprol. 2008;74:311–321.

FIVEYEAR VIEW 4JODF UIF ëSTU SFQPSUFE DBTF PG UIF EJTFBTF 131 IBT SFNBJOFE B DPOTJTUFOUMZ SFDPSEFE BOE SFTFBSDIFE FOUJUZ *UT FUJPMPHZ BOE NBOBHFNFOU IBT BMXBZT CFFO B DIBMMFOHF *U JT TFFO JO BEVMUT BT XFMM BT DIJMESFO 0DDBTJPOBMMZ 131 NBZ CF BTTPDJBUFE XJUI PUIFS EJTFBTFT BOE JU JT TQFDVMBUFE UIBU UIF EJTPSEFS NBZ CF UIF SFTVMU PG BO BCOPSNBM JNNVOF SFTQPOTF UP BOUJHFOJD TUJNVMBUJPO

SKINmed. 2012;10:18–23

.JSBMMFT &4 /VOF[ . %F -BT )FSBT .& FU BM 1JUZSJBTJT SVCSB QJlaris and human immunodeficiency virus infection. Br J Dermatol. 1995;133:990–993.

4BODIF[ 3FHBOB . 'VFOUFT $( $SFVT - FU BM 1JUZSJBTJT SVCSB QJMBSJT and HIV infection: a part of the spectrum of HIV-associated follicular syndrome. Br J Dermatol. 1995;135:818–819.

Piamphongsant T, Akarphant R. Pityriasis rubra pilaris: a new proposed classification. Clin Exp Dermatol. 1994;19:134–138.

Petter MF. Pityriasis rubra pilaris, with particular reference to vitamin medication and dietary control. Penn Med J. 1936;39:864–866.

1JUZSJBTJT 3VCSB 1JMBSJT

03*(*/"- $0/53*#65*0/

January/February 2012 7

Gunther S, Alston W. Follicular keratoses. Pilot studies of serum level of vitamin A and liver function tests during administration of retinoic acid in hyperkeratosis follicularis et parafollicularis (Kyrleâ&#x20AC;&#x2122;s disease), pityriasis rubra pilaris, and keratosis follicularis (Darierâ&#x20AC;&#x2122;s disease). Dermatologica. 1973;147:274â&#x20AC;&#x201C;283.

Ayres S Jr, Mihan R, Scribner MD. Synergism of vitamin A and & XJUI EFSNBUPMPHJD BQQMJDBUJPO Cutis. 1979;23:600â&#x20AC;&#x201C;603, 689â&#x20AC;&#x201C;690.

4LJOOFS 3# +S 3PTFOCFSH &8 1VDFWJDI .7 FU BM $PE MJWFS PJM BOE TLJO diseases. J Am Acad Dermatol. 1981;5:222.

10 #SVOTUJOH -" 4IFBSE $ %BSL BEBQUBUJPO JO QJUZSJBTJT SVCSB QJMBSJT Arch Dermatol Syphilol. 1941;43:42â&#x20AC;&#x201C;61. 11 8FJOFS "- -FWJO "" 1JUZSJBTJT SVCSB QJMBSJT PG GBNJMJBM UZQF FYQFSJence in therapy with carotene and vitamin A. Arch Dermatol Syphilol. 1943;48:288â&#x20AC;&#x201C;296. 12 Webster JR, Falk AB. Pityriasis rubra pilaris; clinical and laboratory observation on combined treatment with corticotropin and vitamin A. AMA Arch Dermatol Syphilol. 1952;65:685â&#x20AC;&#x201C;700.

31 Hunter GA, Forbes IJ. Treatment of pityriasis rubra pilaris with azathioprine. Br J Dermatol. 1972;87:42â&#x20AC;&#x201C;45. 32 Wetzig T, Sticherling M. Juvenile pityriasis rubra pilaris: successful treatment with ciclosporin. Br J Dermatol. 2003;149:202â&#x20AC;&#x201C;203. 33 7BO EF ,FSLIPG 1$ 4UFJKMFO 1. 5PQJDBM USFBUNFOU PG QJUZSJBTJT SVCSB pilaris with calcipotriol. Br J Dermatol. 1994;130:675â&#x20AC;&#x201C;678. 34 )BFOTTMF )" #FSUTDI )1 &NNFSU 4 FU BM &YUSBDPSQPSFBM QIPUPDIFNPUIFSBQZ GPS UIF USFBUNFOU PG FYBOUIFNBUJD QJUZSJBTJT SVCSB QJMBSJT Clin Exp Dermatol. 2004;29:244â&#x20AC;&#x201C;246. 35 1PQPWB - %BSMFOTLJ 3 5TBOLPW / 1FOJDJMMJO BOE WJUBNJO " BT QPTTJCMF therapeutic agents in pityriasis rubra pilaris. J Dtsch Dermatol Ges. 2010;8:354â&#x20AC;&#x201C;356. 36 (SFHPSJPV 4 "SHZSJPV ( $ISJTUPĂĽEPV & 7SBOPV " 3JHPQPVMPT % 5SFBUment of pityriasis rubra pilaris with pimecrolimus cream 1%. J Drugs Dermatol. 2007;6:340â&#x20AC;&#x201C;342.

13 Irgang S. Pityriasis rubra pilaris responsive to ascorbic acid. Australas J Dermatol. 1968;9:211â&#x20AC;&#x201C;217. 14 8BUU 5- +JMMTPO 0' 1JUZSJBTJT SVCSB QJMBSJToQFOJDJMMJO BOE BOUJUVCFS DVMBS drugs as possible therapeutic agents. Arch Dermatol. 1965;92:428â&#x20AC;&#x201C;430. 15 'MFJTTJOFS + )BQQMF 3 &USFUJOBUF JO UIF USFBUNFOU PG KVWFOJMF QJUZSJBTJT rubra pilaris. Arch Dermatol. 1981;117:749â&#x20AC;&#x201C;750. 16 'VJ[J "' "MUPNBSB ( #FSHBNBTDIJNJ - FU BM 1JUZSJBTJT SVCSB QJMBSJT BOE the retinol binding protein. Br J Dermatol. 1981;104:253â&#x20AC;&#x201C;256. 17 (PMETNJUI -" 8FJOJSJDI "& 4IVQBDL + 1JUZSJBTJT SVCSB QJMBSJT SFTQPOTF UP 13-cis-retinoic acid (isotretinoin). J Am Acad Dermatol. 1982;6:710â&#x20AC;&#x201C;715. 18 4FIHBM 7/ 4SJWBTUBWB ( "HHBSXBM ", FU BM &GĂĽDBDZ PG JTPUSFUJOPJO JO QJUZriasis rubra pilaris: unapproved use. Int J Dermatol. 2006;45:1238â&#x20AC;&#x201C;1240. 19 7BO EFS ,FSLIPG 1$ 4UFJKMFO 1. 5PQJDBM USFBUNFOU PG QJUZSJBTJT SVCSB pilaris with calcipotriol. Br J Dermatol. 1994;130:675â&#x20AC;&#x201C;678. 20 Vergilis-Kalner IJ, Mann DJ, Wasserman J, Petronic-Rosic V, Tsoukas MM. Pityriasis rubra pilaris sensitive to narrow band-ultraviolet B light therapy. J Drugs Dermatol. 2009;8:270â&#x20AC;&#x201C;273. 21 Kirby B, Watson R. Pityriasis rubra pilaris treated with acitretin and OBSSPX CBOE VMUSBWJPMFU # 3F 5- Br J Dermatol. 2000;142:376â&#x20AC;&#x201C;377. 22 Hanke CW, Steck WD. Childhood-onset pityriasis rubra pilaris treated with NFUIPUSFYBUF BENJOJTUFSFE JOUSBWFOPVTMZ Cleve Clin Q. 1983;50:201â&#x20AC;&#x201C;203. 23 Wetzig T, Sticherleng M. Juvenile pityriasis rubra pilaris: successful treatment with cyclosporine. Br J Dermatol. 2003;149:202â&#x20AC;&#x201C;203. 24 Usuki K, Sekiyama M, Shimada T, et al. Three cases of pityriasis rubra pilaris successfully treated with cyclosporine A. Dermatology. 2000;200:324â&#x20AC;&#x201C;327. 25 #SJDF 4- 4QFODFS 4, 4UBOP[PMPM JO UIF USFBUNFOU PG QJUZSJBTJT SVCSB pilaris. Arch Dermatol. 1985;121:105â&#x20AC;&#x201C;106. 26 (PO[BMF[ -PQF[ " 7FMBTFT & 1P[P 5 FU BM )*7 BTTPDJBUFE QJUZSJBTJT rubra pilaris responsive to triple anti-retroviral therapy. Br J Dermatol. 1999;140:931â&#x20AC;&#x201C;934. 27 Bonomo RA, Kormam N, Nagashima-Wholen I, et al. Pityriasis rubra pilarisâ&#x20AC;&#x201C;an unusual cutaneous complication of AIDS. Am J Med Sci. 1997;314:118â&#x20AC;&#x201C;121. 28 )FSCTU 3" 7PHFMCSVDI . &IOJT " FU BM $PNCJOFE VMUSBWJPMFU " radiation and acitretin therapy as a treatment option for pityriasis rubra pilaris. Br J Dermatol. 2000;142:574â&#x20AC;&#x201C;575. 29 )PGFS " .VMMFHHFS 3 ,FSM ) FU BM &YUSBDPSQPSFBM QIPUPDIFNPUIFSBQZ for the treatment of erythrodermic pityriasis rubra pilaris. Arch Dermatol. 1999;135:475â&#x20AC;&#x201C;476.

SKINmed. 2012;10:18â&#x20AC;&#x201C;23

30 "OEFSTPO '& 1JUZSJBTJT SVCSB QJMBSJT USFBUFE XJUI NFUIPUSFYBUF Aust J Dermatol. 1966;8:183â&#x20AC;&#x201C;185.

37 ,BSJNJBO 5FIFSBOJ % 1BSJTTB . 5BOFX " 3FTQPOTF PG KVWFOJMF DJSDVNscribed pityriasis rubra pilaris to topical tazarotene treatment. Pediatr Dermatol. 2008;25:125â&#x20AC;&#x201C;126. 38 Raza N, Bari AU, Dar NR. Juvenile onset classical pityriasis rubra pilaris: every patient may not require systemic therapy. J Coll Physicians Surg Pak. 2007;17:564â&#x20AC;&#x201C;565. 39 3VJ[ (FOBP %1 -PQF[ &TUFCBSBO[ +- /B[ 7JMMBMCB & FU BM 1JUZSJBTJT SVCSB QJMBSJT TVDDFTTGVMMZ USFBUFE XJUI JOĂ˝JYJNBC Acta Derm Venereol. 2007;87:552â&#x20AC;&#x201C;553. 40 $PY 7 -FTFTLZ &# (BSDJB #% FU BM 5SFBUNFOU PG KVWFOJMF QJUZSJBTJT SVCSB pilaris with etanercept. J Am Acad Dermatol. 2008;59:113â&#x20AC;&#x201C;114. 41 4FDLJO % 5VMB & &SHVO 5 4VDDFTTGVM VTF PG FUBOFSDFQU JO UZQFĂš * QJUZSJBTJT rubra pilaris. Br J Dermatol. 2008;158:642â&#x20AC;&#x201C;644. 42 Barth D, Harth W, Treudler R, et al. Successful treatment of pityriasis SVCSB QJMBSJT UZQF VOEFS DPNCJOBUJPO PG JOĂ˝JYJNBC BOE NFUIPUSFYBUF J Dtsch Dermatol Ges. 2009;7:1071â&#x20AC;&#x201C;1073. 43 .VMMFS ) (BUUSJOHFS $ ;FMHFS # FU BM *OĂ˝JYJNBC NPOPUIFSBQZ BT ĂĽSTU MJOF treatment for adult-onset pityriasis rubra pilaris: case report and review of the literature on biologic therapy. J Am Acad Dermatol. 2008;59: 65â&#x20AC;&#x201C;70. 44 3V[[FUUJ . 4BSBDFOP 3 $BSCPOJ * FU BM 5ZQF *** KVWFOJMF QJUZSJBTJT SVCSB QJMBSJT B TVDDFTTGVM USFBUNFOU XJUI JOĂ˝JYJNBC J Eur Acad Dermatol Venereol. 2008;22:117â&#x20AC;&#x201C;118. 45 Garcovich S, Di Giampetruzzi AR, Antonelli G, Garcovich A, Didona B. Treatment of refractory adult-onset pityriasis rubra pilaris with TNFalpha antagonists: a case series. J Eur Acad Dermatol. 2010;24: 881â&#x20AC;&#x201C;884. 46 0 ,BOF % %FWFSFVY $& 8BMTI .: FU BM 3BQJE BOE TVTUBJOFE SFNJTTJPO of pityriasis rubra pilaris with adalimumab treatment. Clin Exp Dermatol. 2009;35:e155â&#x20AC;&#x201C;e156. 47 8BMMJOH )8 4XJDL #- 1JUZSJBTJT SVCSB QJMBSJT SFTQPOEJOH SBQJEMZ UP BEBMJmumab. Arch Dermatol. 2009;145:99â&#x20AC;&#x201C;101. 48 Kerr AC, Ferguson J. Type II adult-onset pityriasis rubra pilaris successfully treated with intravenous immunoglobulin. Br J Dermatol. 2007;156:1055â&#x20AC;&#x201C;1056. 49 -JN +5 5IBN 4/ 1JUZSJBTJT SVCSB QJMBSJT JO 4JOHBQPSF Clin Exp Dermatol. 1991;16:181â&#x20AC;&#x201C;184. 50 %BWJT ,' 8V ++ .VSBTF +& FU BM $MJOJDBM JNQSPWFNFOU PG QJUZSJBTJT SVCSB pilaris with combination eternacept and acitretin therapy. Arch Dermatol. 2007;143:1597â&#x20AC;&#x201C;1599.

1JUZSJBTJT 3VCSB 1JMBSJT

January/February 2012

Volume 10 • Issue 1

REVIEW

The Role of Surgical Debridement in Healing of Diabetic Foot Ulcers Katherine A. Gordon, BS; Elizabeth A. Lebrun, MD; Marjana Tomic-Canic, PhD; Robert S. Kirsner MD, PhD ABSTRACT A critical question in the treatment of chronic wounds is whether and when debridement is needed. The three most common chronic wounds are the diabetic foot ulcer (DFU), the venous leg ulcer, and the pressure or decubitus ulcer. Surgical debridement, aimed at removing necrotic, devitalized wound bed and wound edge tissue that inhibits healing, is a longstanding standard of care for the treatment of chronic, nonhealing wounds. Debridement encourages healing by converting a chronic nonhealing wound environment into a more responsive acute healing environment. While the rationale for debridement seems logical, the evidence to support its use in enhancing healing is scarce. Currently, there is more evidence in the literature for debridement for DFUs than for venous ulcers and pressure ulcers; however, the studies on which clinicians have based their rationale for debridement in DFUs possess methodologic flaws, small sample sizes, and bias. Thus, further studies are needed to develop clinical evidence for its inclusion in treatment protocols for chronic wounds. Here, the authors review the scientific evidence for debridement of DFUs, the rationale for debridement of DFUs, and the insufficient data supporting debridement for venous ulcers and pressure ulcers. (SKINmed. 2012;10:24–26)

question commonly encountered when treating chronic wounds is whether and when debridement is needed. The 3 most common chronic wounds are the diabetic foot ulcer (DFU), the venous leg ulcer, and the pressure or decubitus ulcer. The former 2 chronic wounds have been more extensively studied. Using DFU as an example, certainly the question is of importance, considering that an estimated 15% of the 170 million people currently with diabetes mellitus will develop a foot ulcer during their lifetime.1,2

Debridement encourages healing by converting a chronic nonhealing wound environment into a more responsive acute healing environment.6 Debridement is included in multiple guidelines for the care of DFUs, including the American Diabetes Association, the American College of Foot and Ankle Surgeons, and the Wound Healing Society; however, herein lies the issue: while the rationale for debridement seems logical, the evidence to support its use in enhancing healing is scarce.

The multifactor etiology of DFUs includes peripheral vascular disease along with sensory, motor, and autonomic neuropathy.3 DFUs are a major cause of morbidity and mortality due to increased amputations, infections, and hospitalizations in diabetic patients.4

REVIEW OF CURRENT LITERATURE

At first glance it would seem to be a rather simple question. Surgical debridement is a longstanding standard of care for DFUs, aimed at removing necrotic, devitalized wound bed and wound edge tissue that inhibits healing. Such tissue includes hyperkeratotic epidermis (callus) and necrotic dermal tissue, foreign debris, and harmful bacterial elements.5 Various debridement methods exist, including surgery, wet-to-dry dressings, biosurgery (ie, maggots), enzyme preparations, polysaccharide beads or paste dextranomer polysaccharide, and hydrogels.3 This contribution focuses on surgical debridement.

Many studies on which clinicians have based their rationale for debridement possess methodologic flaws, small sample sizes, and bias.3 A recent paper7 systematically reviewed 5 published clinical trials that investigated surgical debridement of DFUs to enhance healing.5,8,9 These clinical trials were found to be defective in their methodology, statistically insignificant, or lacking in definitive scientific evidence for surgical debridement in the treatment of DFUs.7 In addition, most existing studies are not randomized clinical trials optimized to test the relationship between debridement of DFUs and wound healing. A focused, well-designed study is needed, therefore, to elucidate the effect of surgical debridement on the healing status of chronic wounds.

From the Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL Address for Correspondence: Robert S. Kirsner, MD, PhD, Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine, 1600 NW 10th Avenue, RMSB, Room 2023-A, Miami, FL 33136 • E-mail: rkirsner@med.miami.edu

SKINmed. 2012;10:24–26

January/February 2012

REVIEW

SCIENTIFIC EVIDENCE FOR DFU DEBRIDEMENT The biological and molecular basis for debridement has been investigated in several studies.10,11 Molecular and histologic analyses of biopsies from the nonhealing edge of a chronic wound have been suggested to validate the use of debridement.10 Keratinocytes become activated following wounding and are key players in restoring the epidermal barrier during wound healing.12 Keratinocytes and fibroblasts at the nonhealing edges of chronic wounds were shown to exhibit not only a pathogenic phenotype detrimental to healing but also a slowed migratory capacity.10–13 In chronic wounds, the keratinocytes multiply at a higher rate than usual (hyperproliferation), yet they are unable to migrate into the wound as would be normally expected.10–13 Basically, keratinocytes on a chronic wound edge are capable of proliferating but are unable to migrate properly.12 These nonhealing keratinocytes of the chronic wound edge are marked by induction of c-Myc and nuclearization of β-catenin, which may contribute to the inhibition of migration.10–12 Many clinicians visually identify this nonhealing phenotype as a “callus,” indicating the need for removal to facilitate wound healing.14 Debridement seems to be a reasonable solution to the problem of nonmigratory tissue in the margins of chronic wounds. Researchers suggest that debridement will be effective if unresponsive cells are surgically removed, and cells responsive to wound healing signals and topical agents are optimized.11 RATIONALE FOR DEBRIDEMENT OF DFUS The benefits of debridement include removal of bacteria, senescent cells, and hyperproliferative nonmigratory tissue and stimulation of growth factor activity.15 Bacterial burden in a wound likely impedes healing,16 as greater bacterial load and certain types of bacteria have been shown to reduce healing responses.17,18 Bacteria in chronic wounds stimulate a prolonged inflammatory response with a concomitant release of free oxygen radicals and various lytic enzymes, ultimately causing tissue damage.19 In addition, biofilms, which are communities of bacteria and other organisms embedded in an extrapolysaccharide matrix within the wound bed, show increased resistance to antimicrobial agents and to the host immune system.20,21 Debridement is an effective way to remove bacterial burden and biofilms from nonhealing wounds.

Senescent cells have markedly decreased proliferation and protein production.17 Chronic wound fibroblasts are less receptive to growth factor stimuli,25 making these wounds less likely to heal or respond to treatments.26 Overall, debridement removes both the hyperproliferative edge and the senescent cells of the chronic wound, thus allowing the remaining cells to undergo normal proliferation, migration, response to treatment, and healing. DEBRIDEMENT AND VENOUS ULCERS Another example of a chronic wound is venous ulcer. Venous insufficiency is the most common cause of lower-extremity ulcers and accounts for the development of approximately 1 million venous ulcers in patients in the United States with venous insufficiency.27 There are many theories for the mechanism of venous ulcer development, including pericapillary fibrin cuff deposition, abnormalities of the fibrinolytic system, trapping of growth factors by macromolecules in the dermis, and leukocyte plugging in the vessels of the lower extremities.28–30 The treatment modalities for venous ulcers include bed rest with leg elevation31; compression therapy32; aspirin33; pentoxifylline34; skin grafting,35 including cultured epidermal autografts and allografts36,37; superficial venous surgery38; and debridement.17,39 The data supporting debridement for venous ulcers are even more sparse than for DFUs. The role of debridement in the treatment of venous ulcers has not been proven, although it is used as a standard of care.39 One controlled, prospective cohort study involving 53 patients for 12 months evaluated sharp debridement in combination with standard treatment regimens for nonhealing venous leg ulcers.40 The study group contained ulcers that had slough, nonviable tissue and no granulation tissue, while the control group had ulcers with 15% to 20% granulation tissue without slough or nonviable tissue. Although they failed to reach statistical significance, the authors concluded that sharp debridement was effective at initiating the healing process. They found a 6-cm2 reduction in the mean surface area of the study group ulcers, compared with a 1-cm2 reduction in the control group in the first 4 weeks (P = .02).40 Clinical experience also dictates that venous ulcers are commonly more difficult to debride than most DFUs, and it is more time-consuming for the clinician to achieve viable tissue margins in these cases; therefore, chronic venous ulcers, much like DFUs, are in need of evidence-based standardized treatment plans.

Additionally, growth factors are reduced in chronic wounds, including platelet-derived growth factor, fibroblast growth factor, epidermal growth factor, and transforming growth factor β.22 Dead tissue within chronic wounds, which is removed by surgical debridement, is unreceptive to growth factors.23 In addition, the bleeding and platelet activation caused by debridement stimulates the production of blood-borne growth factors, further promoting wound healing.24 SKINmed. 2012;10:24–26

DEBRIDEMENT AND PRESSURE ULCERS The most common cause of chronic wounds is the pressure ulcer. While the rationale for debridement is excellent as part of standard care when treating pressure ulcers, given the multiple comorbidities coexistent in patients with pressure ulcers, the data supporting debridement for pressure ulcers are the least substantial of the 3 common chronic wounds. Surgical Debridement in DFUs

January/February 2012

REVIEW

CONCLUSIONS Surgical debridement, despite the need for better data, is part of standard care in the treatment of chronic, nonhealing wounds, with better evidence for DFUs than for venous ulcers. Some may be concerned that debridement may create a new portal of entry for bacterial organisms, but studies have shown that the rate of infection does not increase in debrided wounds.40 Debridement is relatively safe and convenient in the outpatient setting, but studies validating the effects on healing continue to be limited. While debridement continues to be a mainstay of treatment, further studies are needed to develop clinical evidence for its inclusion in treatment protocols for chronic wounds. Ideally, a randomized controlled trial would provide the necessary data for future evidence-based practice in the treatment of chronic wounds.

16 Schultz GS, Sibbald RG, Falanga V, et al. Wound bed preparation: a systematic approach to wound management. Wound Repair Regen. 2003;11 suppl 1:S1–S28. 17 Zacur H, Kirsner RS. Debridement: rationale and therapeutic options. Wounds. 2002;14(suppl E):2E–7E. 18 Bucknall TE. The effect of local infection upon wound healing: an experimental study. Br J Surg. 1980;67:851–855. 19 Robson MC, Stenberg BD, Heggers JP. Wound healing alterations caused by infection. Clin Plast Surg. 1990;17:485–492. 20 Robson MC, Heggers JP. Surgical infection. II. The beta-hemolytic streptococcus. J Surg Res. 1969;9:289–292. 21 Serralta VW, Harrison-Balestra C, Cazzaniga AL, Davis SC, Mertz M. Lifestyles of bacteria in wounds: presence of biofilms? Wounds. 2001;13:29–34. 22 Kerstein MD, Reis ED. Current surgical perspectives in wound healing. Wounds. 2001;13:53–58. 23 Mulder GD, Vande Berg JS. Cellular senescence and matrix metalloproteinase activity in chronic wounds. Relevance to debridement and new technologies. J Am Podiatr Med Assoc. 2002;92:34–37. 24 Hunt TK, Hopf H, Hussain Z. Physiology of wound healing. Adv Skin Wound Care. 2007;13(2 suppl):6–11.

REFERENCES 1

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053.

25 Hasan A, Murata H, Falabella A, et al. Dermal fibroblasts from venous ulcers are unresponsive to the action of transforming growth factor-beta 1. J Dermatol Sci. 2007;16:59–66.

American Diabetes Association. Consensus development conference on diabetic foot wound care: April 7–8, 1999; Boston, MA. Adv Wound Care. 1999;12:353–361.

26 Margolis DJ, Berlin JA, Strom BL. Which venous leg ulcers will heal with limb compression bandages? Am J Med. 2000;109:15–19.

Edwards J, Stapley S. Debridement of diabetic foot ulcers. Cochrane Database Syst Rev. 2010;(1):CD003556.

Margolis DJ, Kantor J, Berlin JA. Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. Diabetes Care. 1999;22:692–695.

Cardinal M, Eisenbud DE, Armstrong DG, et al. Serial surgical debridement: a retrospective study on clinical outcomes in chronic lower extremity wounds. Wound Repair Regen. 2009;17:306–311.

27 Valencia IC, Falabella A, Kirsner RS, Eaglstein WH. Chronic venous insufficiency and venous leg ulceration. J Am Acad Dermatol. 2001;44: 401–421; quiz 422–424. 28 Falanga V, Eaglstein WH. The “trap” hypothesis of venous ulceration. Lancet. 1993;341:1006–1008. 29 Browse NL, Burnand KG. The cause of venous ulceration. Lancet. 1982;2:243–245. 30 Thomas PR, Nash GB, Dormandy JA. White cell accumulation in dependent legs of patients with venous hypertension: a possible mechanism for trophic changes in the skin. Br Med J (Clin Res Ed). 1988;296:1693–1695.

Golinko MS, Joffe R, Maggi J, et al. Operative debridement of diabetic foot ulcers. J Am Coll Surg. 2008;207:e1–e16.

Lebrun E, Tomic-Canic M, Kirsner RS. The role of surgical debridement in healing of diabetic foot ulcers. Wound Repair Regen. 2010;18:433–438.

31 Abu-Own A, Scurr JH, Coleridge Smith PD. Effect of leg elevation on the skin microcirculation in chronic venous insufficiency. J Vasc Surg. 1994;20:705–710.

Steed DL, Donohoe D, Webster MW, Lindsley L. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group. J Am Coll Surg. 1996;183:61–64.

32 Blair SD, Wright DD, Backhouse CM, Riddle E, McCollum CN. Sustained compression and healing of chronic venous ulcers. BMJ. 1988;297:1159–1161.

Piaggesi A, Schipani E, Campi F, et al. Conservative surgical approach versus non-surgical management for diabetic neuropathic foot ulcers: a randomized trial. Diabet Med. 1998;15:412–417.

33 Layton AM, Ibbotson SH, Davies JA, Goodfield MJ. Randomised trial of oral aspirin for chronic venous leg ulcers. Lancet. 1994;344:164–165.

10 Piaggesi A, Viacava P, Rizzo L, et al. Semiquantitative analysis of the histopathological features of the neuropathic foot ulcer: effects of pressure relief. Diabetes Care. 2003;26:3123–3128. 11 Saap LJ, Falanga V. Debridement performance index and its correlation with complete closure of diabetic foot ulcers. Wound Repair Regen. 2002;10:354–359. 12 Brem H, Stojadinovic O, Diegelmann RF, et al. Molecular markers in patients with chronic wounds to guide surgical debridement. Mol Med. 2007;13:30–39. 13 Stojadinovic O, Brem H, Vouthounis C, et al. Molecular pathogenesis of chronic wounds: the role of beta-catenin and c-myc in the inhibition of epithelialization and wound healing. Am J Pathol. 2005;167:59–69. 14 Tomic-Canic M, Ayello EA, Stojadinovic O, Golinko MS, Brem H. Using gene transcription patterns (bar coding scans) to guide wound debridement and healing. Adv Skin Wound Care. 2008;21:487–492; quiz 493–494. 15 Morasso MI, Tomic-Canic M. Epidermal stem cells: the cradle of epidermal determination, differentiation and wound healing. Biol Cell. 2005;97:173–183.

SKINmed. 2012;10:24–26

34 Jull AB, Waters J, Arroll B. Pentoxifylline for treating venous leg ulcers. Cochrane Database Syst Rev. 2002;(1):CD001733. 35 Douglas WS, Simpson NB. Guidelines for the management of chronic venous leg ulceration. Report of a multidisciplinary workshop. British Association of Dermatologists and the Research Unit of the Royal College of Physicians. Br J Dermatol. 1995;132:446–452. 36 Limova M, Mauro T. Treatment of leg ulcers with cultured epithelial autografts: treatment protocol and five year experience. Wounds. 1995;7:170–180. 37 Phillips TJ, Kehinde O, Green H, Gilchrest BA. Treatment of skin ulcers with cultured epidermal allografts. J Am Acad Dermatol. 1989;21(2 pt 1):191–199. 38 Olivencia JA. Subfascial endoscopic ligation of perforator veins (SEPS) in the treatment of venous ulcers. Int Surg. 2000;85:266–269. 39 de Araujo T, Valencia I, Federman DG, Kirsner RS. Managing the patient with venous ulcers. Ann Intern Med. 2003;138:326–334. 40 Williams D, Enoch S, Miller D, et al. Effect of sharp debridement using curette on recalcitrant nonhealing venous leg ulcers: a concurrently controlled, prospective cohort study. Wound Repair Regen. 2005;13:131–137.

Surgical Debridement in DFUs

January/February 2012

Volume 10 • Issue 1

CORE CURRICULUM Virendra N. Sehgal, MD, Section Editor

Cutaneous Tuberculosis: A Diagnostic Dilemma Virendra N. Sehgal, MD;1 Prashant Verma, MD;2 Sambit N. Bhattacharya, MD;2 Sonal Sharma, MD;3 Navjeevan Singh, MD;3 Nishant Verma, MD4

Cutaneous tuberculosis continues to be one of the most difficult conditions to diagnose. It is a challenge particularly in developing countries due to the lack of resources. The authors define the classification and clinical manifestations considered predictive of its diagnosis.

uberculosis (TB) is a common disease worldwide,1 and its clinical incidence has been impacted by the emergence of the human immunodeficiency virus (HIV), increased transmigration from endemic countries, and its transmission in health care facilities, prisons, homeless shelters, and other crowded settings.2–5 TB is largely an airborne infection; however, skin manifestations may be caused by hematogenous spread or the contiguity from latent and/or active foci of infection. Primary inoculation, although uncommon, is another known mode of transmission. HIV infection, intravenous drug abuse, diabetes mellitus, immunosuppressive therapy, malignancies, end-stage renal disease, and infancy may predispose to TB. Although cutaneous TB (CTB) is a wellrecognized clinical entity, it often poses a diagnostic dilemma for physicians6; therefore, it is important to perform a careful review of clinical presentations in each patient, which may prove predictive of its diagnosis.7,8 CLASSIFICATION

from the underlying lesion is a characteristic feature of both scrofuloderma and TB cutis orificialis (TBCO). In attempt to embellish the preceding classification, it has been divided into multibacillary and paucibacillary variants based on the bacterial load. The former is recognized by the characteristic morphology of the organism in the tissue sections stained with Ziehl-Neelsen method, complemented by in vitro recovery of M tuberculosis, while sparse bacilli on histological examination and rare in vitro culture isolation2 identify the latter. Unfortunately, it is difficult to distinguish the organisms in paucibacillary TB. CLINICAL FEATURES Although the prevalence of CTB accounts for 1.5% of all cases of TB, it is, nevertheless, important to consider the entity when patients present with a suggestive clinical morphology. CTB has many forms, including multibacillary and paucibacillary CTB, which are defined in detail below. MULTIBACILLARY CTB

The most widely accepted CTB classification is based on the route of infection.6,9 Exogenous inoculation occurs after the direct inoculation of Mycobacterium tuberculosis into the skin of a person who is susceptible to infection (vide infra). This may cause TB verrucosa cutis (TBVC), TB chancre, and some cases of lupus vulgaris (LV), whereas endogenous infection is caused by either lymphatic or hematogenous spread or a contiguous extension. Occasionally, lymphatic spread is seen in LV. Hematogenous spread, on the other hand, is responsible for acute miliary TB, metastatic tubercular abscess, gummatous TB, papulonecrotic tuberculid (PNT), and lupus vugaris. Contiguous extension

TB CHANCRE/INOCULATION TB Tuberculous chancre (primary inoculation TB) is a variant of multibacillary CTB that results from direct introduction of mycobacteria into the skin or mucosa of an individual who neither had tubercular infection in the past nor was immunized with Bacille Calmette-Guérin (BCG). Trauma also facilitates the entry of the organism into the skin.10,11 Face and other exposed areas are vulnerable sites of introduction. The organism multiplies in tissue macrophages and migrates to

From the Dermato-Venereology (Skin/VD) Center, Sehgal Nursing Home, Panchwati, Delhi;1 the Departments of Dermatology and STD2 and Pathology,3 University College of Medical Sciences and Associated Guru Teg Bahadur Hospital, Delhi; and the Department of Microbiology, Maulana Azad Medical College and Associated Chacha Nehru Bal Chikitsalaya, Delhi,4 India Address for Correspondence: Virendra N. Sehgal, MD, Dermato-Venerology (Skin/VD) Center, Sehgal Nursing Home, A/6 Panchwati, Delhi 110 033 India • E-mail: drsehgal@ndf.vsnl.net.in

SKINmed. 2012;10:28–33

January/February 2012

CORE CURRICULUM

regional lymph nodes. An inflammatory papule develops in 2 to 4 weeks after inoculation that breaks down into a firm, nonhealing, shallow, nontender, undermined ulcer with a granulomatous base. Painless regional lymphadenopathy is a cardinal sign, appearing after about 3 to 8 weeks. Numerous bacilli are demonstrable at the inoculation site and regional lymph node. The ultimate ulceroglandular lesion is a “mirror image” of the Ghon’s complex. Its clinical course varies according to the hostimmune response.12 The primary lesion heals with scarring after 1 to 3 months; however, with a less effective host-immune response, the bacterial load remains high, and healing may be delayed up to 12 months. Regional nodes may suppurate, erode, and perforate the surface of overlying skin, resulting in scrofuloderma. Latent foci of infection may persist at the site and progress to either LV or TBVC despite evident tuberculin sensitivity. Hematogenous dissemination of mycobacteria from skin can result in TB at other sites, particularly bones or joints, or progress to acute miliary disease with poor outcome.

pattern of millet-sized, multiple, tiny lesions on chest x-ray, distributed throughout the lung fields. It may hematogenously infect any number of organs including the lungs, liver, and spleen in patients with advanced TB. There is a systemic failure of the cell-mediated immune system that allows and facilitates the spread of infection, resulting in rapid deterioration and death.4,17,18 Certain events, infections, and medications that suppress the body’s cell-mediated immune system may precipitate this infection. Although miliary TB is rare and well known for its occurrence in children, it is an increasingly serious infection in immunosuppressed patients, such as those infected with HIV and those on long-term oral corticosteroid therapy or other immunosuppressive therapies for organ transplant or inflammatory and autoimmune conditions. Cutaneous skin lesions associated with miliary TB consist of small, erythematous to violaceous papules or pustules with hemorrhagic necrosis and umbilication affecting a substantial portion of the body. Healing is indicated by the presence of atrophic, depressed scars surrounded by a brownish, hyperpigmented halo.

SCROFULODERMA (TB COLLIQUATIVE CUTIS)

METASTATIC TUBERCULOUS ABSCESSES (GUMMA)

Scrofuloderma (TB colliquative cutis) is the most common form of CTB in children. It results from the direct extension from an underlying TB focus, such as a regional lymph node or infected bone or joint, to the overlying skin. Lesions present as firm, painless, subcutaneous, red-brown nodules overlying an infected focus, which gradually enlarge and suppurate, forming ulcers and sinus tracts that drain watery, purulent, and/or caseous material. The ulcers heal with typical puckered scarring.13

Metastatic tuberculous abscesses (gumma) may either arise from the breakdown of an old healed tubercle that still has live organisms or in immunocompromised individuals.2,4 Accordingly, it is usually seen in malnourished children and immunosuppressed adults.6 Single or multiple, nontender, fluctuant nodules develop, forming draining sinuses and abscesses (Figure 1). Nodules may occur at any location without specific predominance.

TB CUTIS ORIFICIALIS The lesions associated with TBCO are frequently characterized by erythematous, edematous nodules, and/or plaques. Painful central ulceration covered by necrotic pseudomembranous material with an irregular border is apparent. Constitutional symptoms of TBCO include fever, malaise, weight loss, and night sweats. The oral mucosa and tongue are the most commonly afflicted sites.2 The exact mechanism resulting in TBCO is unknown; however, ingestion of bacilli in sputum from active pulmonary TB, hematogenous and lymphatic spread, and direct spread from adjacent organs has been alleged,14 with ingestion of bacilli in sputum being the most accepted mode.15 There has been a reported case of isolated perianal TB without pulmonary or gastrointestinal involvement.16 DISSEMINATED MILIARY TB Disseminated miliary TB is characterized by a wide dissemination of M tuberculosis in the body and shows a distinctive

SKINmed. 2012;10:28–33

Figure 1. Metastatic tuberculous abscesses (gumma): a single, nontender, fluctuant nodule, draining sinus is apparent.

Cutaneous Tuberculosis

January/February 2012

CORE CURRICULUM

PAUCIBACILLARY CTB

TB VERRUCOSA CUTIS TBVC occurs after direct inoculation of M tuberculosis into the skin of previously infected individuals. It manifests as a painless, solitary, purplish or brownish red warty plaque that may extend peripherally, causing central atrophy, or form fissures that exude pus or keratinous material (Figure 2). It is often accompanied by lymphadenopathy. Skin lesions may evolve and persist for years, although spontaneous resolution may also occur. Response to treatment is favorable.6,19 LUPUS VULGARIS LV is a chronic and progressive form of CTB that is widely described as the most common form. Lesions occur on normal skin as a result of direct extension from underlying deeper TB focus, by lymphatic or hematogenous spread, after primary inoculation or BCG vaccination, or in scars of old scrofuloderma.20 Lesions are typically small, solitary, nodular, sharply defined, and reddish brown with a gelatinous consistency. “Apple-jelly” nodules present on the head and neck of individuals in Western

Figure 3. Lupus vulgaris: well-circumscribed plaque, displaying coalesce of discrete, red-brown papules, elevated verrucous border, and central atrophy.

countries, while lesions on the lower extremities or buttocks are present in individuals in tropical and subtropical areas. It has several clinical variations such as classic plaque or keratotic hypertrophic, ulcerative, and vegetating. The plaque type begins as discrete, red-brown papules that coalesce and form plaques with a slightly elevated verrucous border and central atrophy (Figure 3). Persistent lesions may damage underlying tissue and ulcerate, causing severe disfigurement and an increased risk of skin cancer.21 TUBERCULIDS The relationship between tuberculids and TB is a subject of continuing debate. They are generalized exanthems with a moderate to high degree of host immunity to TB. Patients are usually in good health and show (1) positive tuberculin skin test results; (2) inactive tuberculous involvement of viscera or lymph nodes; (3) negative staining and culture for pathogenic mycobacteria in affected tissue; and (4) skin lesions that heal with remission or treatment of TB. Its morphological variations include lichen scrofulosorum (LS),22 erythema induratum of Bazin (EIB), and PNT.

Figure 2. Tuberculosis verrucosa cutis illustrating verrucous, hyperkeratotic fissured lesions. SKINmed. 2012;10:28–33

Tuberculids may be classified into 2 groups: (1) true tuberculids, and (2) facultative tuberculids. M tuberculosis plays a major etiologic role in the former, while it is one of several possible etiologic agents in the latter. Tuberculids were once believed to be a result of hypersensitivity to the presence of mycobacterial antigens within a host of previously acquired immunity to TB; however, most are now known not to be uniquely caused by M tuberculosis. PNT and LS are still widely accepted as true tuberculids and EIB as a facultative tuberculid.22

Cutaneous Tuberculosis

January/February 2012

CORE CURRICULUM to lesions during exposure to cold weather. Lesions are chronic, slow to resolve (if at all), and result in atrophic hyperpigmented scarring after several months (Figure 5). Although patients show TB skin hypersensitivity, acid-fast bacilli (AFB) are rarely identified. A study from Spain demonstrated that about 10% of cases were positive for M tuberculosis using polymerase chain reaction (PCR).26 A case series and literature review revealed that organisms, such as Mycobacterium bovis and Mycobacterium marinum, may also be involved in the etiology of EIB, although no evidence of such was found during the investigation. It was suggested that EIB has diverse etiologies with varying pathogenesis, leading to similar histological changes, and the cases analyzed may not have had an infectious etiology (suggesting a facultative tuberculid picture).27

Figure 4. Lichen scrofulosorum: multiple, small, grouped, firm, perifollicular, lichenoid papules and/or plaques.

PAPULONECROTIC TUBERCULID

LICHEN SCROFULOSORUM

Papulonecrotic tuberculid occurs as a chronic and recurrent symmetric eruption of necrotizing skin papules appearing in clusters and healing with varioliform scars (Figure 6). Tubercle bacilli are difficult to demonstrate, but patients typically have an internal focus of TB and are tuberculin sensitive, and skin lesions resolve after anti-TB therapy. TB DNA has been detected in these lesions using PCR amplification reactions.28 Lesions appear on the exterior aspects of extremities, knees, elbows, buttocks, and lower trunk in a symmetric distribution, often in clusters. Individual lesions are asymptomatic, small, dusky red papules with a central punctum or crust. Involution is common after 6 to 8 weeks.29

LS is an eruption of multiple, small, grouped, asymptomatic, firm, perifollicular, lichenoid papules and/or plaques (Figure 4), most often affecting children or young adults, that progresses and subsides within weeks to months without scarring.4,23 An association between LV, caries of the spine, LS,24 and its unusual occurrence in pulmonary TB25 has been described in the past. ERYTHEMA INDURATUM OF BAZIN EIB is a TB-associated panniculitis that presents with multiple, painful, recurring, ulcerated nodules that affect the legs of women.4,6 Pre-existing vascular disease may predispose patients

DIAGNOSIS

Figure 5. Erythema induratum occupying the lower leg.

Diagnosis of CTB is based on relative and absolute criteria, in addition to supportive immunologic evidence.30

SKINmed. 2012;10:28â&#x20AC;&#x201C;33

Figure 6. Papulonecrotic tuberculid.

Cutaneous Tuberculosis

January/February 2012

CORE CURRICULUM

RELATIVE DIAGNOSIS

Health Organization (WHO), it is important to be aware of the diagnostic modalities thus far available in the global arena.31

CARDINAL MORPHOLOGIC FEATURES (VIDE SUPRA) A characteristic history of evolution of the disease is distinct in re-infection and re-activation. In re-infection, a history of primary infection or BCG vaccination must be obtained. The latter forms an important component of the immunization program in some countries, including India, and may be identified by a BCG vaccination scar at the insertion point on the left deltoid. In re-activation, on the other hand, a history of TB, established by clinical and/or investigative procedures, followed by cure and an asymptomatic period on completion of specific anti-tubercular therapy. Often, the only evidence of past infection may be pulmonary scarring and calcification visible on radiography. Subsequently, any event that lowers the cell-mediated immunity may re-activate the condition, resulting in its relapse. MANTOUX TEST A positive Mantoux test indicates the cell-mediated skin hypersensitivity to tuberculin. The response in re-infection may be higher as compared with that in re-activation TB. This in vivo test correlates well with the migratory index of lymphocytes to tuberculin antigen, assayed through leukocyte migration inhibition test. A strongly positive reaction, however, indicates active TB. It has only a limited diagnostic application in countries where the infection is highly prevalent and BCG forms an integral part of the immunization program and the majority of adults are tuberculin positive; nevertheless, it may be a useful adjunct in developed countries.

NONTUBERCULOUS MYCOBACTERIA Physicians should be aware of nontuberculous mycobacteria (NTMB) in the current context, because they are environmental organisms capable of causing chronic disease in humans worldwide. The prevalence of NTMB disease is steadily increasing and has emerged in previously unrecognized populations. They, too, are a diagnostic challenge.32 TB verrucosa cutis–like lesions may be caused by M bovis.33 ATYPICAL MYCOBACTERIOSIS Mycobacterium avium-intracellulare (MAI) is now a wellestablished cause of cervical lymphadenitis, simulating scrofuloderma, especially in the pediatric age group in the developed world.34 In addition, LV-like morphology may also be encountered following primary MAI infection.35 HIV INFECTION AND CTB HIV-infected patients are vulnerable to contract TB.36 TB may present as a rapidly progressive disease in immunosuppressed patients. Miliary TB is common and may be associated with cutaneous manifestations.37 Disseminated CTB may show a high yield of mycobacterium from an unusual dermatitis in this group. Despite the dissemination of the organism, the diagnosis of TB may be difficult.38,39 In addition, atypical presentations of oesophago-pleurocutaneous and pleuro-cutaneous fistula may be seen.40,41

Microscopic examination of the tissue section may depict a tuberculoid and tuberculous granuloma. The former, characterized by a focal accumulation of epithelioid cells, a few giant cells, and surrounding mantle of mononuclear cells, is a relative parameter encountered in LV and TBVC. It also demonstrates caseation necrosis in the center. It may be possible to demonstrate AFB on Fite’s stain. This granuloma fulfills an absolute criterion for diagnosis of TB and typifies scrofuloderma.

In addition to the decrease in tuberculin reactivity, atypical chest radiographic patterns are common. Biopsy and aspirates of peripheral and regional lymph nodes, liver, and bone marrow provide the highest yield and are used for early diagnosis.42 Co-lesional acquired immunodeficiency syndrome–associated cutaneous Kaposi’s sarcoma and M tuberculosis–associated granulomatous inflammation have recently been documented.43 Tuberculous gumma, new-onset cervical lymphadenopathy, and worsening of the pre-existing lymphadenitis, yet another highrisk immune reconstitution inflammatory syndrome, has previously been described.44

ABSOLUTE DIAGNOSIS An absolute diagnosis consists in the demonstration of AFB on Ziehl-Neelsen’s staining of the smear, prepared from material from lesions. The colonies should be further subjected to biochemical and pigment production tests to confirm M tuberculosis. Recovery of M tuberculosis on inoculation of material from lesions into guinea pigs.

CONCLUSIONS

In an effort to achieve universal access to high-quality diagnosis and ultimate patient-centered treatment as envisaged by World

Reviewing the prevalence and variations in the clinical expression of CTB across the globe may assist in evolving a uniform pattern of the disease vital for a core curriculum. The comprehension of the text is, therefore, crucial in developing treatment strategy through the recommendations of WHO. WHO believes that the same treatment regimen for pulmonary and/or extrapulmonary TB should be used.45

SKINmed. 2012;10:28–33

Cutaneous Tuberculosis

January/February 2012

CORE CURRICULUM 25 Seghal VN, Chander R, Logani K. Lichen scrofulosorum: an unusual expression of pulmonary tuberculosis in a child. J Eur Acad Dermatol Venereol. 1995;4:71–74.

REFERENCES 1

Sehgal VN, Wagh SA. The history of cutaneous tuberculosis. Int J Dermatol. 1990;29:666–668.

Bravo FG, Gotuzzo E. Cutaneous tuberculosis. Clin Dermatol. 2007;25:173–180.

Fariña MC, Gegundez MI, Piqué E, et al. Cutaneous tuberculosis: a clinical, histopathologic, and bacteriologic study. J Am Acad Dermatol. 1995;33:433–440.

MacGregor RR. Cutaneous tuberculosis. Clin Dermatol. 1995;13:245–255.

Bhutto AM, Solangi A, Khaskhely NM, et al. Clinical and epidemiological observations of cutaneous tuberculosis in Larkana, Pakistan. Int J Dermatol. 2002;41:159–165.

Barbagallo J, Tager P, Ingleton R, et al. Cutaneous tuberculosis: diagnosis and treatment. Am J Clin Dermatol. 2002;3:319–328.

Regnier S, Ouagari Z, Perez ZL, et al. Cutaneous miliary resistant tuberculosis in a patient infected with human immunodeficiency virus: case report and literature review. Clin Exp Dermatol. 2009;34:e690–e692.

Rai VM, Shenoi SD, Gowrinath. Tuberculous gluteal abscess coexisting with scrofuloderma and tubercular lymphadenitis. Dermatol Online J. 2005;11:14.

Lai-Chong JE, Perez A, Tang V, et al. Cutaneous manifestations of tuberculosis. Clin Exp Dermatol. 2007;32:461–466.

26 Vieites B, Suárez-Peñaranda JM, Pérez Del Molino ML, et al. Recovery of Mycobacterium tuberculosis DNA in biopsies of erythema induratum— results in a series of patients using an improved polymerase chain reaction technique. Br J Dermatol. 2005;152:1394–1396. 27 Bayer-Garner IB, Cox MD, Scott MA, et al. Mycobacteria other than Mycobacterium tuberculosis are not present in erythema induratum/ nodular vasculitis: a case series and literature review of the clinical and histologic findings. J Cutan Pathol. 2005;32:220–226. 28 Quirós E, Bettinardi A, Quirós A, et al. Detection of mycobacterial DNA in papulonecrotic tuberculid lesions by polymerase chain reaction. J Clin Lab Anal. 2000;14:133–135. 29 Freiman A, Ting P, Miller M, et al. Papulonecrotic tuberculid: a rare form of cutaneous tuberculosis. Cutis. 2005;75:341–346. 30 Sehgal VN. Cutaneous tuberculosis. Dermatol Clin. 1994;12:645–653. 31 The Regional Strategic Plan for TB Control 2006–2015. World Health Organization, Regional Office for South-East Asia, World Health House, Indraprastha Estate, Mahatma Gandhi Road, New Delhi 110002, India.

10 Glickman FS, Price E. Primary inoculation complex (tuberculous chancre). Arch Dermatol. 1969;100:646–647. 11 Ara M, Seral C, Baselga C, et al. Primary tuberculous chancre caused by Mycobacterium bovis after goring with a bull’s horn. J Am Acad Dermatol. 2000;43:535–537.

32 Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416. 33 Wolff K, Tappeiner G. Mycobacterial diseases: tuberculosis and atypical mycobacterial infection. In: Fitzpatrick TB, Eisen AZ, Wolff K, eds. Dermatology in General Medicine. 3rd ed. New York, NY: McGraw Hill; 1987:2152–2170. 34 Starke JR. Management of nontuberculous mycobacterial cervical adenitis. Pediatr Infect Dis J. 2000;19:674–675.

12 Mataix J, Botella R, Herrero A, et al. Tuberculous primary complex of the skin. Int J Dermatol. 2008;47:479–481.

35 Kullavanijaya P, Sirimachan S, Surarak S. Primary cutaneous infection with Mycobacterium avium intracellulare complex resembling lupus vulgaris. Br J Dermatol. 1997;136:264–266.

13 Kiliç A, Gül U, Soylu S, et al. Scrofuloderma: a forgotten disease? Skinmed. 2007;6:303–304. 14 Sharma MP, Bhatia V. Abdominal tuberculosis. Indian J Med Res. 2004;120:305–315.

36 Starke JR. Tuberculosis. In: Jenson HB, Baltimore RS, eds. Pediatric Infectious Diseases: Principles and Practices. Philadelphia, PA: WB Saunders; 2002:396–419.

15 Ichihashi K, Katoh N, Takenaka H, et al. Orificial tuberculosis: presenting as a refractory perianal ulcer. Acta Derm Venereol. 2004;84:331–332.

37 Sharma SK, Mohan A, Sharma A, et al. Miliary tuberculosis: new insights into an old disease. Lancet Infect Dis. 2005;5:415–430.

16 Akgun E, Tekin F, Ersin S, et al. Isolated perianal tuberculosis. Neth J Med. 2005;63:115–117. 17 Sehgal VN, Sharma S, Verma P, et al. Disseminated cutaneous tuberculosis an atypical presentation of re-infection (secondary) tuberculosis in an immuno-competent individual. Am J Dermatopathol. 2011. Sep 13. [Epub ahead of print] 18 Regnier S, Ouagari Z, Perez ZL, et al. Cutaneous miliary resistant tuberculosis in a patient infected with human immunodeficiency virus: case report and literature review. Clin Exp Dermatol. 2009;34:e690–e692.

38 Regnier S, Ouagari Z, Perez ZL, et al. Cutaneous miliary resistant tuberculosis in a patient infected with human immunodeficiency virus: case report and literature review. Clin Exp Dermatol. 2009;34:e690-e692. 39 Corbett EL, Crossley I, De Cock KM, et al. Disseminated cutaneous Mycobacterium tuberculosis infection in a patient with AIDS. Genitourin Med. 1995;71:308–310. 40 Arif M. Oesophago-pleuro-cutaneous fistula in an HIV-positive patient. Braz J Infect Dis. 2010;14:183–185.

19 Afshar K, Mundi M. Tuberculosis verrucosa cutis. Mayo Clin Proc. 2004;79:1562.

41 Gulinelli A, Toledo DO, Coelho-Neto AP, et al. Parasternum pleuralcutaneous fistula in a severely immunosuppressed HIV-positive patient. Braz J Infect Dis. 2010;14:183–185.

20 Marcoval J, Servitje O, Moreno A, et al. Lupus vulgaris. Clinical, histopathologic, and bacteriologic study of 10 cases. J Am Acad Dermatol. 1992;26:404–407. 21 Akoglu G, Karaduman A, Boztepe G, et al. A case of lupus vulgaris successfully treated with antituberculous therapy despite negative PCR and culture. Dermatology. 2005;211:290–292. 22 Frankel A, Penrose C, Emer J. Cutaneous tuberculosis: a practical case report and review for the dermatologist. J Clin Aesthet Dermatol. 2009;2:19–27.

42 Shafer RW, Kim DS, Weiss JP, Quale JM. Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection. Medicine (Baltimore). 1991;70:384–397. 43 Ramdial PK, Sing Y, Subrayan S, et al. Granulomas in acquired immunodeficiency syndrome-associated cutaneous Kaposi sarcoma: evidence for a role for Mycobacterium tuberculosis. J Cutan Pathol. 2010;37:827–834.

23 Singal A, Bhattacharya SN. Lichen scrofulosorum: a prospective study of 39 patients. Int J Dermatol. 2005;44:489–493.

44 Sharma SK, Dhooria S, Barwad P, et al. A study of TB-associated immune reconstitution inflammatory syndrome using the consensus case-definition. Indian J Med Res. 2010;131:804–808.

24 Sehgal VN, Srivastava G, Sharma VK. Lupus vulgaris, caries of the spine and lichen scrofulosorum—an intriguing association. Clin Exp Dermatol. 1987;12:280–282.

45 World Health Organization. Treatment of tuberculosis guidelines. Treatment of extrapulmonary TB and of TB in special situations. 4th ed. Geneva 27, Switzerland; 2009: 95–99.

SKINmed. 2012;10:28–33

Cutaneous Tuberculosis

January/February 2012

Volume 10 • Issue 1

SELF-TEST REVIEW QUESTIONS W. Clark Lambert, MD, PhD, Section Editor Instructions: For each of the following numbered questions, choose the most appropriate lettered response(s) Unless directed to choose only one lettered response, all, some, or none of the responses may be correct. 1)

a. b. c. d. e. f. 2)

acute military tuberculosis. gummatous tuberculosis. lupus vulgaris. papulo-necrotic tuberculid. tuberculous chancre. tuberculosis verrucosa cutis.

a. Acute military tuberculosis b. Gummatous tuberculosis

direct spread from adjacent organs. hematogenous spread. ingestion of bacilli in sputum. lymphatic spread. exogenous inoculation due to the direct inoculation of Mycobacterium tuberculosis into the skin/mucosa of a person who is susceptible to infection.

“Apple-jelly” nodules present on the head and neck of individuals in Western countries are most characteristic of: (Choose the single best response.) a. b. c. d. e.

Which of the following is widely described as the most common form of cutaneous tuberculosis? (Choose the single best response.)

Lupus vulgaris Papulo-necrotic tuberculid Tuberculous chancre Tuberculosis verrucosa cutis

The most accepted mode of development of tuberculosis cutis oroficialis is: (Choose the single best response.) a. b. c. d. e.

Exogenous inoculation, due to the direct inoculation of Mycobacterium tuberculosis into the skin of a person who has been previously infected but is susceptible to infection, is most likely to be responsible for: (Choose the single best response.) a. b. c. d. e. f.

c. d. e. f.

Exogenous inoculation, due to the direct inoculation of Mycobacterium tuberculosis into the skin of a person who is susceptible to infection, may be responsible for: (Answer as many as apply.)

erythema induratum of Bazin. lichen scrofulosorum. lupus vulgaris. papulonecrotic tuberculid. tuberculosis verrucosa cutis.

ANSWERS TO SELF-TEST REVIEW QUESTIONS: 1) c, e, f; 2) f; 3) c; 4) c; 5) c

From the Departments of Pathology and Dermatology, UMDNJ-New Jersey Medical School, Newark, NJ Address for Correspondence: W. Clark Lambert, MD, PhD, Room C520 MSB, UMDNJ-NJMS, 185 South Orange Avenue, Newark, NJ 07101 • E-mail: lamberwc@umdnj.edu

RESTLESS LEG SYNDROME Drugs that may cause restless leg syndrome (RLS) Alcohol

Haldol

Prozac

Topamax

Caffeine

Iron

Remeron

Ultram

Celexa

Klonopin

Risperdal

Zoloft

Dilantin

Neurotin

Seroquel

Zyprexa

Elavil

Paxil

Adapted from Litt, JZ. Curious, Odd, Rare, and Abnormal Reactions to Medications. Fort Lee, NJ: Barricade Books; 2009:107.

Arnika Forte

速

The New Gold Standard for treating bruising, swelling, pain 1st and only combination of Arnica Montana 30x and Bromelain

Arnika Forte速 SPEED THE HEALING

One convenient capsule twice a day All natural, safe, physician - formulated

Speed the healing time from bruising, swelling and pain after surgery or dermal filler injections

To Order Call 484-568-0306

January/February 2012

Volume 10 • Issue 1

COSMETIC SCIENCE Howard A. Epstein, PhD, Section Editor

Repelling Insects With Safe and Effective Alternatives to DEET Howard A. Epstein, PhD

n addition to the annoying itch that results from biting insects, insect-borne diseases, including Lyme disease, encephalitis, Rocky Mountain spotted fever, and West Nile virus, are all causes of concern for many individuals who wish to enjoy the outdoor environment during the warmer months of the year. The military of various nations experienced the same problems and have conducted much research in developing repellents to protect their soldiers. The Indian Army used oils of citronella, camphor, and paraffin as repellents. These agents were effective for limited periods and therefore the search for more effective repellents continued. In 1953, N, N-diethyl-m-toluamide (DEET) was discovered (Figure 1). As of 2007, it was estimated that 15 million people in the United Kingdom, 78 million people in the United States, and 200 million people globally use DEET each year.1 Over the years, as cases of insect-borne diseases continued to be reported in the news, so has the use of DEET. Reports of adverse reactions associated with DEET have increased with its use. HEALTH-RELATED ISSUES AND CONSUMER CONCERNS

In 2004, the Oregon State University (OSU) Agricultural Experiment Station issued a press release entitled “OSU Scientist Gives Safety Tips for Use of DEET Against Mosquitoes & West Nile Virus.” In the release, Dr Damiel Sudakin, an assistant professor at OSU’s Department of Environmental and Molecular Toxicology and toxicologist at the Agricultural Experiment Station was quoted as expressing concern that hundreds of adverse reactions, most commonly affecting the skin, are reported each year. The majority of these adverse reactions occur when DEET is overused or misused.2 In 2009, Science Daily published a paper entitled “Popular Insect Repellent DEET Is Neurotoxic.”3 The contribution referenced a study that concluded that DEET is not simply a behavior-modifying chemical, but also inhibits the activity of a key central nervous system enzyme, acetylcholinesterase, in both insects and mammals.4

In 2004, the Agency for Toxic Substances & Disease Registry issued a report on the health effects of DEET in humans. The report mentioned 6 cases of DEET ingestion, 3 led to death after ingestion of 15 mL to 50 mL of 47.5% to 95% DEET filled in bottles. In 2 of these cases, the individuals drank an unspecified amount of alcohol. In the third case, the individual ingested an unspecified number of pills with 50 mL of DEET. In yet another case, a woman ingested 15 mL to 25 mL of 95% DEET and was admitted to a hospital with right and left atrial enlargement that returned to normal within 24 hours. This woman survived with no further cardiac abnormalities.5 From 1961 to 2002, the Agency reported 8 deaths related to DEET exposure, 3 resulting from deliberate ingestion, and 2 following dermal exposure to DEET. The remaining 3 cases were girls aged 17 months, 5 years, and 6 years. All 3 children were described as having “heavy, frequent, or nightly applications of DEET.” The 6-year-old had congenital ornithine carbamoyl transferase deficiency, which may have contributed to her death.5 Two other reported cases involved 2 men, aged 27 and 30 years, who developed severe psychological effects from exposure to DEET. In both cases, the men recovered after hospitalization.5 MILITARY AND GOVERNMENT PERSONNEL: DERMAL EFFECTS OF DEET EXPOSURE Unique cutaneous side effects were reported in 15 soldiers who applied military-issued DEET repellents. One soldier applied a 33% DEET repellent to his skin without washing it off at bedtime. He developed a vesiculobullous eruption, which cleared after 14 days. Another soldier who went to bed without removing DEET applied to his skin woke up 8 hours later complaining of a burning sensation and skin eruptions. A 10-day treatment with corticosteroids cleared the condition. Other soldiers reported burning skin and erythema after application of 50% DEET solution applied just before bedtime. Three soldiers were referred to treatment by a dermatologist: 2 of the soldiers developed a permanent scar and 1 required corrective surgery.5

From EMD Chemicals Inc, Gibbstown, NJ Address for Correspondence: Howard A. Epstein, PhD, EMD Chemicals Inc, One International Plaza, Suite 300, Philadelphia, PA 19113 • E-mail: howard.epstein@merckgroup.com

SKINmed. 2012;10:36–39

January/February 2012

COSMETIC SCIENCE seizures associated with the dermal application of DEET, with fewer than 3 applications.5

ALTERNATIVES TO DEET Picaridin, 1-piperidine carboxylic acid-2(2-hydroxxyethyl)-1methpropylester (Figure 2) was developed by Bayer in the 1980s. It is a synthetic molecule chemically based on the active agent in pepper (Piper sp). Picaridin was first registered with the US Environmental Protection Agency (EPA) in 2001 and entered the market in 2005. Picaridin has a favorable safety profile, most likely because the compound has not been as commercially available for as long as DEET, and therefore there is far less information regarding adverse reactions.

Figure 1. DEET CAS 134–62–3.

Other controlled studies in which DEET was applied to 63 volunteers with a gauze pad soaked in DEET determined that DEET should be washed from skin prior to sleeping directly related to the irritant effects of DEET.5 Additional studies involving 143 National Park Service employees at Everglades National Park resulted in 36 of the workers having adverse health effects to the applied DEET. The effects included skin or mucous membrane irritation, transient numb or burning lips, dizziness, disorientation, and difficulty in concentration. Headache and nausea were also reported.5 MULTIPLE CASE STUDIES OF DEET EXPOSURE An analysis of phone calls to poison control centers in the United States from 1985 to 1989 represented more than 6 million human exposures to a variety of chemicals. Of these, 9086 were related to DEET. Of the DEET-related calls, 54% of patients had no symptoms at the time of the call and 40% had symptoms thought to be related to DEET exposure. The most commonly reported exposure was inhalation of DEET or spray into the eyes. These exposures were more likely to cause adverse reactions compared with cases in which small quantities of DEET were ingested. Of the individuals with symptoms, 88% did not require medical attention, 35% had minor skin irritation, and 1% experienced disorientation or brief seizures. There was a reported death from deliberate consumption of an 8-oz bottle of DEET. Children were not more likely to develop side effects than adults.5 CASE REPORTS OF CHILD EXPOSURES During 1961 to 2002, 14 of the 17 reported cases of significant DEET toxicity were in children younger than 8 years. The most frequently reported symptoms of DEET toxicity in children were lethargy, headaches, tremors, involuntary movements, seizures, and convulsions.5 The common route of exposure in children is frequently dermal or accidental ingestion. Adverse effects have been reported in an 18.5-month child who was sprayed with 20% DEET daily for 3 months and a 6-year-old who was sprayed with 15% DEET on 10 occasions. Generally, children recover from exposure. In 1989, there were 4 cases of children ages 3 to 7 years and a 29-year-old man having generalized SKINmed. 2012;10:36–39

The first report of a contact allergy during commercial use was reported in 2005, in which a 39-year-old man experienced an itchy erythematous reaction to a spray a few hours after application to the skin.1 Australian soldiers evaluated 19.2% Picaridin compared with 35% DEET in a gel formulation, with significantly more soldiers reporting mild discomfort and irritation with the use of the DEET gel. Published studies indicate that Picaridin may be as effective as DEET. There are variations in repellent efficacy depending on species of insect and levels of use. The literature reports that Picaridin is aesthetically more “elegant” than DEET in various formulations.1 It is registered for use on the human body and clothing to repel biting flies, ticks, chiggers, fleas, and mosquitoes.6 NATURAL AND EFFECTIVE ALTERNATIVES IR3535, [3-(N-acetyl-N-butyl)aminopropionic acid ethyl ester] (Figure 3) has been marketed by Merck KGaA, Darmstadt, Germany, for the past 30 years. It was registered by the US EPA in 1999. IR3535 is unique in that it is classified as a biopesticide repellent. DEET and Picaridin are classified as conventional insect repellent pesticides. The EPA defines a biopesticide as a pesticide derived from natural materials including animal, plant, bacteria, and minerals. Canola oil and baking soda have pesticidal applications and are considered biopesticides.7 Biochemical pesticides are naturally occurring substances that control pests

O C

Me O

O N

CH2

Figure 2. Picaridin, Chemical Abstracts Service registry number 119515–38–7.

Figure 3. Ethyl butylacetylaminopropionate (IR3535), Chemical Abstracts Service registry number 52304–36–6. Alternatives to DEET

January/February 2012

COSMETIC SCIENCE

by nontoxic mechanisms. The EPA has established a special committee to determine the most appropriate classification based on established criteria.7 Biopesticides are usually less toxic than conventional pesticides. They generally affect only the target pest and closely related organisms compared with broad-spectrum conventional pesticides that may affect other organisms including birds and mammals.7 IR3535 received this classification because it is functionally identical to naturally occurring b-alanine. It is a substituted B amino acid that contains 98% 3-(N-acetyl-N-butyl) aminopropionic acid, ethyl ester as an active ingredient and 2% inert ingredients. The end groups are not likely to contribute to toxicity and it acts to control the target pest via a nontoxic mode of action.7 In various studies, IR3535 has been shown to be as effective as DEET. As with Picaridin the formulation, level of repellent, and species of insect may be a factor with respect to repellent efficacy.1 IR3535 is also reported to be more cosmetically elegant than DEET when evaluated in various human

studies. As of publication in 2007, the authors of Insect Repellents: Principles, Methods, and Uses claim there were no reported adverse reactions to IR3535.1 IR3535 is registered for use as an insect repellent against mosquitoes, deer ticks, body lice, and biting flies. The formulated products are applied directly to skin. The low toxicity data for IR3535 implies that there is reasonable certainty of no harm for the general population, as well as subgroups including infants and children.7 REVIEW OF TOXICITY DATA FOR DEET, PICARIDIN, AND IR3535 Tables I and II review toxicological data obtained from various sources. Regarding safety classification, the World Health Organization (WHO) classification for IR3535 is hazard class U, indicating that the compound is unlikely to present acute hazard in normal use.8 The WHO classified Picaridin as class III, indicating a slight hazard.9,11 DEET was also designated as class III by the WHO.12,13

Table I. Comparative Toxicology Data for IR3535,7,8 Picaridin,9 and DEET10

TEST

IR3535

PICARIDIN

DEET

REPORTED DOSE

Acute toxicity oral rat (lethal dose, 50%)

>5000

2236

2170

mg/kg body weight

Acute dermal toxicity rabbit or rat (lethal dose, 50%)

>3000

>2000

4280

mg/kg body weight

Acute inhalation (lethal dose, 50%)

>5.1

>4.3

mg/L

Eye irritation in rabbit

Irritating to eye

Moderate irritant

Irritating

Skin sensitization in guinea pig

Dermal sensitization human (NOEL)

mg/kg/d

Subchronic dermal rat (NOEL)

3000

200

300

mg/kg/d

Developmental rat (oral)

1000

400

250

mg/kg/d

Ames test (Salmonella typhimurium)

Nonmutagenic

Micronucleus assay

Nonmutagenic

Abbreviations: DEET, N, N-diethyl-m-toluamide; NA, not applicable; NOEL, no observed effect level. Higher scores indicate lower potential for toxicity.

Table II. Information From Various EPA Fact Sheets5,7,9

EPA FACT SHEET CLASS

IR3535

PICARIDIN

DEET

Acute inhalation toxicity

Primary dermal irritation

III

Acute oral

III

Acute dermal

III

Primary eye

III

Abbreviations: DEET, N, N-diethyl-m-toluamide; EPA, Environmental Protection Agency. Category I, very highly or highly toxic; category II, moderately toxic; category III, slightly toxic; category IV, practically nontoxic. SKINmed. 2012;10:36â&#x20AC;&#x201C;39

Alternatives to DEET

January/February 2012

COSMETIC SCIENCE

CONCLUSIONS Insect repellents are more effective at higher concentrations. In addition to the level of actives in the formulation, the degree of efficacy may be related to the species of insect to be repelled. Another factor is proper use of the repellent. When there is concern that label directions for use may not be properly followed, the best option is to suggest the compound with the least hazard risk. The WHO notes that classification criteria are guide-points intended to supplement but never substitute for special knowledge, sound clinical judgment, or experience with a compound.13 REFERENCES

National Pesticide Information Center. Picaridin Technical Fact Sheet. Corvalis, OR: Oregon State University; March 2009. http://npic.orst. edu. Accessed July 14, 2011.

United States Environmental Protection Agency. Pesticides: Regulating Pesticides. 3-[N-Butyl-N-acetyl]-aminopropionic acid, ethyl ester (113509) Technical Document. Washington, DC: United States Environmental Protection Agency; February 1999. http://.epa.gov/opp00001/biopesticides/ ingredients. Accessed July 13, 2011.

World Health Organization. Specifications and Evaluations for Public Health Pesticides. Ethyl Butylacetylaminopropionate also known as IR3535 3-(N-acetyl-N-butyl) aminopropionic acid ethyl ester. Geneva, Switzerland: World Health Organization; February 2006. htt://www.who. int/quality/en/. Accessed July 12, 2011.

United States Environmental Protection Agency. EPA New Pesticide Fact Sheet Picaridin. Washington, DC: United States Environmental Protection Agency; May 2005. http://www.epa.gov/opprd001/factsheets/. Accessed July 12, 2011.

10 United States Environmental Protection Agency. Reregistration Eligibility Decision (RED) DEET. Washington, DC: United States Environmental Protection Agency; September 1998. EPA738-R-010.

Debboun M, Frances SP, Strickman D, eds. Insect Repellents: Principles, Methods, and Uses. Boca Raton, FL: CRC Press; 2006.

Gewin V. OSU scientist gives safety tips for use of DEET against mosquitoes & West Nile virus. http://extension.oregonstate.edu/news/ release/2004/08/osu-scientist. Accessed June 24, 2011.

Science Daily. Popular insect repellant DEET is neurotoxic. http://www. sciencedaily.com/releases/2009/08/090804193230.htm. Accessed June 24, 2011.

Corbel V, Stankiewicz M, Pennetier C, et al. Evidence for inhibition of cholinesterases in insect and mammalian nervous systems by the insect repellant deet. BMC Biology. 2009;7:47.

12 World Health Organization. International Program on Chemical Safety PCS INCHEM. Data Sheet on Pesticide No. 80 DEET. Geneva, Switzerland: World Health Organization. WHO/VBC/DS/87.80. http://www.inchem. org/documents/pds/pds/pest80. Accessed June 24, 2011.

Agency for Toxic Substances & Disease Registry Division of Toxicology and Environmental Medicine. Health Effects in Humans: DEET (N,NDiethyl-meta-toluamide). Atlanta, GA: Agency for Toxic Substances and Disease Registry; December 6, 2004. http://www.atsdr.cdc.gov/consultations/deet/health-effects.html. Accessed July 12, 2011.

13 World Health Organization. IPCS, IOMC. The WHO Recommended Classification of Pesticides by Hazard and Guidelines to Classification 2009. Geneva, Switzerland: World Health Organization; 2010. http://www.who.int/ipcs/publications/pesticides_hazard. Accessed July 12, 2011.

11 World Health Organization. Specifications and Evaluations for Public Health Pesticides. Icaridin, 1-piperidinecarboxylic acid 2-(2-hydroxxxyethyl)-1methylpropylester also known as isobutyl piperidine carboxylate. Geneva, Switzerland: World Health Organization; October 2004. http://www.who. int/quality/en/. Accessed July 12, 2011.

VINTAGE LABEL

Courtesy of BuyEnlarge, Philadelphia, PA

SKINmed. 2012;10:36–39

Alternatives to DEET

January/February 2012

Volume 10 • Issue 1

PERILS OF DERMATOPATHOLOGY W. Clark Lambert, MD, PhD, Section Editor

It’s Not Just Who You Are, It’s Also Where You Are: The Cutaneous Leiomyosarcoma Dilemma Gizem Tumer, MD; Carmen F. Castilla, BS; W. Clark Lambert, MD, PhD “To understand a name you must be acquainted with the particular of which it is a name.”—Bertrard Russell

eiomyosarcoma of the skin is a rare soft tissue neoplasm of smooth muscle origin. Treatment and prognosis of this lesion are dependent on its depth, with deep soft tissue tumors carrying a significantly worse prognosis and requiring more extensive surgery than cutaneous ones. It is essential that all physicians involved know this. It is also critical that the dermatopathologist report the depth of a leiomyosarcoma in order for the clinician to render appropriate therapy. Failure to report the location of this neoplasm and/or failure to comprehend the prognostic significance of this information, can lead to inappropriate therapy and increased morbidity in patients.

is uncommon and mortality related to tumor progression is unusual.2,6–10 In contrast to cutaneous leiomyosarcoma, subcutaneous leiomyosarcoma presents as a larger mass of a higher grade. Although still superficially located above the fascia, the local recurrence rate and metastatic rate of subcutaneous leiomyosarcoma is closer to the more ominous deep soft tissue leiomyosarcoma.5,6,11

CLASSIFICATION

Based on the differences in their prognoses, investigators proposed the term atypical intradermal smooth muscle neoplasm instead of cutaneous leiomyosarcoma to highlight the benign nature of cutaneous leiomyosarcoma vs the more aggressive soft tissue leiomyosarcoma and subcutaneous leiomyosarcoma. The same group also argued that grading primary dermal atypical smooth muscle neoplasms is inappropriate given the fact that the only prognostic predictor is margin status at the time of excision and no other reliable prognostic factor has been identified.5 While we respect these investigators’ opinion, we believe that thus terming such lesions is a bit like a tail wagging the dog. We believe it is more sensible to name a tumor in the most logical way based on its histological features, and subsequently to note if some subset of these lesions has a different prognosis.

Three classifications of smooth muscle tumors of the skin have been described1: • Atypical smooth muscle tumor of the dermis (purely dermal lesion); • Cutaneous leiomyosarcoma (dermal lesion with minimal extension into the subcutis); • Subcutaneous leiomyosarcoma.2 Microscopically, the cutaneous leiomyosarcoma lesion involves the dermis and focally, the subcutis. It is composed of bluntended, cigar-shaped fusiform neoplastic spindle cells with eosinophillic cytoplasm forming fascicles and bundles.2–5 This neoplasm may appear in two different architectural patterns: a fasciculated growth pattern and a pilar-type architectural pattern (Figure 1 and Figure 2). The latter generally represents a low-grade neoplasm showing histologic features suggestive of pilar leiomyoma with the addition of a variable degree of cytological atypia and mitoses.2

TREATMENT

CLINICAL FINDINGS

Treatments for cutaneous and deep soft tissue leiomyosarcoma differ significantly. Unlike deep soft tissue leiomyosarcoma, which requires extensive surgery, the standard treatment for cutaneous leiomyosarcoma and subcutaneous leiomyosarcoma is wide local excision, with margins ranging from 2 cm to 5 cm.12,13 Mohs’ micrographic surgery (MMS) has also been used for cutaneous leiomyosarcomas. This technique can be beneficial as it provides the ability to examine all margins as the lesion is excised while sparing normal tissue.9 At this time, only a few small studies investigating MMS have been reported and further studies are required to investigate this technique.13–16

Cutaneous leiomyosarcomas typically follow an indolent clinical course. Local recurrence does occur; however, distant metastasis

From the Departments of Dermatology and Pathology, UMDNJ-New Jersey Medical School, Newark, NJ Address for Correspondence: W. Clark Lambert, MD, PhD, Room C520 MSB, UMDNJ-NJMS, 185 South Orange Avenue, Newark, NJ 07103 • E-mail: lamberwc@umdnj.edu

SKINmed. 2012;10:40–41

January/February 2012

PERILS OF DERMATOPATHOLOGY

Figure 2. Spindle cell lesion with areas of mitosis (arrowheads).

Figure 1. Subcutaneous skin biopsy of tumor cells composed of cigar-shaped spindle cells with mitotic figures (black arrows) (hematoxylin-eosin stain, original magnification ×20).

Mentzel T. Sarcomas in the skin of the elderly. Clin Dermatol. 2011;29:80–90.

OBSERVATIONS

De Giorgi V, Sestini S, Massi D, et al. Superficial cutaneous leiomyosarcoma: a rare, misleading tumor. Am J Clin Dermatol. 2008;9:185–187.

Due to the increased risk of metastasis and the worse prognosis of subcutaneous leiomyosarcoma, an analysis of the subcutaneous tissue is crucial when the diagnosis of cutaneous leiomyosarcoma is made. Undergrading of the tumor may occur if a shave biopsy is utilized to diagnose the lesion.

Kraft S, Fletcher CD. Atypical intradermal smooth muscle neoplasms: clinicopathologic analysis of 84 cases and a reappraisal of cutaneous “leiomyosarcoma.” Am J Surg Pathol. 2011;35:599–607.

Svarvar C, Böhling T, Berlin O, et al. Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group. Cancer. 2007;109:282–291.

Brown MD. Recognition and management of unusual cutaneous tumors. Dermatol Clin. 2000;18:543–552.

Ikari Y, Tokuhashi I, Haramoto I, et al. Cutaneous leiomyosarcoma. J Dermatol. 1992;19:99–104.

Swanson PE, Stanley MW, Scheithauer BW, Wick MR. Primary cutaneous leiomyosarcoma: a histological and immunohistochemical study of 9 cases, with ultrastructural correlation. J Cutan Pathol. 1988;15: 129–141.

In contrast to deep soft tissue leiomyosarcomas, which may require extensive surgery, overly aggressive treatment or mutilating surgeries are not warranted in cutaneous leiomyosarcoma. The standard of care for cutaneous leiomyosarcoma remains wide excisional biopsy; however, recent studies have shown benefits to using MMS. The dermatopathologist must report the depth of the tumor and the closest distance from the margin in order to provide the best therapeutic approach. The clinician must then understand the significance of this interpretation. Failure to distinguish and report the exact depth of this neoplasm or a failure of the clinician to understand the significance of this information may lead to inappropriate and aggressive treatment with excess morbidity.

10 Fields JP, Helwig EB. Leiomyosarcoma of the skin and subcutaneous tissue. Cancer. 1981;47:156–169. 11 Massi D, Franchi A, Alos L, Cook M. Primary cutaneous leiomyosarcoma: clinicopathological analysis of 36 cases. Histopathology. 2010;56: 251–262. 12 Tsut Sumido A, Yoshida T, Yamamoto Y, Itoh T. Management of superficial leiomyosarcoma: a retrospective study of 10 cases. Plast Reconst Surg. 2005;116:8–12. 13 Humphreys TR, Finkelstein DH, Lee JB. Superficial leiomyosarcoma treated with Mohs micographic surgery. Dermatol Surg. 2004;30:108–112. 14 Starling J 3rd, Coldiron BM. Mohs micrographic surgery for the treatment of cutaneous leiomyosarcoma. J Am Acad Dermatol. 2011;64: 1119–1122.

REFERENCES 1

Hornick JL, Fletcher CD. Criteria for malignancy in nonvisceral smooth muscle tumors. Ann Diagn Pathol. 2003;7;60–66.

Massi D, Franchi A, Alos L, et al. Primary cutaneous leiomyosarcoma: clinicopathological analysis of 36 cases. Histopathology. 2010;56: 251–262.

SKINmed. 2012;10:40–41

15 Huether MJ, Zitelli JA, Brodland DG. Mohs micographic surgery for the treatment of spindle tumors of the skin. J Am Acad Dermatol. 2001;44:656–659. 16 Annest NM, Grekin SJ, Stone MS, Messingham MJ. Cutaneous leiomyosarcoma: a tumor of the head and neck. Dermatol Surg. 2007;33:628–633.

It’s Not Just Who You Are

7PMVNF t *TTVF

January/February 2012

INFECTIOUS DISEASE CAPSULE Jack M. Bernstein, MD, Section Editor

It May Be Vulgar, but It Isnâ&#x20AC;&#x2122;t a Bad Word %BWJE 4BVOEFST .% 1,2 5IPNBT )FSDIMJOF .% 2 Jack M. Bernstein, MD1,2

ZFBS PME JNNJHSBOU GSPN $PTUB 3JDB QSFTFOUFE XJUI B ZFBS IJTUPSZ PG SJHIU FBS VMDFSBUJPOT XJUI BTTPDJBUFE JOUFSNJUUFOU TDBOU CMPPEZ QVSVMFOU ESBJOBHF É¨FSF XBT OP BOUFDFEFOU USBVNB BOE OP GFWFST DIJMMT OJHIU TXFBUT PS XFJHIU MPTT 4JY NPOUIT QSFWJPVTMZ 2VBOUJ'&30/ 5# (PME UFTUJOH $FMMFTUJT -JNJUFE $IBETUPOF .FMCPVSOF 7JDUPSJB "VTUSBMJB XBT QPTJUJWF BOE UIF DIFTU Y SBZ XBT OFHBUJWF )F XBT OPU USFBUFE GPS MBUFOU UVCFSDVMPTJT 5# 0O QIZTJDBM FYBNJOBUJPO UIF QBUJFOU XBT BGFCSJMF BOE IJT WJUBM TJHOT XFSF TUBCMF " Ã«SN TIBMMPX BOE DSVTUFE SJHIU IFMJY BOE MPCVMF VMDFSBUJPOT XFSF QSFTFOU 'JHVSF "CEPNJOBM FYBNJOBUJPO SFWFBMFE MFGU VQQFS RVBESBOU UFOEFSOFTT BOE TQMFOPNFHBMZ 4LJO CJPQTZ SFTVMUT PG UIF SJHIU MPCVMF TIPXFE NJYFE JOÃ¬BNNBUPSZ JOÃ«MUSBUJPO XJUI MZNQIPDZUFT QMBTNB DFMMT BOE FQJUIFMPJE DFMM IJTUJPDZUJD OPODBTFBUJOH HSBOVMPNBT 'JHVSFÎ&#x2030; 3FTVMUT GSPN BDJE GBTU CBDJMMJ "'# and GVOHBM TUBJOT XFSF OFHBUJWF 1PMZNFSBTF DIBJO SFBDUJPO GPS 5# XBT OFHBUJWF É¨F QSFTVNQUJWF EJBHOPTJT PG MVQVT WVMHBSJT XBT NBEF BOE JTPOJB[JE SJGBNQJO FUIBNCVUPM BOE QZSB[JOBNJEF XFSF TUBSUFE " NPOUI BOE B IBMG BGUFS TUBSUJOH USFBUNFOU UIF MFTJPOT SFHSFTTFE BOE ESBJOBHF DFBTFE 'JHVSF É¨F QBUJFOU DPOUJOVFE ESVH USFBUNFOU GPS NPOUIT GPMMPXFE CZ NPOUIT PG JTPOJB[JE BOE SJGBNQJO

T DBSSJOH MFTJPOT UIBU QFSTJTU GPS UP EFDBEFT CFGPSF EJBHOPTJT 4 *O BO *OEJBO TUVEZ OFBSMZ POF UIJSE PG QBUJFOUT XJUI MVQVT WVMHBSJT QSFTFOUFE ZFBST BGUFS EJTFBTF POTFU 3 -FTJPOT UZQJDBMMZ CFHBO BT Ã¬BU BOE SFE CSPXO QBQVMFT UIBU FOMBSHFE UP GPSN FSZUIFNBUPVT BOE WJPMBDFPVT QMBRVFT XJUI BUSPQIJD DFOUFST BOE Ã«SN SBJTFE FEHFT %JBTDPQZ SFWFBMT B DIBSBDUFSJTUJD iBQQMF KFMMZw DPMPS 4 -FTJPOT NPTU DPNNPOMZ JOWPMWF UIF IFBE BOE OFDL QBSUJDVMBSMZ UIF OPTF BOE FBST 1

$VUBOFPVT 5# JT SBSFMZ EJBHOPTFE FWFO JO DPVOUSJFT JO XIJDI B IJHI QSFWBMFODF PG 5# JT QSFTFOU *O B 4QBOJTI EFSNBUPMPHZ DFOUFS UIF JODJEFODF PG DVUBOFPVT 5# EVSJOH ZFBST XBT 1 7BSJBOUT PG DVUBOFPVT 5# JODMVEF QSJNBSZ JOPDVMBUJPO 5# 5# WFSSVDPTB DVUJT MVQVT WVMHBSJT TDSPGVMPEFSNB NJMJBSZ 5# PG UIF TLJO PSJÃ«DJBM 5# BOE UVCFSDVMJET 2 -VQVT WVMHBSJT JT UIF NPTU DPNNPO UZQF PG DVUBOFPVT 5# SFQSFTFOUJOH PG DVUBOFPVT 5# DBTFT EVSJOH ZFBST JO *OEJB 3 -VQVT WVMHBSJT VTVBMMZ PDDVST BT B SFTVMU PG IFNBUPHFOPVT MZNQIBUJD PS EJSFDU TQSFBE GSPN WJTDFSBM 5# *OPDVMBUJPO BGUFS USBVNB PDDVST MFTT DPNNPOMZ 1

"T UIF OVNCFS PG CBDJMMJ JO DVUBOFPVT 5# JT TNBMM NPOUIT PG USFBUNFOU GPS DVUBOFPVT 5# JT MJLFMZ BEFRVBUF 4UBOEBSE UIFSBQZ XPVME JODMVEF JTPOJB[JE SJGBNQJO FUIBNCVUPM BOE QZSB[JOBNJEF GPS NPOUIT GPMMPXFE CZ JTPOJB[JE BOE SJGBNQJO GPS NPOUIT o8 &WJEFODF PG 5# BU PUIFS TJUFT TIPVME CF FYDMVEFE CFGPSF TUBSUJOH BOUJUVCFSDVMPVT NFEJDBUJPOT *G Mycobacterium tuberculosis JT JTPMBUFE GSPN BOPUIFS TJUF JU TIPVME CF UFTUFE GPS SFTJTUBODF 3

DIAGNOSIS )FNBUPYZMJO BOE FPTJO TUBJOJOH PG TLJO CJPQTZ UJTTVF TIPXT FQJEFSNBM IZQFSQMBTJB BOE IZQFSUSPQIJD DIBOHFT JOWPMWJOH UIF VQQFS BOE NJE EFSNJT &QJUIFMPJE DFMM HSBOVMPNBT BOE MZNQIPDZUFT QSFEPNJOBUF $BTFBUJPO OFDSPTJT JT SBSFMZ QSFTFOU 3FTVMUT GSPN -PWFOTUFJO +FOTFO DVMUVSF BOE ;JFIM /FFMTFO TUBJOJOH PG TQFDJNFOT BSF PGUFO OFHBUJWF 4 0OMZ PG QBUJFOUT XJUI MVQVT WVMHBSJT IBE "'#oQPTJUJWF TLJO CJPQTZ TQFDJNFOT JO UXP DPNCJOFE *OEJBO TUVEJFT 4 5VCFSDVMJO TLJO UFTUJOH BOE JOUFSGFSPO HBNNB SFMFBTF BTTBZT NBZ CF IFMQGVM CVU BSF OPU EJBHOPTUJD *G DVUBOFPVT 5# JT TVTQFDUFE CVU OPU DPOÃ«SNFE DMJOJDBM JNQSPWFNFOU XJUI FNQJSJD BOUJUVCFSDVMPVT UIFSBQZ DPOÃ«SNT UIF EJBHOPTJT TREATMENT

CONCLUSIONS

$VUBOFPVT 5# JT B DIBMMFOHJOH EJBHOPTJT UIBU JT VODPNNPO FWFO JO IJHI QSFWBMFODF SFHJPOT GPS 5# -VQVT WVMHBSJT JT B É¨F DMJOJDBM QSFTFOUBUJPO PG MVQVT WVMHBSJT JT PGUFO OPOTQFDJÃ«D WBSJBOU PG DVUBOFPVT 5# UIBU JT QBSUJDVMBSMZ EJÃ¯DVMU UP EJBH1BUJFOUT NPTU DPNNPOMZ QSFTFOU XJUI DISPOJD VMDFSBUJOH BOE OPTF HJWFO JUT OPOTQFDJÃ«D DMJOJDBM QSFTFOUBUJPO BOE UIF SFMBUJWF CLINICAL MANIFESTATIONS

From the Department of Veterans Affairs Medical Center, Dayton, OH,1 and the Department of Medicine, Wright State University School of Medicine, Dayton, OH2 Address for Correspondence: Jack M. Bernstein, MD, Research (151), VA Medical Center, 4100 West Third Street, Dayton, OH 45428 t & NBJM KBDL CFSOTUFJO!XSJHIU FEV

SKINmed. 2012;10:42â&#x20AC;&#x201C;43

Âª 1VMTF .BSLFUJOH $PNNVOJDBUJPOT --$

*/'&$5*064 %*4&"4& $"146-&

January/February 2012

Figure 3. 3JHIU IFMJY BOE MPCVMF B NPOUI BOE B IBMG BGUFS TUBSUJOH BOUJUVCFSDVMPVT UIFSBQZ

Figure 1. 3JHIU IFMJY BOE MPCVMF VMDFSBUJPOT

XIJDI 5# JOGFDUT NVDI PG UIF XPSME T QPQVMBUJPO DMJOJDJBOT TIPVME IBWF B IJHI DMJOJDBM TVTQJDJPO GPS DVUBOFPVT 5# JO QBUJFOUT XJUI DIBSBDUFSJTUJD TLJO MFTJPOT BOE SJTL GBDUPST GPS 5# FYQPTVSF REFERENCES

Figure 2. 4LJO CJPQTZ PG UIF SJHIU MPCVMF TIPXJOH NJYFE JOÃ½BNNBUPSZ JOÃ¥MUSBUJPO XJUI MZNQIPDZUFT QMBTNB DFMMT BOE FQJUIFMPJE DFMM IJTUJPDZUJD OPODBTFBUJOH HSBOVMPNBT

EJÃ¯DVMUZ JO JTPMBUJOH "'# GSPN TLJO CJPQTZ TQFDJNFOT *O UIJT SFQPSU IJTUPSJDBM DMVFT UP UIF EJBHOPTJT PG DVUBOFPVT 5# JODMVEFE JNNJHSBUJPO GSPN BO FOEFNJD SFHJPO GPS 5# BOE QPTJUJWF 2VBOUJ'&30/ 5# (PME UFTUJOH $FMMFTUJT -JNJUFE $IBETUPOF .FMCPVSOF 7JDUPSJB "VTUSBMJB 3BQJE DMJOJDBM JNQSPWFNFOU XJUI FNQJSJD BOUJUVCFSDVMPVT UIFSBQZ DPOÃ«SNFE UIF EJBHOPTJT PG MVQVT WVMHBSJT XIFO QIZTJDBM FYBNJOBUJPO Ã«OEJOHT BOE IJTUPQBUIPMPHZ XFSF OPOTQFDJÃ«D *O BO FSB JO

SKINmed. 2012;10:42â&#x20AC;&#x201C;43

'BSJOB .$ (FHVOEF[ .* 1JRVFF & FU BM $VUBOFPVT UVCFSDVMPTJT B DMJOJDBM IJTUPQBUIPMPHJD BOE CBDUFSJPMPHJD TUVEZ J Am Acad Dermatol. o

5BQQFJOFS ( 8PMGG , 5VCFSDVMPTJT BOE PUIFS NZDPCBDUFSJBM JOGFDUJPOT *O 'JU[QBUSJDL 5# &JTFO "; 8PMGG , FU BM FET Dermatology in General Medicine. UI FE /FX :PSL /: .D(SBX )JMM o

,VNBS # .VSBMJEIBS 4 $VUBOFPVT UVCFSDVMPTJT B UXFOUZ ZFBS QSPTQFD UJWF TUVEZ Int J Tuberc Lung Dis. o

4FIHBM 7/ 4SJWBTUBWB ( ,IVSBOB 7, FU BM "O BQQSBJTBM PG FQJEFNJPMPH JD DMJOJDBM CBDUFSJPMPHJD IJTUPQBUIPMPHJD BOE JNNVOPMPHJD QBSBNFUFST JO DVUBOFPVT UVCFSDVMPTJT Int J Dermatol. o

$IPOH -: -P ,, $VUBOFPVT UVCFSDVMPTJT JO )POH ,POH B ZFBS SFUSP TQFDUJWF TUVEZ Int J Dermatol. o

"NFSJDBO 5IPSBDJD 4PDJFUZ $FOUFST GPS %JTFBTF $POUSPM BOE 1SFWFOUJPO *OGFDUJPVT %JTFBTFT 4PDJFUZ PG "NFSJDB 5SFBUNFOU PG UVCFSDVMPTJT MMWR Recomm Rep. o

#MVNCFSH ). -FPOBSE ., +BTNFS 3. 6QEBUF PO UIF USFBU NFOUÃ¹ PGÃ¹ UVCFSDVMPTJT BOE MBUFOU UVCFSDVMPTJT JOGFDUJPO JAMA. o

4NBMM 1. 'VKJXBSB 1* .BOBHFNFOU PG UVCFSDVMPTJT JO UIF 6OJUFE 4UBUFT N Engl J Med. o

*U .BZ #F 7VMHBS CVU *U *TO U B #BE 8PSE

2XU WK <HDU DW WKH 3DOD]]R +RWHO LQ /DV 9HJDV

5HJLVWHU 1RZ IRU 6SHFLDO 5DWHV

+RWHO 5RRPV $YDLODEOH DW *UHDW 5DWHV

#8' 6*' #6'^ 7KXUVGD\ 1RYHPEHU WK DW $0 Â± 6DWXUGD\ 'HFHPEHU VW DW 30

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

)RU LQIRUPDWLRQ RQ VSRQVRUVKLS RSSRUWXQLWLHV DQG $WWHQGHH HQUROOPHQW FRQWDFW 1DWDVKD 0RKU &RXUVH 'LUHFWRU -RHO 6FKOHVVLQJHU 0 ' 9LVLW ZZZ &RVPHWLF6XUJHU\)RUXP FRP (PDLO LQIR#&RVPHWLF6XUJHU\)RUXP FRP

January/February 2012

Volume 10 • Issue 1

CASE STUDY Vesna Petronic-Rosic, MD, MSc, Section Editor

Unusually Severe Case of Dermatosis Neglecta Jake E. Turrentine, BS; Travis W. Blalock, MD; Loretta S. Davis, MD An 18-year-old black woman with cerebral palsy was admitted for evaluation of an intrathecal baclofen pump site infection. The dermatology service was consulted for treatment suggestions of a presumed diagnosis of chronic tinea capitis. Three courses of oral griseofulvin during the past 2 years failed to resolve the patient’s chronic scalp dermatosis. Scalp lesions first began about 2 years earlier after hospitalization for placement of an intrathecal baclofen pump. The patient was unable to care for her scalp due to her cerebral palsy, and her mother interpreted the scalp condition as infectious. No routine shampoo care, scalp care, or topical treatment was performed for more than 1½ years. The mother felt that touching the patient’s scalp might cause pain and noted that the majority of her time was spent concentrating on more critical medical issues. Physical examination revealed coalescing hyperkeratotic plaques extending dorsally from the anterior hairline to the occipital scalp with small flecks of keratinous debris throughout the remaining hair (Figure 1). The plate-like plaques were devoid of hair, except at a few fissures where a few tufts of hair emerged. No cervical lymph nodes were appreciated on palpation. Treatment was initiated with compresses consisting of large warm water–soaked towels 4 times daily. Three times a day, a nursing staff applied 5% salicylic acid in olive oil to the scalp under a shower cap for approximately 1 hour. Over the following 2 days, a significant reduction in keratinous debris was appreciated. Within 2 weeks, the bulk of the plaques had been removed (Figure 2). At 6-week follow-up, the underlying scalp showed areas of fibrosis and possible scarring with a few emerging tufts of hair. On the basis of history and response to treatment with salicylic acid and routine scalp care, the patient was diagnosed with an unusually severe case of dermatosis neglecta.

he term dermatosis neglecta was originally coined in 1995 when three cases of an “unwashed dermatosis” were presented by L. Poskitt and colleagues.1 In all cases, the patients committed what Poskitt described as “acts of omission” by failing to wash their skin in the affected areas. The resulting hyperpigmented, hyperkeratotic dermatosis resolved by vigorously washing with soap and water or, in severe areas, by applying 5% salicylic acid in aqueous cream twice daily. Our patient had a severe case that responded well to salicylic acid followed by routine washing. Because the patient was subsequently lost to follow-up, we were unable to evaluate hair regrowth. Periodic shedding of the outermost cellular layers is an essential component of normal keratinocyte development. In the stratum corneum, protein-rich, lipid-depleted keratinocytes are the “bricks” that are held together by hydrophobic intercellular membranes and desmosomes, making up the “mortar.”2,3 Genetic defects in this system—either in the keratinocytes themselves or their intercellular molding—can lead to abnormal retention of stratum corneum, causing disorders such as ichthyosis vulgaris and recessive X-linked ichthyosis. Ichthyosis vulgaris is caused by defective profilaggrin, a keratinocyte protein, and

recessive X-linked ichthyosis is caused by a deficiency in steroid sulfatase, an enzyme in the intercellular domain.4 These genetic abnormalities of adherent stratum corneum illustrate the importance of regular shedding of superficial keratinocyte layers. Dermatosis neglecta represents a failure to cleanse adequately a particular area of skin, leading to the buildup of adherent hyperpigmented scales. Thus, dermatosis neglecta can be understood as a self-induced “defect” in normal keratinocyte shedding that causes abnormal accumulation of cellular layers and debris. Dermatosis neglecta typically occurs in an area of hyperesthesia or prior trauma where the patient refuses to scrub the skin.5 Also, as in our patient, dermatosis neglecta can develop in situations where a patient is unable to properly care for an area of skin because of physical or mental disability. A similar condition described in the literature is terra firma forme dermatosis (TFFD), which is a disorder of unknown etiology characterized primarily by disordered keratinization.6–8 In TFFD, the classic clinical finding is a dark, dirty-looking, slightly raised hyperkeratotic skin lesion that is completely asymptomatic. Cases of TFFD respond to 70% isopropyl alcohol rubs but not to cleansing with normal soap and water; therefore, TFFD can be distinguished

From the Division of Dermatology, Medical College of Georgia, Augusta, GA Address for Correspondence: Travis W. Blalock, MD, Medical College of Georgia, Division of Dermatology, 1004 Chafee Avenue, Augusta, GA 30904 • E-mail: tblalock@mcg.edu

SKINmed. 2012;10:46–47

January/February 2012

CASE STUDY

Figure 1. Crusted, plate-like plaques on the scalp at initial presentation.

Figure 2. Almost complete resolution of scalp plaque following 2 weeks of therapy.

clinically from dermatosis neglecta by the lack of response to normal washing and, of course, the absence of historical clues of neglect. Given its rapid response to inexpensive and simple treatment, dermatosis neglecta should be considered in the evaluation of a pigmented, hyperkeratotic skin lesion. If identified, a skin biopsy can often be avoided. Physicians should always inquire about skin care habits when gathering history about an unexplained skin lesion and should review and recommend normal skin hygiene, when a patient fails to respond to a full course of standard therapy for an alternate diagnosis. REFERENCES 1

Poskitt L, Wayte J, Wojnarowska F, Wilkinson JD. “Dermatosis neglecta”: unwashed dermatosis. Br J Dermatol. 1995;112:827–829.

Elias PM. Epidermal lipids, barrier function, and desquamation. J Invest Dermatol. 1983;80:44s–49s.

Williams ML. Ichthyosis: mechanisms of disease. Pediatr Dermatol. 1992;9:365–368.

Elias PM, Crumrine D, Rassner U, et al. Basis for abnormal desquamation and permeability barrier dysfunction in RXLI. J Invest Dermatol. 2004;122:314–319.

Lucas JL, Brodell RT, Feldman SR. Dermatosis neglecta: a series of case reports and review of other dirty-appearing dermatoses. Dermatol Online J. 2006;12:5.

Akkash L, Badran D, Al-Omari AQ. Terra firma forme dermatosis: case series and review of the literature. J Dtsch Dermatol Ges. 2009;7:102– 107.

Guarneri C, Guarneri F, Cannavo SP. Terra firma-forme dermatosis. Int J Dermatol. 2008;47:482–484.

Raveh T, Gilead LT, Wexler MR. Terra firma forme dermatosis. Ann Plast Surg. 1997;39:542–545.

VINTAGE LABEL

Courtesy of BuyEnlarge, Philadelphia, PA SKINmed. 2012;10:46–47

Dermatosis Neglecta

January/February 2012

Volume 10 • Issue 1

CASE STUDY

Fixed-Drug Eruption Caused by Ashwagandha (Withania somnifera): A Widely Used Ayurvedic Drug Virendra N. Sehgal, MD; Prashant Verma, MD; Sambit N. Bhattacharya, MD

A 28-year-old man with decreased libido received ashwagandha in the usual daily dosage of 5 g for 10 days. During this period, he experienced a burning and/or itching sensation as well as discoloration of the skin/mucous membrane confined to the penis. He had a similar type of eruption at the same site 6 months prior while taking ashwagandha. Examination of the skin surface was conspicuous and marked by the presence of a dusky, erythematous, oval, eroded plaque of 3 cm, affecting the glans penis and prepuce (Figure). The drug was withdrawn and topical 0.05% clobetasol propionate cream was administered along with cetrizine dihydrochloride, an H1-receptor blocker, 10 mg daily for 1 month. There was a perceptible amelioration of the lesion, resulting in residual greyish white pigmentation. He was prescribed oral drug provocation with 1 g of ashwagandha powder. Within 12 hours, a flare-up developed at the earlier site, confirming the causality.

ixed-drug eruption, one of the most well-recognized adverse drug reactions, is characterized by a peculiar, sudden onset of round and/or oval, edematous, dusky red macules/plaques on the skin and/or mucous membranes accompanied by burning and/or itching.1 Several drugs have been incriminated in its causation, the details of which have been specifically recounted in a recent comprehensive review.2 Ashwagandha belongs to an alternative system of medicine and has a long medicinal history. It is an innocuous agent that has not been associated with any cutaneous drug reactions to date. Fixed-drug eruption following the use of ashwagandha is an uncommon occurence; hence, the current report.

Ashwagandha literally means “horse smell” (ashwa = horse, gandha = smell), for its wet roots smell similar to horse’s urine. Withania somnifera, also known as ashwagangha, Indian ginseng, winter cherry, ajagandha, kanaje hindi, and samm al ferakh, the offending indigenous drug, is derived from a plant in the Solanaceae or nightshade family.3 It is a beautiful, delicate plant native to India, Pakistan, and Sri Lanka. It is considered the king of herbs among ayurvedic medicines. It has a medicinal history of 4000 years and is a well-accepted, vital drug in Ayurveda and Indian traditional medicine.4 It has been conventionally used for calming the mind and relieving

weakness, nervous exhaustion, and arthritis. In addition, it is used for building sexual energy. Ashwagandha root is said to be beneficial in people who do physical labor or exercise a lot, helping the body adapt to physical stress. In addition, its paste is recommended for external use in the treatment of carbuncles, ulcers, and nondescript swellings. Bedsores and wounds are also amenable to topical application of ashwagandha leaves. CONCLUSIONS Ashwagandha is said to possess anti-inflammatory, anti-tumor, antistress, antioxidant, immunomodulatory, hemopoeitic, and rejuvenating effects.5 In addition, it is thought to exert a positive influence on the endocrine, cardiopulmonary, and central nervous systems.6 Ashwagandha’s mechanism of action is still speculative, and toxicity studies have revealed it to be a safe compound.7–9 REFERENCES 1

Sehgal VN, Bhattacharya SN, Verma P. Physiopathology of adverse cutaneous drug reactions—applied perceptions: Part I. Skinmed. In press.

Sehgal VN, Srivastava G. Fixed drug eruption (FDE): changing scenario of incriminating drugs. Int J Dermatol. 2006;45:897–908

Winters M. Ancient medicine, modern use: Withania somnifera and its potential role in integrative oncology. Altern Med Rev. 2006;11:269–277.

From the Dermato-Venereology (Skin/VD) Center, Sehgal Nursing Home, Panchwati-Delhi, India; the Department of Dermatology and STD, University College of Medical Sciences and Guru Teg Bahadur Hospital, Shahdara, Delhi, India Address for Correspondence: Virendra N. Sehgal, MD, Dermato-Venereology (Skin/VD) Center, Sehgal Nursing Home, A/6 Panchwati, Delhi 110 033, India • E-mail: drsehgal@ndf.vsnl.net.in

SKINmed. 2012;10:48–49

January/February 2012

CASE STUDY 4

Rasool M, Varalakshmi P. Protective effect of Withania somnifera root powder in relation to lipid peroxidation, antioxidant status, glycoproteins and bone collagen on adjuvant-induced arthritis in rats. Fundam Clin Pharmacol. 2007;21:157–164.

Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev. 2000;5:334–346.

Sehgal VN, Srivastava G. Traditional/ayurvedic pharmacotherapy of skin diseases. Skinmed. 2010;8:282–284.

Behl PN, Arora RB, Srivastava G. Traditional Indian Dermatology Concept of Past and Present. 1st ed. New Delhi, India: SISD Publication; 1992.

Behl PN, Srivastava G. Herbs Useful in Dermatological Therapy. 2nd ed. New Delhi, India: CBS Publishers; 2004.

Sehgal VN, Grangwani OP. Fixed drug eruptions: a study of epidemiological, clinical and diagnostic aspects of 89 cases from India. J Dermatol. 1988;15:50–54.

Figure. Fixed-drug eruption affecting the glans and prepuce of the penis.

VINTAGE LABEL

Courtesy of BuyEnlarge, Philadelphia, PA

SKINmed. 2012;10:48–49

Fixed-Drug Eruption Caused by Ashwagandha

January/February 2012

Volume 10 • Issue 1

CASE STUDY

Chronic Lymphocytic Leukemia Revealed by a Granulomatous Zosteriform Eruption Sondes Trojjet, MD;1 Houda Hammami, MD;1 Inès Zaraa, MD;1,2 Alia Bouzguarrou, MD;1 Meriem Joens, MD;1 Slim Haouet, MD;2,3 Amel Ben Osman, MD;1,2 Mourad Mokni, MD1,2

A 70-year-old woman presented with an atypical erythematopapular zosteriform eruption of 3 weeks’ duration. The patient had no history of previous vesicular eruption. She developed a painful burning sensation on the neck. Clinical examination revealed a cluster of small erythematous firm papules and plaques in a zosteriform distribution on the left ear, face, neck, and shoulder (Figure 1A). The lesions were unilateral and did not cross the midline. Multiple cervical and axillary lymph nodes were palpable. Laboratory tests revealed an increase in white blood cells of 25,000/mm3, with 17,910/mm3 lymphocytes and a normal range of hemoglobin, platelets, creatinine, and liver enzymes. Erythrocyte sedimentation rate was 87 mm. Blood smear results showed small, morphologically mature lymphocyte cells. In immune phenotyping, lymphocyte cells co-express CD5 and B-cell–surface antigens CD19 and CD23, as well as a restriction of kappa immunoglobulin light chains. The cells were CD22-, CD79b-, CD38-, CD10-, CD25- and FMC7-. Computed thoracoabominal tomography revealed cervical, mediastinal, abdominal, and pelvic adenopathy confirming the diagnosis of B-cell chronic lymphocytic leukemia (B-CLL) stage B. Histology of a skin biopsy from a papule showed a dense nodular granulomatous infiltrate in the dermis (Figure 2A). The infiltrate contained epithelioid and giant cells surrounded by lymphocytes and plasma cells. Small monomorphic lymphocytes without mitotic figures predominated (Figure 2B). The epidermis was irregularly thickened. Immunohistology revealed a polymorphous infiltrate with a phenotype of reactive T lymphocytes (CD3, CD5 positive) (Figure 2C), B lymphocytes (CD20 positive) (Figure 2D). Epithelioid and giant cells were positive for CD68 (Figure 2E). A latent herpes zoster infection with granulomatous reaction at the site of zoster lesions was highly suspected as the patient reported a unilateral burning sensation without a history of vesicular zosteriform eruption. She received treatment with intravenous acyclovir 10 mg/kg every 8 hours. The papular lesions resolved markedly (60%) on macular plaques at the end of the treatment. Following topical treatment with corticosteroids, the lesions healed completely within 4 weeks (Figure 1B). Concerning leukemia, our patient was monitored without therapy by the hematologist.

arious cutaneous lesions may appear at sites of prior herpes zoster infection, such as annular granuloma, sarcoidal granuloma, granulomatous vasculitis, Kaposi’s sarcoma, and pseudolymphoma.1 These cutaneous lesions may appear immediately after resolving vesicular lesions or at varying times after the acute eruption. We describe in this report an unusual case of a granulomatous zosteriform eruption revealing a B-cell chronic lymphocytic lymphoma. Our patient is of special interest because she presented with a granulomatous eruption arising after a probable latent zoster revealing B-CLL. Unfortunately, varicella-zoster virus DNA detection was not performed in our case. Granulomatous reactions and specific infiltrations at sites of resolved cutaneous herpes zoster lesions in patients with

B-CLL have been described as a rare clinical event.2,3 The cause of granulomatous reactions caused by varicellazoster virus remains to be elucidated.4 Type III and type IV hypersensitivity reaction,5 isotopic response,6,7 and viral etiologies2are thought to be possible provoking factors. A study of granulomatous reactions associated with herpes zoster lesions for the presence of varicella-zoster virus genome using the polymerase chain reaction suggested that varicella-zoster virus DNA is detected in cases where eruption occurred immediately in the wake of resolving vesicular herpes zoster lesions.2 In this case, differential diagnosis includes specific cutaneous infiltrates with neoplastic B cells. The clinical resolution of the lesions after treatment with acyclovir and topical steroids confirms the benign nature of the granulomatous infiltration.

From the Department of Dermatology, La Rabat Hospital, Tunis Tunisia;1 the Faculté de Médecine de Tunis, Tunis El Manar University, Tunis, Tunisia;2 and the Department of Pathology, La Rabta Hospital, Tunis, Tunisia3 Address for Correspondence: Ines Zaraa, MD, Dermatology Department, La Rabta Hospital, Jabbari, Bab Saadoun, Tunis, 1007 Tunisia • E-mail: inesrania@yahoo.fr

SKINmed. 2012;10:50–52

January/February 2012

CASE STUDY

Figure 1A. Clustered erythematous papules and plaques on right neck and shoulder.

Figure 2A. Histology of skin papule showing a dense nodular granulomatous infiltrate in the dermis (hematoxylin and eosin stain, original magnification ×40).

Figure 2B. Granulomatous infiltrate containing small mature lymphocytes with no significant atypia, epithelioid, or giant cells (hematoxylin and eosin stain, original magnification ×100).

Figure 1B. Healing of clustered erythematous papules and plaques within 4 weeks.

CONCLUSIONS

REFERENCES

An atypical zosteriform eruption should alert dermatopathologists to the possibility of an associated hematological dyscrasia, mainly B-CLL.

SKINmed. 2012;10:50–52

Requena L, Kutzner H, Escalonilla P, et al. Cutaneous reactions at sites of herpes zoster scars: an expanded spectrum. Br J Dermatol. 1998;138:161–168.

Chronic Lymphocytic Leukemia

January/February 2012

CASE STUDY

Figure 2C. The majority of infiltrating cells staining positively with the pan–T-cell marker CD3 (CD 3 staining [Novocastra, Newcastle upon Tyne, UK], original magnification ×40).

Figure 2E. Epithelioid and giant cells staining positive with CD68 (CD 68 staining [DakoCytomation, Glostrup, Denmark], original magnification ×40). 2

Serfling U, Penneys NS, Zhu WY, et al. Varicella-zoster virus DNA in granulomatous skin lesions following herpes zoster. A study by the polymerase chain reaction. J Cutan Pathol. 1993;20:28–33.

Wakelin SH, Young E, Kelly S, Turner M. Transient leukaemia cutis in chronic lymphocytic leukaemia. Clin Exp Dermatol. 1997;22;148–151.

Cerroni L, Zenahlik P, Kerl H. Specific cutaneous infiltrates of B-cell chronic lymphocytic leukemia arising at the site of herpes zoster and herpes simplex scars. Cancer. 1995;76: 26–31.

Gibney MD, Nahass GT, Leonardi CL. Cutaneous reactions following herpes zoster infections: report of three cases and a review of the literature. Br J Dermatol. 1996;134:504–509.

Schena D, Barba A, Chieregato C. Granulomatous folliculitis as a manifestation of post-herpetic isotopic response. J Eur Acad Dermatol Venereol. 2001;15:473–475.

Ruocco V, Ruocco E, Ghersetich I, et al. Isotopic response after herpesvirus infection: an update. J Am Acad Dermatol. 2002;46:90–94.

Figure 2D. The infiltrating cells staining positively with the pan–B-cell marker CD20 (CD 20 staining [DakoCytomation, Glostrup, Denmark], original magnification ×40).

VINTAGE LABEL

Courtesy of BuyEnlarge, Philadelphia, PA SKINmed. 2012;10:50–52

Chronic Lymphocytic Leukemia

Grand Wailea, Maui • February 4–8, 2012

20 12 Register Now for the 8th Annual Conference! February 4–8, 2012

Grand Wailea : Maui, Hawaii

Plan to attend the 8th Annual Maui Derm Conference! “Cutting edge, a great blend of science and clinical medicine and a world class faculty” describe Maui Derm 2012. Our faculty will share with you the most important developments in medical and cosmetic dermatology vital to your practice. Our live patient demonstration workshops in lasers, Botulinum Toxin A and fillers have set the standard for “hands on” workshops. Our format has been specifically designed to allow optimal time for discussion with our faculty.We are certain that you will find this to be an outstanding and memorable educational event that you will not want to miss. Put Maui Derm on your calendar for 2012!

Featured Lectures

Hot Topics • Cases for the Panel • Seminars • Workshops • Basic Science

Medical Dermatology: Basic Science, Hot Topics, Cases for the Panel, Point:Counterpoint, Seminars, “How I Do It” Cutaneous Oncology • Acne/Rosacea • Pediatric Dermatology • Infectious Diseases Psoriasis • Skin of Color • Life Threatening Dermatoses • Master’s CPC • Ofﬁce Surgery • Practice Management

Cosmetic Dermatology: From Basic Science to Case Based Discussion and “How I Do It” Botulinum Toxin A and Fillers • Lasers • Sclerotherapy

2012 Faculty * Matthew Avram, MD Neal Bhatia, MD Andrew Blauvelt, MD Valerie Callender, MD Joel Cohen, MD Lawrence Eichenﬁeld, MD Rebecca Fitzgerald, MD Keith T. Flaherty, MD Sheila Friedlander Fallon, MD Ilona Frieden, MD Michael Gold, MD Mitchel Goldman, MD Pearl Grimes. MD Derek Jones, MD Arthur Kavanaugh, MD Suzanne Kilmer, MD David Laub, MD Philip LeBoit, MD Craig Leonardi, MD Stuart Maddin, MD Ashfaq Marghoob, MD

Chairman: Dr. George Martin Sam Moschella, MD Stuart Nelson, MD Kevin Pinski, MD Phoebe Rich, MD Ted Rosen, MD E. Vic Ross, MD Alan Shalita, MD Ava Shamban, MD Daniel Siegel, MD Eggert Stockﬂeth, MD Bruce Strober, MD, PhD Neil Swanson, MD James Treat, MD Hensin Tsao, MD Sandy Tsao, MD Guy Webster, MD, PhD Wm. Philip Werschler, MD John Zone, MD * Subject to Change

MAUI DERM 2012 HAS SPECIAL/REDUCED RATES AT THE

Grand Wailea and the Wailea Marriott “Lunch with the Faculty” – Controversial Topics, Case-based Discussions For more details, visit our website at

Interactive Workshops Small Group, Live Patient, Hands-On Demonstrations: Botulinum Toxins/Fillers, Sclerotherapy

www.acmd-derm-hawaii.com

January/February 2012

Volume 10 • Issue 1

CORRESPONDENCE MYCOBACTERIUM MARINUM CUTANEOUS INFECTION WITH SPOROTRICHOID DISTRIBUTION TREATED WITH AZITHROMYCIN MONOTHERAPY To the Editor: Mycobacterium marinum is an aerobic, waterborne mycobacterium commonly found in nonchlorinated water in a worldwide distribution. It is also the most common atypical Mycobacterium to cause infection in humans. Infection is not transmittable from person to person, and skin infections due to M marinum are rare.1 There is no established treatment of choice for M marinum infection, probably because it is a multidrug-resistant species. Its treatment has been based primarily on personal experience without the benefit of large studies.2 To our knowledge, this is the first case of cutaneous M marinum infection treated with azithromycin monotherapy. A 52-year-old-woman, a cleaning worker in our hospital, was referred to our department because of the appearance of red nodules on the left palm and left forearm in a sporotrichoid distribution (Figure 1). She mentioned that the first lesion appeared on her hand 6 months previously and new lesions gradually appeared and increased in number and size during this period. She also reported a private fish aquarium usually cleaned by her without using hand protection. The remainder of her medical history was unremarkable.

Routine laboratory tests including human immunodeficiency virus test were within normal limits. The patient underwent surgical skin biopsy of the nodule of the forearm, and histologic examination revealed the presence of tuberculoid structures with neutrophils and macrophages (Figure 2). Results from periodic acid-Schiff and Ziehl-Neelsen stains were negative. Cultures taken from the lesions were negative for bacilli or atypical mycobacteria. Chest and right hand radiological evaluations were normal. The patient reported an episode of headache after doxycycline intake, a ciprofloxacin-associated morbilliform eruption, and frequent gastrointestinal symptoms after drug administration. She told us she could receive azithromycin without a problem; therefore, we decided to try azithromycin 500 mg (tabs Zinfect 500 mg, Verisfield, Athens, Greece) 3 times a week for 2 months and re-evaluation. To our surprise, complete clinical cure was obtained after 8 weeks of treatment (Figure 3). No relapse has been observed after 10 months of follow-up. M marinum infection, also called “fish tank granuloma,” “aquarium granuloma,” or “swimming pool granuloma” seems to represent an opportunistic disease and occurs after approximately 2 weeks of direct (traumatic) inoculation of the organism either from fish fins and bites or from the handling of aquariums.1 Solitary red-to-violaceous plaques or nodules with an overlying crust or verrucous and/or ulcerate surface is a common clinical presentation in immunocompetent patients. Inflammatory

Figure 2. Histologic examination revealed the presence of tuberculoid structures (hematoxylin and eosin stain, original magnification ×100).

Figure 1. Mycobacterium marinum skin infection of the left palm with sporotrichoid distribution on the left forearm.

SKINmed. 2012;10:54–55

January/February 2012

CORRESPONDENCE

nodules, abscesses with a sporotrichotic type of distribution, followed by nodular lymphangitis can develop in severely immunosuppressed patients.3 Over a period of months, involvement of deeper soft tissues (tenosynovitis, arthritis, bursitis, and/or osteomyelitis of the underlying bone) may be life-threatening.4 Lesions may be either painful or painless. Lung involvement, disseminated infection, and bacteremia have been rarely reported.1

trimethoprim sulfamethoxazole, and ciprofloxacine as monotherapy are usually effective treatment options. In severe infections, a combination of rifampicin and ethambutol seems to be the recommended regimen. Surgical treatment is usually unnecessary, and where it should be performed must be cautiously determined.1,2

The organism can be isolated from the lesion as well as from infected fish or aquariums; however, in clinical practice, diagnosis remains largely presumptive based on clinicohistologic features. Histopathologic examination usually reveals a nonspecific inflammatory infiltrate.1

Azithromycin shows good response in vitro against other than Mycobacterium tuberculosis mycobacteria. There is only one case of M marinum infection in a patient who underwent lung transplantation successfully treated with surgical removal of the lesions and a 12-month administration of a combination of azithromycin and ethambutol.5 Azithromycin seems to be a promising option to treat M marinum skin infections, although, further studies—or at least cases—are needed to establish the effectiveness of the drug.

Treatment of M marinum infections is challenging. In superficial cutaneous infections, minocycline, clarithromycin, doxycycline,

REFERENCES 1

Rallis E, Koumantaki-Mathioudaki E. Treatment of Mycobacterium marinum cutaneous infections. Expert Opin Pharmacother. 2007;8: 2965–2978.

Edelstein H. Mycobacterium marinum skin infections. Report of 31 cases and review of the literature. Arch Intern Med. 1994;154: 1359–1364.

Bartralot R, Garcia-Patos V, Sitjas, et al. Clinical patterns of cutaneous nontuberculous mycobacterial infections. Br J Dermatol. 2005;152:727–734.

Wu TS,Chiu CH,Su LH et al. Mycobacterium marinum infection in Taiwan. J Microbiol Immunol Infect. 2002;35:42–46.

Torres F, Hodges T, Zamora MR. Mycobacterium marinum infection in a lung transplant recipient. J Heart Lung Transplant. 2001;20: 486–489. —Efstathios Rallis, MD, PhD, Department of Dermatology, Veterans Administration Hospital (NIMTS), Athens, • E-mail: efrall@otenet.gr; Evangelos Falidas, MD, 1st Department of General Surgery, Veterans Administration Hospital (NIMTS), Athens; Panagiotis Stavropoulos, MD, PhD, Department of Dermatology, University of Athens, “A.Syggros” Hospital, Athens, Greece

Figure 3. Complete clearance of the lesions was achieved after 8 weeks of azithromycin treatment.

FORMULARY OF DR GEORGE C. ANDREWS Nail Bleach Oxalic acid

Gm xxx

Distilled water

2000 cc

Perfume

Qs ad

The above may be irritating—ingredients should be on poison label with a word of caution. Submitted by Douglas D. Altchek, MD, New York, NY

THE Aesthetic Show of the Year

World-Class Faculty Pre-Show Educational Sessions Advanced Hands-On Training THE Aesthetic Awards Patient Tx Workshops TM

UÊ,iVi ÛiÊfÓääÊ vvÊÀi} ÃÌÀ>Ì ÊviiÃ UÊ,iVi ÛiÊV « i Ì>ÀÞÊÕ«}À>`iÊÌ Ê6 *Ê i LiÀÊÃÌ>ÌÕÃ UÊ-Ì>ÀÊ Ê>Ê ÛiÊw }Ê vÊAesthetic TV

To register visit www.aestheticshow.com or call + 1 (949) 830-5409

CANCUN 2012 January 31st to February 4th Cancun Quintana Roo, Mexico

www.WCOCD2012.com info@WCOCD2012.com + (52 55) 5531- 0865 + (52 55) 5203- 6454 Abstract submission deadline:

O c tober 30 th, 2011

WK $QQXDO 6FLHQWLÃ&#x20AC;F &RQIHUHQFH

7HQQHVVHH 6RFLHW\ IRU /DVHU 0HGLFLQH DQG 6XUJHU\ .BSDI "QSJM %PXOUPXO )JMUPO

/BTIWJMMF 5/

$ ZHHNHQG RI HGXFDWLRQDO OHDUQLQJ DQG WUDLQLQJ WR JURZ \RXU NQRZOHGJH RI ODVHUV OLJKW VRXUFHV DQG WKH FRVPHWLF LQGXVWU\

/DVHU )XQGDPHQWDOV )LOOHU 7R[LQ 8SGDWH 7DWWRR 5HPRYDO 9DVFXODU 3LJPHQW /DVHUV $EODWLYH DQG 1RQ $EODWLYH 5HVXUIDFLQJ /DVHU +DLU 5HPRYDO 7UHDWLQJ 6NLQ RI &RORU /DVHU /LSR )DW *UDIWLQJ ,QGXVWU\ :RUNVKRSV ([KLELWV

,QIRUPDWLRQ 6FKHGXOHV DQG 5HJLVWUDWLRQ DYDLODEOH DW WQODVHUVRFLHW\ FRP

)DFXOW\

0DU\ 3 /XSR 0'

(ULF ) %HUQVWHLQ 0'

'DUUHO / (OOLV 0'

0LFKDHO + *ROG 0'

0LFKHO $ 0F'RQDOG 0'

%ULDQ 6 %LHVPDQ 0'

-XOLXV : )HZ 0'

3DWULFN - &ODUN

'DYLG - *ROGEHUJ 0'

-DVRQ 1 3R]QHU 0'

Locoid Lipocream® Cream, 0.1% (hydrocortisone butyrate 0.1% cream) For Topical Use Only

Rx Only

BRIEF SUMMARY INDICATIONS AND USAGE Locoid Lipocream is a topical corticosteroid indicated for: relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in adults and the treatment of mild to moderate atopic dermatitis in patients 3 months to 18 years of age. WARNINGS AND PRECAUTIONS Reversible hypothalamic-pituitary-adrenal (HPA) axis suppression may occur, with the potential for glucocorticosteroid insufficiency. Consider periodic evaluations for HPA axis suppression if Locoid Lipocream is applied to large surface areas or used under occlusion. If HPA axis suppression is noted, reduce the application frequency, discontinue use, or switch to a lower potency corticosteroid. Systemic effects of topical corticosteroids may also include manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria. Pediatric patients may be more susceptible to systemic toxicity due to their larger skin surface-to-body-mass ratios. Initiate appropriate therapy if concomitant skin infections develop. Discontinue use if irritation develops. ADVERSE REACTIONS The most common adverse reactions (>1%) are HPA axis suppression and application site reactions. The following additional local adverse reactions have been reported infrequently with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions included: irritation, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, miliaria and telangiectasia. USE IN SPECIFIC POPULATIONS Pregnancy Pregnancy Category C. Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.There are no adequate and well-controlled studies in pregnant women. Therefore, Locoid Lipocream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Please refer to full prescribing information for detailed information regarding systemic embryofetal development studies. Nursing Mothers Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when Locoid Lipocream is administered to a nursing woman. Pediatric Use Safety and efficacy in pediatric patients below 3 months of age have not been established. Because of higher skin surface-to-body-mass ratios, pediatric patients are at a greater risk than adults of HPA axis suppression when they are treated with topical corticosteroids. They are therefore also at a greater risk of glucocorticosteroid insufficiency after withdrawal of treatment and of Cushing’s syndrome while on treatment. Eighty-six (86) pediatric subjects (5 months to less than 18 years of age) with moderate to severe atopic dermatitis affecting at least 25% of body surface area (BSA) treated with Locoid Lipocream three times daily for up to 4 weeks were assessed for HPA axis suppression. The disease severity (moderate to severe atopic dermatitis) and the dosing regimen (three times daily) in this HPA axis study were different from the subject population (mild to moderate atopic dermatitis) and the dosing regimen (two times daily) for which Locoid Lipocream is indicated. Five of the 82 evaluable subjects (6.1%) demonstrated laboratory evidence of suppression, where the sole criterion for defining HPA axis suppression was a serum cortisol level of less than or equal to 18 micrograms per deciliter after cosyntropin stimulation. Suppressed subjects ranged in age from 5 months to 16 years and, at the time of enrollment, had 25% to 95% BSA involvement. These subjects did not develop any other signs or symptoms of HPA axis suppression. At the first follow up visit, approximately one month after the conclusion of treatment, cosyntropin stimulation results of all subjects had returned to normal, with the exception of one subject. This last subject recovered adrenal function by the second post treatment visit, 65 days post-treatment. Cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have also been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include low plasma cortisol levels to an absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Geriatric Use Clinical studies of Locoid Lipocream did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Carcinogenesis, Mutagenesis, Impairment of Fertility No studies were conducted to determine the photococarcinogenic or dermal carcinogenic potential of Locoid Lipocream. Hydrocortisone butyrate revealed no evidence of mutagenic or clastogenic potential based on the results of two in vitro genotoxicity tests (Ames test and L5178Y/TK+ mouse lymphoma assay) and one in vivo genotoxicity test (mouse micronucleus assay). No evidence of impairment of fertility or effect on mating performance was observed in a fertility and general reproductive performance study conducted in male and female rats at subcutaneous doses up to and including 1.8 mg/kg/day (0.7X maximum topical human dose [MTHD]). Mild effects on maternal animals, such as reduced food consumption and a subsequent reduction in body weight gain, were seen at doses ≥0.6 mg/kg/day (0.2X MTHD). PATIENT COUNSELING INFORMATION Patients using Locoid Lipocream should receive the following information and instructions: Apply a thin layer to the affected skin two or three times daily for corticosteroidresponsive dermatoses in adults. Consult with your physician to determine if treatment is needed beyond 2 weeks. Apply a thin film to the affected skin areas two times daily for atopic dermatitis in patients 3 months of age and older. Safety of Locoid Lipocream in pediatric patients has not been established beyond 4 weeks of use. Rub in gently. Avoid contact with the eyes. Do not bandage, otherwise cover, or wrap the affected skin area so as to be occlusive unless directed by your physician. Do not use Locoid Lipocream in the diaper area, as diapers or plastic pants may constitute occlusive dressings. Do not use Locoid Lipocream on the face, underarms, or groin areas unless directed by your physician. If no improvement is seen within 2 weeks, contact your physician. Do not use other corticosteroid-containing products while using Locoid Lipocream without first consulting your physician. Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Protect from freezing. Keep out of the reach of children.

Manufactured for: Triax Pharmaceuticals, LLC Cranford NJ 07016 By: Ferndale Laboratories, Inc. Ferndale MI 48220 Locoid Lipocream is a registered trademark of Astellas Pharma Europe BV licensed to Triax Pharmaceuticals, LLC.

Marketed and Distributed By: Triax Pharmaceuticals, LLC Cranford NJ 07016 www.Locoid.com

131B301 Rev 11/09

Now younger eczema patients have something to smile about

Now approved for use in children down to 3 months of age

The power of an ointment with the elegance of a cream Locoid Lipocream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, including the treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. Safety and effectiveness in pediatric patients below 3 months of age have not been established. Reversible HPA axis suppression may occur, with the potential for corticosteroid insufficiency. Consider periodic evaluations for HPA axis suppression if applied to large surface areas or used under occlusion. Systemic effects of topical corticosteroids may also include manifestations of Cushingâ&#x20AC;&#x2122;s syndrome, hyperglycemia, and glucosuria. Pediatric patients may be more susceptible to systemic toxicity due to their large skin surface-to-body-mass ratios. Initiate appropriate therapy if concomitant skin infection develops. Discontinue use if irritation develops. Please see full Prescribing Information on adjacent page. Visit us at www.locoid.com (hydrocortisone butyrate 0.1%) Cream ÂŠ2010 Triax Pharmaceuticals, LLC. All rights reserved. Locoid is a registered trademark of Astellas Pharma Europe B.V. licensed to Triax Pharmaceuticals, LLC. LOC-0410-01